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The thesis entitled "Development of analytical methods for the determination of 
cardiovascular drugs in pharmaced'tlki^ J^n'nralatioflsj^ bomprises of five chapters. 
Chapter 1 describes a general introduction of the subject matter, which 
includes: 
• a discussion on the role of various branches of science such as chemistry, 
pharmacology, microbiology and biochemistry in the field of drug research. The drug 
development is a complex process and requires a broad spectrum of knowledge. A 
brief account of various aspects of drug development starting from the discovery of 
the drug molecules, quantitation and identification of impurities during their 
development, dosage form related investigations, role of various regulatory authorities 
in setting a standard for the approval of new drugs and the specifications for post 
approval manufacture. 
• a brief overview of the analytical techniques employed in pharmaceutical analysis. 
• true meaning of validation of analytical method utilized in drug analysis. 
• a description of the classification of drugs based on pharmacological action on 
human organs, and a brief literature and chemical structures of the four drugs, i.e, 
losartan potassium, irbesartan, nicorandil and lisinopril. An abundant and well-
composed list of references is given at the end of this chapter, comprising 246 
citations taken from the world's leading scientific journals of the field, various 
regulatory guidelines and books. 
The second chapter describes a validated kinetic spectrophotometric method for 
the determination of losartan potassium. The method is based on oxidation of the 
losartan potassium with allcaline potassium permanganate at room temperature 
(25±1°C). The reaction is followed spectrophotometrically by measuring the increase 
in absorbance with time at 603 nm and the initial rate; fixed time (at 12.0 min) and 
equilibrium time (at 90.0 min) methods are adopted for constructing the calibration 
graphs. All the calibration graphs are linear in the concentration range of 7.5 - 60.0 ^g 
ml"' and the calibration data resulted in the linear regression equations: 
V =-6.422 X 10"''+1.173 xlO'^C, 
A = 3.30x 10"''+5.28 X 10'^  C and 
A = -2.09x 10"-+1.05 X 10"'C 
for initial-rate, fixed time and equilibrium time methods, respectively. The limits of 
detection for initial rate, fixed time and equilibrium time methods are 0.71, 0.21 and 
0.19n,g ml"', respectively. The activation parameters such as Ea, AH^ AS^and AG^ 
are also determined for the reaction and found to be 87.34 KJ mol"', 84.86 KJ mol" , 
50.96 JK"' mol"' and -15.10 KJ mol"', respectively. The variables are optimized and 
the proposed methods are validated as per ICH guidelines. The method has been 
applied successfully to the estimation of losartan potassium in commercial tablets. The 
performance of the proposed methods was judged by calculating paired t- and F-
values. The analytical results of the proposed methods when compared with those of 
the reference method show no significant difference in accuracy and precision and 
have acceptable bias. 
In chapter three, a new kinetic spectrophotometric method for the 
determination of irbesartan in pharmaceutical formulations has been discussed. The 
method is based on the reaction of carboxylic acid group of the oxidized irbesartan 
with a mixture of potassium iodate (KIO3) and iodide (KI) to form yellow coloured 
triiodide ions in aqueous medium at 30 ± 1°C. The reaction is followed 
spectrophotometrically by measuring the rate of change of absorbance at 352 nm. The 
initial-rate and fixed-time (AA) methods are adopted for constructing the calibration 
curves, which are found to be linear over the concentration ranges of 10.0 - 60.0 and 
7.5 - 60.0 ^g ml"' respectively. The regression analysis of calibration data yielded the 
linear equations: 
rate = -2.138 X 10'^+ 1.058 x lO^^C and 
AA = -3.75x 10"^  +3.25 X 10'^  C 
for initial rate and fixed time (A A) methods, respectively. The limit of detection for 
initial rate and fixed time methods are 0.21 and 2.40 |ig ml'', respectively. The 
various activation parameters such as Ea, AH*, AS^ and AG* are also calculated for 
the reaction and found to be 70.95 ± 0.43 KJmol"', 68.48 ± 0.21 KJ mol'', 16.54 ± 0.24 
JK"' mol"' and -4.94 ± 0.07 KJ mol"', respectively. The proposed methods are 
optimized and validated as per the guidelines of International Conference on 
Harmonisation (USA). The point and interval hypothesis tests have been performed 
which indicate that there is no significant difference between the proposed methods 
and the reference method. The methods have been successfully applied to the 
determination of irbesartan in commercial dosage forms. 
The fourth chapter describes a validated and sensitive visible 
spectrophotometric method for the quantitation of nicorandil in pharmaceutical 
formulations. The method is based on the reduction of nitroxy ethyl group of 
nicorandil to carbonyl derivative and nitrite ion by Zn / NH4CI. The nitrite ion 
undergoes diazotization with sulphanilamide in presence of HCl followed by coupling 
with N-(l-naphthyl) ethylenediamine dihydrochloride (NED) to form a coloured 
product with X^ ax at 525 nm. Under the optimized experimental conditions, Beer's 
law is obeyed in the concentration range of 0.4 - 12.0|ag ml'' with molar absorptivity 
of 1.92 X 10'' 1 mol' cm'. The statistical analysis of calibration data yields the linear 
regression equation: A = 6.304 x 10"^  + 9.13 x 10"^  C with correlation coefficient of 
0.9999. The limits of detection and quantification are 0.05 and 0.15 |ig ml'', 
respectively. The results obtained by the proposed method are acceptable with average 
recoveries of 100.0 - 100.1 %. The results of the proposed method are compared with 
those of the reference method by point and interval hypothesis tests, which showed 
excellent agreement and there is no significant difference in accuracy and precision of 
methods compared. 
The fifth chapter includes two simple, rapid, sensitive and economical 
spectrophotometric methods for the quantification of lisinopril in drug formulations. 
Method A utilizes the reaction of primary amino group of the drug with N-
bromosuccinimide in acetone to form a yellow coloured product, which absorbed 
maximally at 353 nm. Method B is based on the charge transfer complexation reaction 
of drug with chloranil in 1,4-dioxan-acetonitrile medium to give purple coloured 
product. Beer's law is obeyed in the concentration ranges of 10 - 200 and 24 - 600 ^g 
ml'' with molar absorptivity of 1.40 x 10^  and 7.28 x 10^  1 mof'cm"' for methods A 
and B, respectively. The regression analysis yields the calibration equations: 
A = -2.44x 10""+3.16 X lO'^Cand 
A = 5.39x 10'"+ 1.65 X 10'^ C 
for methods A and B, respectively. The correlation coefficient for both the calibration 
curve is found to be 0.9999. The intra and interday precision were less than 1.60 %. 
The optimum experimental conditions for the proposed methods were investigated. 
Methods A and B have been successfully applied for the analysis of lisinopril in drug 
formulations. The results are validated statistically and compared with those of British 
pharmacopoeia method. 
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Chapter 1 
^eneraC Introduction 
Driven by chemistry but increasingly guided by pharmacology and clinical 
sciences, drug research has contributed more to the progress of medicine during the 
past century than any other scientific factor. Chemistry, pharmacology, microbiology 
and the biochemistry helped shape the course of drug discovery and bring to a level 
where new drugs are no longer generated solely by the imagination of chemists but 
result from a dialogue between biologists and chemists. This dialogue, centered on 
biochemical mechanism of action, stems from the understanding of biological 
structure and function and gives rise to the creation of novel chemical structures. 
Drug development begins with the discovery of a drug molecule that has 
demonstrated therapeutic value to control, combat, prevent or cure diseases. The 
synthesis and characterization of such drug molecules i.e. active pharmaceutical 
ingredients (APIs) and their testing to generate preliminary safety and therapeutic 
efficacy data are prerequisites to identification of drug candidates for further detailed 
investigations. The preclinical or early drug development stage where these 
preliminary data are generated usually includes single and repeat-dose animal 
toxicology studies. 
Prior to embarking on major investigations on the drug candidate, it is prudent 
to understand the physical and chemical properties of API (preformulation studies) 
and their impact on dosage form selection and design, impurity profiles of the API, 
and the stability of the drug molecule. Quantification of the impurities and 
identification of those impurities above the established threshold is essential to 
evaluate the toxicity profiles of these impurities to distinguish these from that of the 
API, when applicable. Also critical is the information on stability of the API by itself 
and in formulated material to establish shelf life (expiration dates) of the API by itself 
and in its formulated state so that the identity, purity, and strength of the API can be 
assured during all phases of clinical trials and data from human clinical studies are 
reliable for the evaluation of toxicity and efficacy. The investment made on early 
developing and validating analytical methods for their robustness can minimize the 
need for further revision and solidify fiirther progress in drug development. 
Specific dosage form- related investigations should translate the information 
available on physicochemical properties of the drug substance to the formulation of 
the product. The main emphasis is on understanding the properties of the API and 
resulting interaction or compatibility with the excipients to achieve the desired 
formulation that produces a consistently high quality drug product during 
manufacturing. For solid dosage forms, crystal properties, solubility, particle size, 
wettability, flow and other information should be considered for optimization of 
mixing, granulation, and dissolution. Stability of the drug substance and retention of 
the crystal properties of the active drug substance during various phases of the 
manufacturing process will require investigation, as well as the blend and dosage 
form content uniformity. 
For semisolids, such as creams and ointments, similar consideration of 
solubility, stability, and preservative effectiveness would apply. For liquid dosage 
form, solubility and stability will be important consideration for oral liquids, and in 
addition, viscosity for suspensions. For antibacterial liquid dosage form preservative 
stability and effectiveness should also be considered. For liquid dosage forms with 
ophthalmic and opticules, the method of sterilization and its effect on stability of the 
API and excipients assume special significance for inhalation products, control of 
particle size of delivered medication (which should be < 5|a) is a significant 
component of preformulation development. Inhalation aerosols should be formulated 
sterile. Therefore, the effect of the method of sterilization on the stability of excipients 
and API should be an important consideration. 
Assurance of sterility for parenteral product is critical, and the effect of the 
method of sterilization on the excipient, drug substance, and preservative (when 
applicable) stability requires investigation. For dosage form where preservatives are 
used, in addition to chemical studies, antimicrobial properties of the preservatives 
should be investigated to assure the preservative effectiveness. Compendial tests 
(antimicrobial preservative effectiveness tests, microbial limits test and sterility test, 
and biological assay test for antibiotics) appropriate to as specific dosage form should 
be tested to evaluate the microbiological component during preformulation studies 
Origin of impurities 
Impurities in the drugs are originated from various sources and phases of 
synthetic process and preparation of pharmaceutical dosage forms. A sharp difference 
between the process- related impurities and degradation products is always not 
possible. However, majority of the impurities arc characteristic of synthetic route of 
the manufacturing process. Since there are several possibilities of synthesizing a drug, 
it is possible that the same product of different sources may give rise different 
impurities. For example, in some of the recent papers, the impurities profiles of 
orbofiban [2] trimethoprim [3], and fluoxetine HCl [4] originated fi:om different 
sources have been described. Generally the origin of impurities could be from any of 
the following steps during synthesis. 
• Last intermediate of synthesis 
• Products of incomplete reaction during the synthesis 
• Products of over reaction 
• Impurities in the starting materials of the synthesis 
• Impurities originating from the solvents of the reaction 
• Impurities originating from the catalysts 
• Products of the side-reactions 
• Degradation product as impurities 
• Enantiomeric impurities 
• Residual solvents 
• Inorganic impurities 
• Impurities in excipients 
• Polymorphs as impurities 
Types of impurities 
Impurities associated with the APIs are classified into three groups for 
regulatory purposes as organic, inorganic and residual solvents [5]. 
• Organic impurities may arise from the starting material, (most often form the 
isomeric impurities) synthetic intermediate (incomplete reaction or excess reagent 
used) byproducts, degradation products, reagents, ligands, and catalysts. The 
reagents, ligands and catalyst are less commonly found in APIs; in some cases,, 
they may pose a problem as impurities. 
• Inorganic impurities present in pharmaceutical products originate from the 
equipments used and from reagents, catalysts, heavy metals, drying agents and 
filter aids. The main sources of impurity of heavy metals are the water used in the 
processes and the reactors (if stainless steel reactors are used), where acidification 
or acid hydrolysis takes place. These impurities of heavy metals can easily be 
avoided using demineralized water and glass-lined reactors. 
ftiL^d^^ 
» Residual solvents and other volatile impurities must be detected and assayed not 
only because of their potential toxicity and deleterious environmental effects but 
also because they can impart undesirable organoleptic characteristics to drugs. 
Since residual solvents arise in excipients and occasionally in the manufacturing of 
drug products. According to International Conference on Harmonization (ICH) 
guidelines, residual solvents can be grouped into three categories based on the 
possible risk to human health [5]. Category 1 includes solvents such as benzene 
(2ppm limit) and carbon tetrachloride (4 ppm limit). The solvents belonging to 
category II are methylene chloride (600 ppm limit), methanol (3,000 ppm limit) 
pyridine (200 ppm limit), toluene (890 ppm limit), N, N-dimethyl formamide (880 
ppm limit), and acetonitrile (410 ppm limit). The solvents of the category II are 
most commonly used during the manufacturing process. Acetic acid, acetone, 
isopropyl alcohol, butanol, ethanol, and ethyl acetate are solvents of category III. 
The solvents have higher tolerence limits. ICH guidelines [6] have recommended 
daily exposure of 50 mg or less per day. 
Regulatory aspect 
Control is more important today than ever. Until the beginning of the 20th century, 
drug products were produced and sold having no imposed control. Quality was 
generally poor. Many products were patent medicines of dubious value. Some were 
harmful and addictive. In 1937, ethylene glycol was used as a vehicle for an elixir of 
sulphanilamide, which caused more than 100 deaths [7]. Thereupon the Food, Drug 
and Cosmetic act was revised requiring advance proof of safety and various other 
controls for new drugs. The impurities to be considered for new drugs are listed in 
regulatory document of the Food and Drug Administration (FDA) [8], International 
Conference on the Harmonization of the Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) [9] and the United States Pharmacopoeia 
(USP) [10]. Nevertheless, there are many drugs in existence, which have not been 
studied in such detail. The USP and National Formulary (NF) are the recognized 
standards for potency and purity of new drugs. These compendia have become official 
upon adoption of the first food and drug act. They formulate legal standards of 
quality, purity and strength of new drugs. The good manufacturing practices provide 
minimum quality standards for production of pharmaceuticals as well as their 
ingredients [11]. The ICH, which took place in Yokohama, Japan in 1995, has 
released new guidelines on impurities in new drug products [12]. These guidelines 
have a number of advantages, both for the industry and the regulators. The most 
critical aspect of the elaboration of the guidelines was the definition of the levels of 
impurities for the identification and quantification (Table 1.1). Quantification is the 
process of acquiring and evaluating data for establishing the biological safety of an 
individual impurity or a given impurity profile at the levels specified. The level of any 
impurity present in a new drug substance that has been adequately tested in safety and 
clinical studies is considered qualified. A rationale for selecting impurity limits based 
on safety consideration has to be provided. The 'Decision Tree for Safety Studies' 
(Fig. 1.1) describes consideration for the qualification of impurities when threshold 
are exceeded. This has some consequence for method development. Analytical 
procedures should be able to separate all the impurities from each other and the 
method should be optimized to separate and quantify them in the dosage forms. 
Stability studies 
The procedure for conducting stability storage studies and testing is provided 
in several ICH [13-16] and FDA guidance [17] documents. The objective of stability 
Table 1.1 ICH guidelines for identification and qualiflcation of impurities in 
bulk drugs and formulations 
Dose 
<lmg 
1-10 mg 
10-100 mg 
100-2 g 
>2g 
Threshold for 
Identification (%) 
1.0 
0.5 
0.2 
0.1 
0.1 
Qualiflcation (%) 
1.0 
1.0 
0.5 
0.2 
0.1 
Decrease degradation 
product level below 
threshold 
Yes 
Above Threshold 
No 
No 
Qualified 
Yes 
Structure elucidated? 
Yes 
Yes 
Toxicity documented and sufficient? 
No 
Related to others 
with known toxicity? 
Yes Acceptable 
justification? 
No No 
Consider patient 
population and 
duration of use 
Yes 
Qualified 
Consider need for: 
1. Genotoxicity studies (point mutation chromosomal aberration) 
2. General toxicity studies (one species, min. 14 days, max. 90 days) 
3. Other specific toxicity endpoint, as appropriate 
I 
Adverse Effects 
Yes 
Consider additional testing 
or removal / lowering level 
of degradation product 
No 
Qualified 
Fig. 1.1 The 'Decision Tree For Safety Studies' 
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testing is to provide evidence of how the quality of a drug product varies with time 
under the influence of a variety of environmental factors such as temperature, 
humidity, and light. This information is used to establish container closure 
specifications, storage conditions, retest periods, and shelf lives (expiration dates) 
for drug substance and drug product. The ICH guidelines also provide information 
on photostability testing of drug substance and drug products [14], stability testing 
of new dosage forms [15], and ways to minimize the number of samples stored and 
tested by bracketing and matrixing [16]. 
Analytical support to stability programmes begins with the stability evaluation of drug 
substance at the preformulation and preclinical stages of drug development. 
Information on the intrinsic stability of an API should be integral part of stability 
evaluation of the API £ind the drug product. To understand the intrinsic stability of the 
API, forced degradation or stress studies are normally performed on the drug 
substance. Stress testing is usually carried out on a single batch of drug substance. 
ICH [13] recommends conducting forced degradation studies for temperature stresses 
in 10°C increments above the accelerated storage temperature condition of 40°C 
(50°C, 60°C, etc.), at a relative humidity of 75 % or greater. In addition, stresses such 
as photodegradation, oxidation, hydrolysis across wide pH ranges (acid and base 
hydrolysis) are recommended, the data generated will help develop stability -
indicating method that can unequivocally separate the API from others and help 
elucidate the pathways of degradation of API. 
A stability-indicating method is required for the evaluation of samples from 
long- term and accelerated storage stability studies and can also be used for assay and 
impurity profiling in drug substance and drug product, stability information will 
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help in developing early-on strategies for formulation, packaging, and storing of the 
API and the drug product (e.g., light resistant packaging). The data from long term 
(25°C ± 2°C and 60 % ± 5% relative humidity (RH) for 12 months) and accelerated 
(40°C ± 2°C and 75 % ± 5% RH for 6 months) stability studies are necessary in 
defining storage conditions and establishing expiration dating for drug substance or 
drug product [13, 17] APIs and drug products may be assessed at higher temperatures, 
especially if there is a potential for exposure to uncontrolled environments such as 
warehouse or shipping conditions 
Ahuja [18] and Gorog [19] have published books covering different aspects 
of impurities, including the government regulations and guidelines and identification 
and monitoring of impurities found in drug products. A recent publication covered 
the importance of impurity analysis in pharmaceutical products [20]. A number of 
recent articles [21-26] have described the analysis of various drugs and their 
impurities using HPLC-electrospray tandem mass spectrometry, GC/MS, LC, 
Capillary electrochromatography, LC-MS-MS, and HPLC. 
Specifications for post approval manufacture, release, and shelf Life 
ICH guidance Q6A [27] addresses specifications (test procedures and 
acceptance criteria) for drug substance and drug products. Specifications are part of a 
total quality control strategy, proposed and justified by the applicants and approved 
by regulatory authorities to assure product quality and consistency of the drug 
substance and drug product during manufacture and through its shelf life. Release 
specification should be influenced by the stability profile of the drug product and 
statistical bounds for release established through assessment of the validated process. 
When tested according to the analytical test procedure listed in the application, the 
API, the excipients, and the drug product should all meet the listed acceptance 
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criteria in order to be released. The regulatory acceptance criteria for drug products 
are generally the same from release throughout shelf life. As stated in ICH guidance, 
the concept of different acceptance criteria for release versus shelf life specification 
applies to drug products only [27]. The following is a summary of specification for 
drug substance and drug product for product release and shelf life evaluation (Fig. 
1.2). 
Assay methods 
From the beginning of official pharmaceutical analysis the aim of including 
assay methods in compendial monographs has been to characterize the quality of 
bulk drug materials by setting limits of their active ingredient content. In recent 
years, the assay methods included in compendial monographs are titrimetry, 
spectrometry, chromatography, capillary electrophoresis and electro analytical 
methods. The present state-of-the-art is reflected by the data in the Table 1.2 based 
on the recent edition of European [28] and US [29] pharmacopoeias. 
Titrimetric methods 
It is apparent from Table 1.2 that in majority of cases titrimetric methods are 
still used. Signs of some modernization are the spreading of non-aqueous titration 
method expanding the field of application of titrimetric methods to (very) weak 
acids and bases as well as potentiometric end point detection improving the 
precision of the methods. Advantages of these methods are saving time and labour, 
high precision and the fact that there is no need of using reference standards. 
Recently titrimetric methods have been used for the determination of captopril 
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Table 1.2: Proportion of various analytical methods prescribed for the assay of 
bulk drug materials in Ph. Eur. 4 [28] and USP XXVII [29] 
Method 
HPLC 
GC 
Titration 
Acid-base 
Aqueous mixtures 
Indicator 
Potentiometric 
Non-aqueous 
Indicator 
Potentiometric 
Redox (lodometry, Nitritometry, ( ;tc.) 
Other (complexometry, argentometry, etc.) 
UV-vis spectrophotometry 
Microbiological assay (antibiotics) 
Other (IR, NMR, polaremetry. fluorimetry, 
absorption spectroscopy, polarography, gravimetry 
atomic 
etc.) 
Ph. Eur. ^  
(%) 
15.5% 
2 % 
69.5 % 
57.5 % 
21 % 
6.5 % 
14.5 % 
36.5 % 
9.5 % 
27% 
6.5 % 
5.5 % 
9.5 % 
3 % 
0.5% 
i USP 27 
(%) 
44% 
2.5 % 
40.5 % 
29.5 % 
5.5 % 
4.5 % 
1% 
24% 
14% 
10% 
5.5 % 
5.5 % 
8.5 % 
2.5 % 
2 % 
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[30], albendozole [31] and gatifloxacin [32] in commercial dosage forms. 
Sparfloxacin [33] was determination by non-aqueous titration method. 
Chromatographic methods 
HPLC methods appeared for the first time for the assay of bulk drug materials in 
1980 [34]. As seen in Table 1.2, this has become the predominant method in USP 
XXVII [29] and - although to a lesser extent- it is one of the most widely used 
methods also in Ph. Eur. 4 [28]. 
The specificity of this method is excellent and at the same time sufficient 
precision is also attainable. However, it has to be mentioned that the high specificity, 
precision and accuracy are attainable only if lengthy system suitability tests are 
carried out prior to the HPLC assay. For the reason the price to be paid for the high 
specificity, precision and accuracy is also high. Fig. 1.3 shows the pie diagram 
indicating the percent usage of various chromatographic techniques from which it 
becomes very clear that HPLC has been the main technique used for analysis of 
impurities in drugs. The choice of proper detection mode is crucial to ensure that all 
the components are detected. With UV detection, this problem could be overcome 
by using a multiple wavelength scanning programme which is capable of monitoring 
several wavelengths simultaneously. It provides assurance that all the UV-absorbing 
components are detected, if present in sufficient quantity. Photodiode-array detectors 
are useful in determining the purity of enantiomeric drugs by HPLC. Most workers 
used the reversed-phase mode with UV absorbance detection whenever appropriate, 
because this provided the best available reliability, analysis time, repeatability and 
sensitivity. In fact, this technique has set the standard against which others are 
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HPTLC 
9% 
LC-MS 
8% 
GC-MS 
2% 
MEKC 
3% 
HPLC 
53% 
Fig. 1.3: Pattern of use of different chromatographic techniques employed 
for analysis of impurities in drugs 
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compared (Fig. 1.4.) Several drugs have been assayed in pharmaceutical 
formulations [35 - 39] and in biological fluids [40 - 42] using HPLC. Thus, HPLC 
provides a major service in answering many questions posed by pharmaceutical 
industry. However, the limitations of HPLC include the cost of columns, solvents 
and a lack of long term reproducibility due to the proprietary nature of column 
packing. Liquid chromatography combined with mass spectrometry (LC-MS) is 
considered as one of the most important techniques of the last decade of 20"^  century 
[43]. It became the method-of-choice for analytical support in many stages of quality 
control and assurance within the pharmaceutical industry [44,45]. Recently HPLC-
MS has been used for assay of drugs [46 - 51]. 
Gas chromatography is a dynamic method for separation and detection of 
volatile organic compounds. Gas liquid chromatography commands a significant 
role in the analysis of pharmaceutical product [52]. The advent of high-molecular 
weight products such as polypeptides, or thermally unstable antibiotics limits the 
scope of this technique. Its principal limitation rests in the relative non-volatility of 
the drug substances. Therefore, derivatization is virtually mandatory, but the 
techniques for producing volatile derivatives of drugs are legion. Recently, gas 
chromatography has been used for assay of drugs such as isotretinion [53], 
fluoxetine, fluvoxamine, clomipramine [54] and nicotine [55]. 
Capillary electrophoresis (CE) is a relatively new analytical technique based 
on the separation of charged analytes through a small capillary under the influence 
of an electric field. In this technique solutes are seen as peaks as they pass through 
the detector and the area of each peak is proportional to their concentration. 
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UV- Ultra Violet detector 
EL- Evaporative Light Scattering detector 
FL- Fluorescence detector 
EC- Electro Chemical detector 
IE- Ion Exchange detector 
UV 
94% 
Fig. 1.4: Usage of different detectors for HPLC analysis of drugs 
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which allows quantitative determinations. CE separations are generally more 
efficient, can be performed on a faster time scale, require only nanoliter injection 
volumes, and in most cases, take place under aqueous conditions. These four 
characteristics of CE have proven to be advantageous for many pharmaceutical 
applications. Several reports have appeared on the application of this technique in 
the routine drug analysis [56 - 58]. Different modes of capillary electrophoresis such 
as capillary zone electrophoresis [59 - 63], miscellar electrokinetic chromatography 
[64-66] isotachophoresis [67,68], capillary gel electrophoresis [69,70] isoelectric 
focusing [71,72] and affinity capillary electrophoresis [73,74] have been developed 
and applied for pharmaceutical purity testing and in bioanalysis of drugs. 
Thin layer chromatography is a popular technique for the analysis of a wide 
variety of organic and inorganic substances, because of its distinct advantages such 
as minimal sample clean-up, wide choice of mobile phases, flexibility in sample 
distinction, high sample loading capacity and low cost. TLC is a powerful tool for 
screening unknovra materials in bulk drugs [75]. It provides a relatively high degree 
of assurance that all possible components of the drug are separated. The high 
specificity of TLC has been exploited to quantitative analytical purpose using spot 
elution followed by spectrophotometric measurement. The TLC method is also 
prescribed in USP XX VII e.g. as "single- steroid Assay (511)" [29]. TLC has been 
utilized for the determination of some steroids [76], pioglitazone [77], celecoxib[78] 
and quinapril and hydrochlorothiazide in combination tablets[79]. 
High performance thin layer chromatography (HPTLC) is a fast separation 
technique and flexible enough to analyze different kind of samples. This technique is 
advantageous in many ways as it is simple to handle and requires short analysis time 
to analyze the complex or the crude sample cleanup. HPTLC evaluates the entire 
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chromatogram with a wide variety of techniques and parameters without time 
constrains. Moreover, there is simultaneous but independent development of 
multiple sample and standards on each plate, leading to an increased reliability of 
results. HPTLC has been used to quantitate drugs as ethinloestradiol and 
cyproterone [80], hydrochlorothiazide [81] and vitamin C and dipyrone [82]. 
Laboratory automation was initiated in the second half of the XX century. 
Steward in the U.S. as well as Ruzicka and Hansen in Denmark, created the flow 
injection analysis (FIA) technique for the automation of chemical procedure [83,84]. 
The introduction of this technique came to revolutionise the concept of automation 
in chemical analysis by allowing instrumental measurement to be carried out in the 
absence of physical equilibrium (without homogenization of sample and carrier / 
reagent) and chemical equilibrium (without completing the reactions) [85 - 88]. 
FIA has got some clear advantages over conventional techniques: 
• Fast determination and on-line sample pre-treatment permitting almost real- time 
monitoring. 
• High sampling frequency allowing high resolution of the dissolution processes. 
• Low sample consumption, introducing minimum disturbance to the volume of 
dissolution medium, particularly when high sampling frequency is involved. 
• Parallel testing in multivessels using a single detector. 
• Simultaneous determination of multicomponents in dosage form. 
• High stable sample pre-treatment and detection capable of continuous operation 
over extended periods 
• Continuous baseline monitoring and on-line recalibration of detection system. 
• Low reagent consumption. 
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Following the general application of computers in routine laboratory a 
second generation of flow analysis was proposed by Ruzicka and Marshall in 1990 
designated sequential injection analysis (SIA) [89]. As with the FIA, this is a non-
segmented continuous flow technique based on the same principle of controlled 
dispersion and reproducible manipulation of the FIA concept, but whose mode of 
functioning is based on the concept of programmable flow. 
The FIA technique has lent an important contribution to the development of 
automation in pharmaceutical analysis and its advantages are well documented in 
several review articles [90 - 95] as well as in a specialized monograph [96]. 
The introduction of SIA has awakened the interest of the scientific community 
for automation in the pharmaceutical area [97]. Many articles dedicated to 
pharmaceutical analysis have been published, including two review articles [98,99], 
applying sequential injection analysis to a wide variety of matrices, such as solid 
matrices (tablets, capsules), pastes (ointments, creams), liquids (emultions, 
suspensions, solutions) and covering various active ingredients with different 
therapeutic activities. By benefiting from the advantages in the economy of reagents 
and the elevated sampling rates, the majority of the applications are dedicated to the 
determination of active ingredients for quality control in pharmaceutical 
formulations. 
UV-Visible spectrophotometry 
Another group of methods in pharmacopoeias are spectrophotometric 
methods based on natural UV absorption and chemical reactions [100]. The 
advantages of these methods are low time and labour consumption. The precision of 
these methods is also excellent. The use of UV-VIS Spectrophotometry especially 
applied in the analysis of pharmaceutical dosage form has increased rapidly over the 
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last few years [101 - 104]. The colorimetric methods are usually based on the 
following aspects: 
• Complex-formation reaction 
• Oxidation-reduction process 
• A catalytic effect 
It is worth mentioning that colorimetric methods are frequently used for the 
assay of bulk materials. For example, the blue tetrazolium assay is used for the 
determination of corticosteroid drug formulations [105,106] and is included in the 
recent edition of US Pharmacopoeia ((351) "Assay for steroids" [29]). The 
colorimetric method is also utilized for the determination of cardiac glycosides and 
is presented in recent edition of European Pharmacopoeia [28]. Several approaches 
using spectrophotometry for determination of active pharmaceutical ingredients in 
bulk drug and formulations have been reported and details of these methods are 
recorded in Table 1.3 [107 - 150]. 
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Table 1.3: Quantitative analysis of drugs in pharmaceutical formulations by 
UV-visible spectrophotometric procedures 
Name of drug Reagents used Am; ax(nm) References 
Acetoaminophen 
Amiodarone HCl 
Amlodipine besylate 
Amoxycillin & 
ampiciliin 
m-Cresoi 
p-Chloranilic acid 
2,3-Dichloro 5,6- dicyano 
1,4- benzoquinone 
p-Chloranilic acid 
Ninhydrin in DMF medium 
2,3-Dichloro 5,6- dicyano 
1,4- benzoquinone 
Ascorbic acid 
KIO, 
Ampiciliin, amoxycillin Folin ciocalteau phenol 
& carbenicillin 
Ascorbic acid l-Chloro-2,4-dinitrobenzene 
Benidipine HCl 
Diclofenac sodium 
Diltiazem HCl 
Methanol 
Tris buffer 
Sodium metavanadate 
Bromothymol blue 
Bromophenol blue 
640 
535 
575 
530 
520 
107 
108 
108 
540 109 
595 110 
580 111 
111 
112 
750,770 
&750 
380 
238 
284,305 
750 
415 
415 
113 
114 
115 
116 
117 
118 
118 
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Famotidine 
Fiunarizine 
dihydrociiloride 
Irbesartan 
Lisiiiopril 
Labetalol HCl 
Losartan potassium 
Levodopa 
Methyldopa 
L-dopa 
Menadione 
Metoprolol tartrate 
Mometasone fiiroate 
Nalidixic acid 
Bromocresol green 
KMn04 in alkaline medium 
Ninhydrin 
Iodine 
Potassium iodate and iodide in 
aqueous medium 
7,7,8,8-Tetracyanoquinodimethane 
p-Chloranilic acid 
Ninhydrin 
Ascorbic acid 
Sodium nitroprusside & 
hydroxylamine hydrochloride 
KMn04 in alkaline medium 
Ce(IV) nitrate in H2SO4 medium 
Ce(IV) nitrate in H2SO4 medium 
NaOH 
NaOH in the presence of amine 
KMn04 in alkaline medium 
Ninhydrin 
Methanol 
Persulphate in alkaline medium 
415 
610 
590 
295,355 
118 
119 
120 
121 
352 
743 
525 
595 
530 
695 
122 
123 
123 
124 
124 
125 
603 
510 
550 
300 
450 
610 
595 
248 
320,390 
126 
127 
127 
128 
129 
130 
131 
134 
133 
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Nicorandil 
Nifedipine 
Norfloxacin 
Carbinoxamine 
Pantoprazole sodium 
Perindopril erbumine 
Ramipril 
Silymarin 
Brucine-sulphanilic acid in H2SO4 410 
medium 
3-Methyl-2-benzotliiazoline 560 
hydrazone HCl-metol 
KMn04 in neutral medium 
4-Methyl amino phenol and K2Cr207 525 
Bromocresol green 
Bromophenol blue 
Bromothymol blue 
Eriochrome Black T 
KOH in dimethylsulphoxide 
Ammonium molybdate 
KMn04 in alkaline medium 
Cu (II) & eosin 
Potassium ferricyanide and 725 
ammonium ferric sulphate 
l-Chloro-2,4-dinitrobenzene 
dimethyl sulphoxide 
in 420 
Potassium iodate and potassium 352 
iodide in aqueous medium 
KMn04 in neutral medium 530 
3-Methyl-2-benzothiazoline 430 
hydrazone & potassium persulphate 
134 
134 
530 
415 
415 
415 
520 
430 
830 
603 
538 
135 
136 
137 
137 
137 
137 
138 
138 
139 
140 
141 
142 
143 
144 
145 
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Trimethoprim 
Thyroxine 
Persulphate in alkaline medium 
Nitrous acid 
355 
420 
146 
147 
Verapamil HCl Chloramine T 
N-Bromosuccinimide 
Potassium metaperiodate 
Tropaeolin 000 No.l 
425 
415 
425 
400 
148 
149 
150 
150 
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The derivative method has found applications not only in UV-
Spectrophotometry but also in infrared [151], atomic absorption, flame 
spectrophotometry [152,153], and fluorimetry [154,155]. The use of derivative 
spectrometry is not restricted to special cases, but may be of advantage whenever 
quantitative study of normal spectra is difficult. Its disadvantage is that the 
differential degrades the signal-to -noise ratio, so that some form of smoothing is 
required in conjunction with differentiation [156] 
For a single-peak spectrum, the first-derivative is a plot of gradient dA / dX of 
the absorption envelop versus wavelength and features maximum and minimum; 
the vertical distance between these is the amplitude, which is proportional to the 
analyte concentration; theoretically, dA / d>^  is zero at A,max for the band in the 
normal spectrum. The second-derivative spectrum, d ^ A / dX^ versus wavelength, 
has two maxima with a minimum between them, at A.max of the normal absorption 
band [157]. In principle, both peak-heights (measured from d A / dX, = 0) are 
proportional to the analyte concentration but the amplitude can also be measured 
by the so-called tangent method, in which a tangent is drawn to the maxima and 
amplitude is measured vertically from tangent to the minimum [158]. The . 
differentiation discriminated against broad bands, emphasizing sharper feature to 
an extent that increases with increasing derivative order, because for bands 
(Gaussian or Lorentzian) the amplitude Dn of the nth derivative is related to the n"' 
power of the inverse of the band width, W, of the normal spectrum [159]: 
Dn a(l/w)" 
Thus, for two bands A and B of equal absorbance but different width, the 
derivative amplitude of the sharper band (A, for example) is greater than that of 
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the broader (B) by a factor that increases with increasing derivative order 
[160,161]: 
Dn / Dn a (WB / WA ) " 
For the reason, the use of derivative spectra can increase the detection 
sensitivity [162 -164] of minor spectral features. For quantitative analysis, if 
Beer's law is obeyed for normal spectrum, the following equation can be obtained: 
d" A / d X" = d" 6 / d X M C 
Where A = Absorbance, e = molar absorptivity, 1 = cell path-length and C= 
concentration of the analyte and this forms the basis of analytical determinations 
[165]. Derivative spectrophotometry has been applied for quantification of drugs 
in pharmaceutical preparations [166-169]. 
Near infrared spectroscopy (NIRS) is a fast and non-destructive technique 
that provides multi constituent analysis of virtually any matrix. In recent years, NIR 
spectroscopy has gained wide acceptance within the pharmaceutical industry for raw 
material testing, product quality control and process monitoring. The growing 
pharmaceutical interest in NIR spectroscopy is probably a direct result of its major 
advantages over other analytical techniques, namely, an easy sample preparation 
without any pretreatments, the possibility of separating the sample measurement 
position and spectrometer by use of fiber optic probes, and the prediction of 
chemical and physical sample parameters from one single spectrum. The major 
pharmacopoeias have generally adopted NIR techniques. The European [170] and 
United States pharmacopoeia [171] address the suitability of NIR instrumentation 
for use in pharmaceutical analysis. NIR spectroscopy combined with multivariate 
data analysis opens many interesting perspectives in pharmaceutical analysis, both 
qualitatively and quantitatively. Within the last 10 years the number of publications 
29 
describing quantitative NIR measurements of active ingredient in intact tablets has 
increased tremendously [172-186]. 
Since the first report appeared in 1996 [187] describing the use of NMR 
spectroscopy to screen for potential drug molecules, the field of NMR based 
screening has evolved rapidly. Over the last few years, a variety of novel approaches 
have been introduced and found widespread application in both pharmaceutical and 
academic research settings. Recently NMR finds its application in quantitative 
analysis in order to determine the impurity profile of the drug [188], in the 
characterization of the composition of the drug products and in quantitation of drugs 
in pharmaceutical formulations and biological fluids [189,190]. 
A gradual increase in the number of articles on the application of Fluorimetry 
and Phosphorimetry in quantitative analysis of various drugs in dosage forms and 
biological fluids have been noticed in recent past [191-193]. 
The application of electrochemical techniques to the analysis of drugs and 
pharmaceuticals has increased greatly over the last few years. The renewed interest 
in electrochemical techniques can be attributed in part to more sophisticated 
instrumentation and to increased understanding of the technique themselves. Here 
the application of the various electrochemical modes in the analysis of drugs and 
pharmaceuticals are presented in Table 1.4 [194-207]. 
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Table 1.4: Determination of drug by various electrochemical techniques 
Technique Drugs determined Remark Reference 
Voitammetry Isoniazid 
Danazole 
Ethinylestradiol 
Lamotrigine 
Rabeprazole 
Clozapine 
Atenalol 
Polarography Artemether 
Josamycin 
Ciclopirox olamine 
Using overoxidized poly 194 
pyrrole glassy carbon 
modified electrode 
Square wave adsorptive 195 
stripping voitammetry 
Performed at a mercury 196 
electrode 
Experimental parameters 197 
optimized 
At glassy carbon electrode 198 
Performed at a mercury 199 
electrode 
Using nanogold modified 200 
indium tin oxide electrode 
201 
202 
203 
Amperometry Salbutamol 
Potentiometry 
Verapamil 
Chlorpromazine 
Clobutinol HCl 
204 
205 
206 
207 
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The field of kinetic method of analysis has been developing since the late 
1950s. Although the field is now mature, it has recently been undergoing a major 
resurgence in activity. The renewed interest can be attributed to advances that have 
been made in principles, in automated instrumentation, in understanding chemical 
and instrumentation, in understanding chemical and instrumental systems, in data 
treatment methods, and in analytical application. Also, it is becoming clear that the 
kinetic approach to analytical chemistry is rather general with several advantages 
over traditional equilibrium approach [208 - 210]. Essentially, kinetic methods rely 
on the measurements of concentration changes (detected via signal changes) in a 
reactant (which may be the analyte itself) with time after the sample and reagents 
have been mixed manually or automatically. There are several approaches that can 
be used for the determination of single components in the absence of any kinetic 
interference (Table 1.5). However, fixed-time and initial rate methods have been 
used more frequently for the determination of drugs in pharmaceutical formulations 
and biological fluids [211-213]. Kinetic automatic techniques are generally based 
on open systems among the most popular of which are stopped flow system [214] 
and the continuous addition of reagent (CAR) technique [215,216]. Several drugs 
have been determined by using the CAR technique with photometric [217] and 
fluorimetric detection [218]. The use of catalysts to accelerate analytical reactions is 
feasible with both reaction rate and equilibrium determinations. In this concern, the 
use of micellar media in kinetic method is recently encouraged to enhance the rate of 
reaction (through micellar catalysis) and may additionally improve the sensitivity 
and selectivity which in turn reduce the analysis time for the analyte [219-221]. 
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Table 1.5: Several kinetic approaches for determination of single component 
A. Direct-computation methods B. Curve-fitting methods 
1. Integral methods 
a. Fixed-time 
i. One-point 
ii. Two-point 
iii. Multipoint 
b. Variable-time 
i. One-point 
ii. Two-Point 
2. Rate methods 
a. Initial-rate 
b. Intermediate-rate 
3. Integrated-signal methods 
1. Integral methods 
a. Linear responses 
b. Non-linear response 
i. Direct computation 
ii. Predictive (extrapolation) 
2. Rate methods 
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Multicomponent kinetic determinations, often called as differential rate methods, are 
also receiving popularity in the field of pharmaceutical research [222,223]. Two new 
approaches i.e. kinetic wavelength pair method [224] and H-point standard addition 
method [225] have been proposed for dealing with overlapping spectra of 
components in the binary mixtures. 
METHOD VALIDATION 
Validation of analytical procedure is a vital aspect not just for regulatory 
purposes, but also for their reliable long-term application. However, a sensible 
validation is also essential from a business perspective because analytical data are 
the basis of many decisions such as batch release, establishment / verification of 
shelf life, etc. 
ICH guidelines should be regarded as basis and philosophy of analytical 
validation, not as a check list. "// is the responsibility of the applicant to choose the 
validation procedure and protocol most suitable for their product [226]. Suitability 
is strongly connected with the requirement and design of the given analytical 
procedure, which obviously varies and must, therefore, be reflected in the analytical 
validation. This includes the identification of the performance parameters relevant 
for the given procedure, the definition of appropriate acceptance criteria, and the 
appropriate design of validation studies. In order to achieve this, the analyst must be 
aware of the fundamental meaning of these performance parameters, calculations, 
and tests and their relationship to his specific application. A lack of knowledge or 
(perhaps) a wrong understanding of "efficiency" will lead to validation results that 
address the real performance of the analytical procedure only partly or insufficiently. 
The process for the development, validation and use of analytical method is shown 
in Fig. 1.5. 
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Calibration model, 
range and linearity 
Define performance 
specifications 
i r 
Devise development 
experiments 
r 
Execute and 
evaluate results 
I 
Plan method validation 
experiments 
; 
Precision and accuracy 
Collate results 
Analyte stability 
Apply validated method 
Fig. 1.5: The process of development, validation and routine use 
of an analytical method. 
35 
Several International Organizations and Regulatory Authorities are involved in 
fixing the criteria for the validations and are listed in Table 1.6. It has been agreed 
that the parameters for evaluation of method reliability and overall performances 
are: 
• confirmation of identity 
• solution stability 
• selectivity/ specificity 
• linearity 
• accuracy and precision 
• limits ofdetection and quantitation 
• recovery 
• robustness/ ruggedness 
• equivalence testing 
The overall validation strategy consists of four components, which are 
prevalidation [227,228], validation proper, study proper and statistical analysis. 
Among all of the International Organizations, the ICH guidelines achieved a 
great deal in harmonizing the definitions of the required validation characteristics 
and their basic requirements. The International Conference on Harmonization of the 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 
has harmonized the requirements in two guidelines [229,230]. 
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Table 1.6 Validation of analytical methods: International definitions 
Organization Applicability Remarks 
lUPAC 
ILAC 
WELAC 
ICH 
ISO 
Worldwide 
Worldwide 
Europe 
Europe, Japan, USA 
Worldwide 
Only pharmaceutical products 
Lack definition of selectivity and specificity 
Abbreviations: 
lUPAC, International Union of Pure and Applied Chemistry 
ILAC, International Laboratory Accreditation Conference 
WELAC, Western European Laboratory Accreditation Co-operation 
ICH, International Conference on Harmonisation 
ISO, International Organization for Standardization 
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The first one summarizes and defines the validation characteristics needed for 
various types of test procedure. The second one extends the previous test to include 
the experimental data required and some statistical interpretation. These guidelines 
serve as a basis worldwide both for regulatory authorities and industries and bring 
the importance of a proper validation to the attention of all those involved in the 
process submission. In order to fulfill the validation responsibilities properly, the 
background of the validation parameters and their consequences must be understood. 
The validation characteristics and their minimum number of determinations required 
if applicable are given in Tabic 1.7 [230]. 
Confirmation of identity 
In general analytical methods consist of a measurement stage, which may be 
preceded by an isolation stage. It is necessary to establish that the signal or reaction 
produced at measurement stage is only due to the analyte and not due to something 
chemically or physically similar or arising as a coincidence. This is the confirmation 
of identity. Whether or not other compounds interfere with the measurement of the 
analyte will depend on the effectiveness of the isolation stage if it was part of the 
method, as well as the specificity / selectivity of the measurement stage. 
Selectivity / Specificity 
Selectivity of a method refers to the extent to which it can determine 
particular analyt(s) in a complex mixture without interference from other component 
in the mixture. The term selectivity and specificity have often been used 
interchangeably. The term specific generally refers to a method that produces a 
response for a single analyte only, while the term selective refers to a method that 
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Table 1.7: Validation characteristics normally evaluated for the different types 
of test procedure [229] and the minimum number of determinations required 
(if applicable) [230] 
Validation 
cliaracteristics 
Specificity'' 
Linearity 
Range 
Accuracy 
Precision 
Repeatability 
Intermediate 
Precision/ rep-
roducibility' 
Detection limit 
Quantitation 
limit 
Minimum 
number 
-
5 concentrations 
-
9 determinations 
over 3 concen-
tration levels 
(e.g. 3 X 3) 
6 determinations 
at 100% or 
9 determinations 
over 3 concen-
tration levels 
(e.g.3X 3) 
2-series 
-
-
Test procedure 
Identity Impurities 
Yes 
No 
No 
No 
No 
No 
No 
No 
Quantitative 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No" 
Yes 
Limit 
Yes 
No 
No 
No 
No 
No 
Yes 
No 
Assay" 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
"Including dissolution, content potency 
''Lack of specificity of one analytical procedure could be compensated by other 
supporting analytical procedure (s). 
"^ Intermediate precision sufficient for submission. 
''May be needed in some cases. 
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provides responses for a number of chemical entities that may or may not be 
distinguished from each other. If the response is distinguished from all other 
responses, the method is set to be selective. Since very few analytical methods 
respond to only one analyte, the use of the terms selectivity is more appropriate than 
specificity. The International Union of Pure and Applied Chemistry (lUPAC) has 
expressed the view that "specificity is the ultimate of selectivity'. The lUPAC 
discourages use of the term specificity and instead encourages the use of term 
selectivity. 
The selectivity of the analytical method must be demonstrated by providing 
data to show the absence of interference with regard to degradation products, 
synthetic impurities and the matrix (excipients present in the formulated product at 
their expected levels). 
Linearity and calibration range 
Evaluation of the linearity of the relationship between the actual analyte 
concentration and the test result from the method, however, is required for 
quantitation testing for impurities, and for assay methods. The requirement for 
linearity is independent of the technology used to ascertain the analyte 
concentration. Many analytical methods are known where the relationship between 
the raw measured data and the analyte concentrations are non-linear. 
Elecfrochemical measurements, for example, rely on the Nemst equation, which 
indicates a logarithmic relationship between the cell voltage and the analyte 
concentration. Spectroscopic measurements rely on Beer's law, which also expresses 
a logarithmic relationship between the measured transmittance data and absorbance, 
absorbance being the quality that theoretically is proportional to the analyte 
concentration. 
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Using spectroscopy as the basis for the discussion here, we find that while Beer's 
law shows that the measured absorbance is proportional to concentration, in practice 
many sources of interference can occur which will cause deviation from the theory. 
For example, stray light will cause deviations from linearity at low transmittance 
levels, as will excessive bandwidth of the monochromator. Saturation of the detector 
or operation at too high a signal level will make the detector response become non-
linear with respect to the optical energy, which will make the computed absorbance 
non-linear (with respect to concentration) at high energy levels (i.e. high 
transmittance of the sample). Other effects also exist. 
"Linearity is defined in section 7 of ICH guidelines [231] as "The linearity of an 
analytical procedure is its ability (within a given range) to obtain test results which 
are directly proportional to the concentration (amount) of analyte in the sample". 
The following quote is found in section III of [232]: 
"In some cases, to obtain linearity between assays and sample concentrations, the 
test data may have to be subjected to a mathematical transformation prior to the 
regression analysis". 
This quote clearly indicates that if raw data is not itself linearly related to the 
analyte concentrations, and then it may be made linear through a mathematical 
transformation. As indicated above, any suitable mathematical function may be used 
for the linearization process. The guidelines also contain the following passage (in 
section III of [232]): 
"If there is linear relationship, test results should be evaluated by appropriate 
statistical methods, for example, by the calculation of a regression line by the 
method of least squares". 
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Fig. 1.6 illustrates the definition of the dynamic range of an analytical 
method, which extends from the lowest concentration at which quantitative 
measurements can be made (limit of quantitation or LOQ) to the concentration at 
which the calibration curve departs from linearity (limit of linearity). To be very 
useful, an analytical method should have a dynamic range of at least two orders of 
magnitude. 
Accuracy 
The ICH guideline recommends the demonstration of accuracy over the 
whole working range. However, if only a narrow range is required (e.g. assay or 
impurities with a low specification limit), a six fold determination at a 100 % test 
concentration as described for the precision studies may also be used. 
Several approaches discussed in the ICH guidelines are given in Table 1.8. 
If the analytical test to be validated is compared with another procedure or 
applied to a reference substance, the probably different specificities must be taken 
into account. Therefore, statistical tests should be performed only if the systematic 
bias based on these differences can be quantified and thus corrected or are 
negligible. Otherwise, the comparison should be performed as a qualitative 
verification of plausibility or an acceptable maximum difference should be defined 
(e.g. 2.0 % for an LC assay). 
Spiking experiments for recovery investigation should be performed as 
closely to the authentic condition as possible so that possible interferences between 
the analyte and matrix can be recognized. This ranges, for example, from the direct 
preparation of the drug product with various contents of active ingredient to which 
the whole analytical procedure is applied to the addition of drug substance stock 
solution to a placebo solution. 
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Fig. 1.6. Useful range of an analytical method: LOQ = Limit of 
quantitation and LOL = Limit of linear response. 
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Table 1.8: Quantitative approaches to demonstrate accuracy according to ICH 
1230] 
Drug Substance Application of the analytical procedure to a reference 
material 
Comparison of the results with those of a second, well 
characterised procedure 
Drug Product Application of the analytical procedure to synthetic 
mixtures of drug product components 
Spiking of analyte to drug product 
Comparison of the results with those of a second, well 
characterised procedure 
Impurities Spiking of the impurity to drug substance or product 
(quantitative) Comparison of the results with those of a second, well 
characterised procedure 
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For the quantitation of the analyte, the same calibration mode as described in 
the final test procedure must be used. Again, statistical tests should be used 
carefully, especially with complex matrices and low concentrations of impurities. 
Alternatively, acceptable deviations from the theoretical recovery of 100 % can be 
defined based on the application, experiences or general statistical considerations. 
Precision 
The precision of an analytical procedure expresses the closeness of 
agreement (degree of scatter) between a series of experiments obtained from 
multiple sampling of the same homogenous sample under the prescribed conditions. 
Precision may be considered at three levels: repeatability, intermediate precision and 
reproducibility. 
Precision should be investigated using homogenous, authentic samples. 
However, if it is not possible to obtain a homogenous sample it may be investigated 
using artificially prepared samples or a sample solution. 
The precision of an analytical procedure is usually expressed as the variance, 
standard deviation or coefficient of variation of a series of experiments. 
Repeatability 
Repeatability expresses the precision under the same operating conditions 
over a short interval of time. Repeatability is also termed intra-assay precision. 
Repeatability should be assessed using: 
a) a minimum of 9 determinations covering the specified range for the procedure 
(e.g., 3 concentrations / 3 replicates each); or 
b) a minimum of 6 determinations at 100 % of the test concentration. 
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Intermediate precision 
The extent to which intermediate precision should be established depends on 
the circumstances under which the procedure is intended to be used. The applicant 
should establish the effects of random events on the precision of the analytical 
procedure. Typical variations to be studied include days, analyst, equipment, etc. It 
is not considered necessary to study these effects individually. The use of an 
experimental design (matrix) is encouraged. 
Reproducibility 
Reproducibility is assessed by means of an inter-laboratory trial. 
Reproducibility should be considered in case of the standardization of an analytical 
procedure, for instance, for inclusion of procedures in pharmacopoeias. These data 
are not the part of marketing authorization dossier. 
Robustness /Ruggedness 
International Conference on Harmonization of technical requirement for 
human use (ICH) [233] defines "robustness/ruggedness" of an analytical procedure 
as a measure of its capacity to remain unaffected by small, but deliberate variation in 
method parameters and provides an indication of its reliability during normal usage 
[234]. Ruggedness is a measure for the susceptibility of a method to srhall changes 
that might occur during routine analysis like small changes of pH values, mobile 
phase composition, temperature etc. Full validation must not necessarily include 
ruggedness testing; it can, however, be very helpful during the method development 
/ prevalidation phase, as problems that may occur during validation are often 
detected in advance. Ruggedness should be tested, if a method is supposed to be 
transferred to another laboratory [235]. 
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Significance of testing 
An important property of an analytical method is that it should be free from 
the systematic error (bias). Determining bias involves analyzing one or more 
standard reference materials whose analyte concentration is known. However, 
random errors make it unlikely that, the measured amount will equal the known 
amount even when no systematic errors are present. In order to decide whether the 
difference between the observed and standard values can be accounted for by 
random variation, a statistical test, i.e., a significant test is used for the interpretation 
of analytical data. 
• Student's /-test: Here comparison is made between two sets of replicate 
measurements made by two different methods; one is the test method while other 
is accepted (reference method). 
,._X\-X2 I «i«2 
where, 
X\ = mean from the test method 
X2 = mean from the accepted (reference) method 
n\ & ^2 ~ number of measurements 
Sp = pooled standard deviation of the individual measurements of two sets is 
given by 
A statistical /-value is calculated and compared with a tabulated value for the 
given number of tests at the desired confidence level. If /cai > hab then there is 
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significant difference between the results obtained by the two methods at the given 
confidence level. But if, c^ai < t^ab then there is no significant difference between the 
methods. It is an accuracy-indicating test. 
• F-Test: This test indicates whether there is a significant difference between the 
two methods (i.e. the new method and the accepted reference method). It can be 
represent as, 
'2 
^ = ^ 
s^ 
Where, 
Si and 82= standard deviation of method 1&2 and Si>S2 
The calculated value of 'F' is compared with the tabulated standard value at the 
selected confidence level and degree of freedom. If Fcai>Ftab then there is 
significant difference between the two methods. It is a precision indicating test. 
Interval hypothesis: 
For practical purposes, the acceptable bias can be calculated statistically 
[236]. 
For example, a test method (method 2) is considered acceptable if its true mean 
value is within ± 2.0 % of that of the reference method (method 1), i.e, 
-0.02 Hi< (|i2- ^i) < 0.02 |i, 
this can be written as 
0.98 <|i2/pii< 1.02 
which can be generalized to 
0L < ^2/^1 < 0u 
48 
where GL and 9u represents the lower and the upper acceptance limits, respectively 
when |i2 is expressed as the proportion of the reference mean [i\. Statistically, GLand 
Gu can be calculated from the relation: 
r o2*2 \ 
0' 
— 2 Stt p lab -  
X, - • - 2 ^ X 2 ^ , 4-
f c 2 . 2 \ 
2 '^ptiab 
X2 
V " 2 ; 
= 0 
The lower limit 6L and the upper limit 6u of confidence interval are obtained as 
0L = 
-b-
-b 
-^b^-
2a 
+ ^b' 
-Aac 
-4ac 
where. 
'" - 2a 
-1 S^t^ 
a = x\ 
« i 
b = -2x\X: 
C = X2 
-2 Slt,^f, 
«2 
where x\ and X2 estimates of |i.i and |j,2 based on ni and n2 measurements 
respectively. Sp^  is the variance of pooled measurements, /tab is the tabulated one 
sided /-value, with ni+n2-2 degrees of freedom at the specified level of significance. 
Testing for outliers 
When a series of replicate measurements of same quantity are made, one of 
the results will appear too different markedly from other. There is then a great 
temptation to discard this "outliers" before calculating the mean and the standard 
deviation of the data or applying statistical tests to compare the data with other 
measurements. The best known method for this purpose is Dixon's Q-test. 
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^ _ I Suspected value - Nearest value I 
I Largest value - Smallest value I 
If Qcai> Qtab at a given confidence level, then the outliers can be rejected. 
CLASSIFICATION OF DRUGS 
All the drugs according to their chemical nature can be divided into organic 
and inorganic compounds. They can be prepared synthetically or reconstituted from 
natural sources product. All the drugs having medicinal importance can be broadly 
divided into two classes. 
Chemical classification 
The drugs are classified according to their chemical structure and properties 
without taking the pharmacological action. In this class most of the drugs are having 
at least an organic substrate; further classification is done in the relevant manner. 
Pharmacological classification 
In this class the drugs are divided according to their action on the organism's 
organ (viz. heart, brain, lymphatic system, respiratory system, endocrine system, 
central nervous system etc.). Hence, these drugs are called cardiovascular, narcotics, 
analgesics, antibiotics, diuretics, and anesthetics etc. Further classification of each 
group is done according to the therapeutic / pharmacological specificity with the 
relevant organ. This thesis deals with the determination of the cardiovascular drugs 
namely losartan potassium, irbesartan, lisinopril and nicorandil. A detailed 
classification of drugs based on pharmacological action on human organs has been 
given in Scheme 1.1. 
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LOSARTAN POTASSIUM 
Losartan potassium, chemically known as 2-butyl-4-chloro-l[[2'-(lH-
tetrazol-5-yl)[l,l'-biphenyl]-4-yl]methyl]-lH-imidazole-5-methanol, is an orally 
active, non-peptide angiotensin II (type ATi) receptor antagonists for the treatment 
of hypertension. Following administration the angiotensin-II blocking activity of the 
losartan is predominantly based on its major active metabolite EXP 3174 (Fig. 1.7), 
a carboxylic acid, to which losartan is converted mainly by CYP 3A4 and 2C9 
isoenzymes [237-239]. The carboxylic acid metabolite EXP-3174 is about five times 
more potent and has longer elimination half-time (ti/2) [240]. Losartan and to a 
higher degree EXP 3174 have proven to be effectively lower elevated arterial blood 
pressure upto 24 h post dose and futhermore, to exert a beneficial effect on the 
regression of vascular and myocardial hypertrophy associated with hypertension 
[237]. The active ingredient losartan potassium has one isomeric process impurity 
(compound A) and two primary degradates previously identified as the acid dimers, 
compound E and F, which form thermally under acid conditions [241, 242] (Fig. 
1.8). The drug is very much confined to cardio protective effects, therefore it is 
important to assay losartan potassium in drug formulations. 
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(b) 
Fig. 1.7 Structure of compounds (a) Losartan Potassium; (b)EXP 3174 
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CH2OH 
H3CH2CH2CH2 
Compound A 
(Process Impurity) 
H3CH2CH2CH2 
Compound E 
(degradate) 
CH2CH2CH2CH3 
N—N 
K^ 
H3CH2CH2CH2 
CH2CH2CH2CH3 
N—N 
K^  
Compound F 
(degradates) 
Fig. 1.8 Structure of process impurity (compound A) and 
degradates (compound E and F) 
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IRBESARTAN 
Irbesartan is chemically known as 2-butyl-3- [[2-(lH-tetrazole-5-yl) (1,1-
biphenyl)-4-yl] methyl]-!,3-diazaspiro [4,4] non-l-en-4-one, which is a selective 
angiotensin II subtype I (ATi) receptor antagonist, having no agonist activity and no 
affinity for the AT2 receptor. The drug had no affinity for ai- or ai- adrenoceptors 
or serotonergic receptors.Irbesartan is indicated for the treatment of hypertension in 
adults, either alone or in combination with other hypertensive agents [243,244] . A 
fixed dose combination of irbesartan plus hydrochlorothiazide is also available, but 
is not indicated for initial therapy in patients with hypertension [245]. The 
recommended starting dosage of irbesartan is 150 mg administered once daily. In 
patients who are volume or salt depleted as a result of vigorous treatment with 
diuretics or haemodialysis, a lower starting dosage (75 mg / day) is recommended 
[243]. The maximum recommended dosage of irbesartan is 300 mg once daily. 
Irbesartan is not presently indicated for the treatment of heart failure [243-245]. A 
clinical study in the hypertensive subjects has demonstrated that irbesartan 
effectively lowers blood pressure with once- daily administration. Irbesartan has a 
bioavaliability of 60- 80 % and this is not affected by concomitant food intake. 
Irbesartan was found to undergo N- glucoronidation on tetrazole moiety during 
in vitro incubations with hepatic microsomes [246]. In addition to the glucoronide 
conjugate of irbesartan the following oxidized metabolites were identified in human 
urine. 
1) a tetrazole N -P-glucuronide conjugate of irbesartan, (2) a monohydroxylated 
metabolite resulting from co-1 oxidation of butyl side chain, (3,4) two different 
monohydroxylated metabolites resulting from oxidation of the 
spirocyclopentane ring, (5) a diol resulting from co-l oxidation of butyl side 
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chain and oxidation of the spirocyclopentane ring,(6) a Iceto metabolite 
resulting from further oxidation of co-l monohydroxy metabolite, (7) a keto-
alcohol resulting from further oxidation of co-1 hydroxyl of the diol, and (8) a 
carboxylic acid metabolite resulting from the oxidation of the terminal methyl 
group of the butyl side chain. 
A Scheme for the biotransformation of irbesartan in humans is presented in 
Scheme 1.2 „ 1 A M * If. " 
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NICORANDIL 
Nicorandil, N - [2-(nitroxy)ethyl] 3-pyridne carboxamide, is a nicotinamide 
derivative wdth a nitrate group in its chemical structure. The drug belongs to a class of 
compound known as potassiun channel activators, which are characterized by their 
arterial vasodilator properties. In addition, nicorandil has vesodilating properties, which 
are attributed to nitrate group. Therefore, by combining these two vasodilator 
mechanisms, nicorandil represents a novel type of compound for use in the treatment of 
angina pectoris. Nicorandil induces vascular smooth muscle relaxation by increasing 
intracellular cyclic guanosine monophosphate (cGMP) levels. Potassium channel 
opening hyperpolarises vascular cell membrane, causing calcium (Ca^ "*") ion channel to 
close and a consequent reduction in intracellular Ca^ * concentration (i.e., indirect 
calcium antagonist) that results in further smooth muscle relaxation and vasodilation. 
Nicorandil is potent vasodilator of the coronary and peripheral vascular beds. Because 
of its effects in reducing preload and afterload, it influences two of the main 
determinants of oxygen demands without imparting myocardial contractility and thus, 
reduces cardiac workload. The drug is rapidly absorbed from the gut. The drug is 
weakly bound to plasma protein. Nicorandil is almost entirely metabolised in the liver. 
There are two predominant biotransformation pathways for nicorandil (Schemel.3) 
(a) oxidation to nicorandil-TV -^oxide and hydroxy nicorandil; and (b) denitration of 
nicorandil to pharmacologically inactive alcohol metabolite [A'^  - (2-hydroxyethyl)-
nicotinamide], followed by further side-chain degradation to nicotinamide and related 
metabolites, including nicotinic acid and N- methyl- nicotinamide.Nicorandil is 
excreted mainly as metabolite in urine. 
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CONH CHj C H , — O N O , XONH CH2 C H , — O N O , 
"Nicorandil-N-oxide WO^^^^^f.!^ Hydroxy nicorandil N 
CONH CH2 CH2—ONO2 
Nicorandil 
CONH CH2 CH2—OH 
N-(2-hydroxyethyl)-nicotinamide 
CONH CH2 COOH 
N Nicotinuric acid 
\ 
CONH2 
COOH 
Nicotinic acid 
Scheme 1.3: Some identified urinary metabolites of nicorandil in animals and man 
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LISINOPRIL 
Lisinopril, N - [(lS)-l-carboxy-3-phenylpropyl]-L-lysyl]-L-proline dihydrate, is an 
effective angiotensin converting enzyme inhibitor. The main action of Hsinopril is to 
inhibit conversion of angiotensin I (inactive) to angiotensin II (active). Hence 
angiotensin II production is inhibited. The drug has several advantages. It does not have 
direct sympatholytic activity. Hence cardiovascular reflexes are intact and postural 
hypotension is rare. It can be administered in patients of hypertension with diabetes 
mellitus or bronchial asthma. It is well tolerated and is used in the treatment of 
hypertension. Lisinopril is a white crystalline powder, soluble in water and sparingly 
soluble in methanol and practically insoluble in acetone and ethanol. It is currently 
supplied as 2.5, 5, 10 and 20 mg tablets. The primary degradation product of lisinopril 
is lisinopril diketopierazine which occurs through an intramolecular condensation. 
(Scheme 1.4) 
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•CHo CH 
Lisinopril 
-CH9 CH 
:0 
COOH 
Lisinopril diketopiperazine 
Scheme 1.4: Structures of lisinopril and lisinopril diketopiperazine 
degradation product 
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INTRODUCTION 
Losartan potassium is chemically known as 2-butyl-4-chloro-l[[2-
(lH-tetrazol-5-yl)[l,r-biphenyl]-4-yl]methyl]-lH-imidazole-5-methanol, 
which belongs to the antihypertensive group of drugs known as angiotensin II 
receptor antagonist. It is highly selective and orally active non-peptide 
antagonist used in the treatment of hypertension with heart failure or renal 
impairment by blocking the binding of angiotensin II to the ATi receptor level 
found in vascular smooth muscle, adrenal gland etc. It is metabolized in the 
body to a pharmacologically active carboxylic acid metabolite (EXP-3174). 
The drug is very much confined with the cardio protective effects, therefore it 
is important to assay losartan potassium in drug formulations. 
The drug is only listed in Martindale The Extra Pharmacopoeia [1], but not 
official in any pharmacopoeia. The reported analytical techniques for its estimation 
include high performance thin layer chromatography [2,3], high performance 
liquid chromatography [4-7] and capillary electrophoresis [8,9]. In the literature, 
only few spectrophotometric methods have been described for the determination of 
losartan potassium. The drug content in pharmaceutical formulations was 
determined by UV-derivative spectrophotometric procedure [10]. The extractive 
spectrophotometric method [II] has also been utilized by forming ion-pair 
complexes of the drug with calmagite and orange-II having maximum absorbance 
at 491 and 486 nm, respectively. However, analytical procedure based on kinetic 
spectrophotometry is still lacking in the literature for the determination of losartan 
potassium in pharmaceutical formulations. Kinetic spectrophotometry is the best 
choice of analytical chemist because of its high sensitivity, selectivity and low 
limit of detection [12]. In this method of analysis measurement can be made under 
dynamic reaction conditions in which the rcaclanls and products arc changing 
continuously with time. Moreover, alkaline potassium permanganate has been used 
for kinetic spectrophotometric determination of famotidine [13] and ritodrine 
hydrochloride [14] in dosage forms. Therefore, there is a need to develop a kinetic 
spectrophotometric method for assay of losartan potassium in pure form and in 
pharmaceutical formulations. 
This chapter describes the development and validation of a kinetic 
spectrophotometric method for the determination of losartan potassium in pure and 
commercial tablets. The method is based on the oxidation of drug with alkaline 
potassium permanganate at 25 ± 1 °C and subsequently the rate of appearance of 
the green coloured product was measured at 603 nm. The initial rate, fixed time 
and equilibrium time methods are followed for the determination of losartan 
potassium in commercial tablets. 
EXPERIMENTAL 
Materials and Methods 
Apparatus 
The absorbance of the solutions was measured with Shimadzu UV-visible 
spectrophotometer (Model no. 1601, Kyoto, Tokyo, Japan) using matched quartz 
cells. 
The heating temperature for colour development was monitored using 
water bath shaker (NSW 133, New Delhi, India). 
Reagents and standards 
0.6 M sodium hydroxide (GR Grade, Merck Limited, Mumbai, India) and 
9.00 X10""' M potassium permanganate (GR Grade, Merck Limited, Mumbai, India) 
were prepared in distilled water. Potassium permanganate solution should be 
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freshly prepared and standardized for its apparent purity by titrimetric procedure 
[15]. The standard test solution of 0.05% losartan potassium (Cipla Ltd., Mumbai, 
India.) was prepared in distilled water. The formulated tablet forms of losartan 
potassium such as Zaart-25 (Cipla Ltd., Mumbai, India), Losacar-25 (Zydus 
Medica, Ahmedabad, India) and Losium-25 (Cadila Pharma, Ahmedabad, India) 
were purchased from the local market. 
Recommended procedures for the determination of losartan potassium 
Initial rate method 
Aliquots of 0.15-1.2 ml of 0.05% losartan potassium were pipetted into a 
series of 10 ml standard flasks. To each flask, 2.0 ml of 0.60 M NaOH and 9.00 x 
10"'' M potassium permanganate were added successively and then diluted with 
distilled water at 25 ± 1°C. The contents of each flask were mixed well and 
increase in absorbance as a function of time was measured at 603 nm. The initial 
rate of the reaction (v) at different concentrations was evaluated by measuring the 
slope of the tangent to the absorbance-time plot. The calibration graphs were 
obtained by plotting the initial rate of reaction (v) versus the molar concentration 
of the losartan potassium (C). The amount of the drug was calculated either from 
the calibration graph or the regression equation. 
Fixed time method 
A fixed time of 12.0 min was selected for the fixed-time method. At this 
preselected fixed time, the absorbance of each sample of drug solution was 
measured at 603 nm against a reagent blank prepared similarly except drug. The 
calibration curve was obtained by plotting the absorbance against the initial 
concentration of losartan potassium. The amount of the drug was computed either 
from calibration curve or regression equation. 
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Equilibrium time method 
The equilibrium reaction condition was achieved at 90.0 min and at this time, 
the absorbance of each sample of drug solution was measured at 603 nm against a 
reagent blank prepared similarly except drug. The calibration curve was 
constructed by plotting the absorbance against the initial concentration of losartan 
potassium, and the concentration of the drug was calculated either from calibration 
curve or corresponding regression equation. 
Determination procedure for losartan potassium in commercial tablets 
For sample preparation of different tablets, the mixed contents of 5.0 tablets 
were weighed and grounded. The powder equivalent to 50 mg losartan potassium 
was stirred well with doubly distilled water. The solution was filtered through 
Whatmann No. 42 filter paper (Whatmann International Limited, Kent, UK) in a 
100.0 ml standard volumetric flask and the residue was washed well with doubly 
distilled water for complete recovery of the drug. The content of each standard 
volumetric flask was then diluted to 100.0 ml with doubly distilled water. The 
recovery of the losartan potassium was calculated from the corresponding linear 
regression equations or calibration curve. 
Determination procedure for synthetic mixtures of losartan potassium 
Synthetic mixtures of losartan potassium were prepared by taking various 
excipients (com starch, lactose, talc and magnesium stearate) commonly used in 
tablet dosage forms with 500.0 \xg of losartan potassium in 10 ml standard 
volumetric flask and tested to study the interferences of these excipients. 
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RESULTS AND DISCUSSION 
Spectral studies 
The aqueous solution of losartan potassium absorbs maximally at 206 nm 
while that of alkaline potassium permanganate solution exhibits an absorption band 
at 530 nm. The course of the reaction starts on the addition of aqueous alkaline 
potassium permanganate to the solution of losartan potassium resulting in the shift 
of absorption band peaking at 603 nm (Fig. 2,1). This band is attributed to the 
formation of manganate ion, in the presence of drug. The intensity of the coloured 
product increases with time leading to the oxidation of drug and therefore, a kinetic 
approach has been exploited for the spectrophotometric determination of losartan 
potassium in drug formulations. 
The stoichiometric ratio between losartan potassium and potassium 
permanganate was evaluated by limiting logarithmic method [16]. In this method, 
two sets of experiments were performed. In the first set, the concentration of 
losartan potassium was varied keeping a constant concentration of KMn04 while in 
the second set, the concentration of losartan potassium was kept constant and 
varying the KMn04 concentration. Log absorbance versus log [Losartan 
potassium] or [KMn04] (Fig. 2.2 a and b) was plotted to evaluate the slope of the 
respective line to determine the order of reaction of the drug with respect to 
KMn04 or vice versa. The slope was found to be unity in the first case and it was 
two in magnitude in the second case thus confirming the molar combining ratio of 
1:2 between losartan potassium and potassium permanganate. Hence the results 
indicated that the two moles of potassium permanganate were consumed by one 
mole of losartan potassium. 
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Fig. 2.1: Absorption spectra of (a) 1.0 ml of 1.085 x 10"^  M losartan 
potassium in doubly distilled water (b) 1.0 ml of 4.50 x 10"^  M KMn04 
+ 2.0 ml of 0.6 M NaOH solutions in doubly distilled water and (c) 1.0 
ml of 1.085 X 10"^  M losartan potassium + 2.0 ml of 9.00 x 10"^  M 
KMn04and 2.0 ml of 6.0 x 10* M NaOH solutions in doubly distilled 
water. Each set is diluted in 10 ml standard flask with doubly distilled 
water. 
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Fig. 2.2: Limiting logarithmic plot for stoichiometric ratio between losartan 
potassium and KMn04 (a) log A vs. log [losartan potassium] and (b) log A vs. 
log [KMn04]. 
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The literature survey reveals that losartan potassium undergoes oxidation of 
the 5-hydroxy methyl group on the imidazole ring [17], resulting in the formation 
of carboxylic acid derivative of losartan potassium. The reaction proceeds in the 
same way, thus potassium permanganate oxidizes losartan potassium in alkaline 
medium. On this basis, the following reaction mechanism (Scheme 2.1) is 
proposed. 
Optimization of variables 
The optimum conditions for the proposed methods responsible for the 
formation of green coloured manganate ion were studied and maintained 
throughout the experiment. 
The effect of temperature on the initial rate of reaction was studied at 298, 
303 and 308 K. It was observed that losartan potassium reacts faster with 
potassium permanganate with increase in temperature. At higher temperatures the 
reaction product may decompose and reproducibility was not better. To avoid this 
and for the sake of good results, the optimum temperature of 298 K was selected 
for the determination process. 
The effect of the KMn04 concentration on the initial rate of reaction (v) was 
studied in the range of 1.80 x 10'''-1.98 x 10''' M. The initial rate of reaction was 
increased with increase in the concentration of KMn04 and became constant at 
1.08 X 10"^  M and remained as such up to 1.98 x lO"'' M. The results are 
summarized in Table 2.1. Therefore, a concentration of 1.80 x 10'^  M was used as 
£in optimum value for the assay procedure. 
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2 OH ,, 
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Losartan potassium Oxidized losartan potassium 
Scheme 2.1. 
89 
Table 2.1.: Effect of [KMn04l and [NaOH] on the initial rate of reaction at 
[Losartan Potassium]= 1.08 x 10"'' 
[KMn04] 
(mol f " ) 
1.80 X 10"^  
3.60 X 10-' 
5.40 X 10"" 
7.20 X 10"' 
9.00 X 10"" 
1.08 X 10"^  
1.26 X 10"' 
1.44 X 10"' 
1.62x10"' 
1.80 X 10'' 
1.98x10-' 
[NaOH] 
(mol L"') 
1.20 X 10"^  
2.40 X 10"^  
3.60 X 10"^  
4.80 X 10"^  
6.00 X 10"^  
7.20 X 10"^  
8.40 X 10"' 
9.60 X 10"^  
1.08 X 10"' 
1.20 X 10"' 
1.32 X 10"' 
Initial rate of 
KMn04 
6.67 X 10"5 
1.29 X 10"" 
1.96 X 10"" 
2.44 X 10"" 
2.58 X 10"" 
5.89 X 10"" 
5.89 X 10"" 
5.89 X lO" 
5.89 X 10"" 
5.89 X 10"" 
5.89 X 10"" 
reaction, v (mol L'' s"') 
NaOH 
1.00 X 10"" 
1.33 X 10"" 
1.83 X 10"" 
2.22 X 10"" 
2.43 X 10"" 
3.11 X 10"" 
3.60 X 10"" 
4.10 X 10"" 
5.89 X 10"" 
5.89 X 10"" 
5.89 X 10"" 
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Table 2.1. shows the effect of NaOH concentration on the initial rate of reaction. 
The V value increased with increase in the concentration of NaOH up to 1.08 x 10"' 
M, after which further increase in the concentration of NaOH resulted in no change 
in the initial rate of reaction. Thus, the concentration of 1.20 x 10'' M was found to 
be most suitable concentration in a volume of 10.0 ml. 
ANALYTICAL PARAMETER AND METHOD VALIDATION 
AW kinetic parameters were performed under pseudo-first order conditions 
at 25 ± 1°C. The initial rates of the reaction were determined from absorbance-time 
plot (Fig. 2.3) by measuring the slopes of the initial tangent to the absorbance-time 
curves and are summarized in Table 2.2. The kinetic equation for the oxidation of 
losartan potassium by potassium permanganate in alkaline medium is written as: 
1/= — = A: r" r" c' en 
For Q^„„^ > 1.08x10-'A/ and Q,„;„ > 1.08 xiO'' M 
dx „ 
The equation (1) reduced to — = /c^C" (2) 
dt 
The order with respect to losartan potassium was determined from the plot of 
logarithm of initial rate of reaction (log v) versus logarithm of molar 
concentration of losartan potassium (log C) and was found to be unity. Thus, the 
oxidation of losartan potassium would obey the pseudo first order reaction and 
equation (2) reduced to 
y = ^ = KC (3) 
at 
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Fig. 2.3: Absorbance-time plot for the oxidation of losartan 
potassium with KMn04 in alkaline medium: 1.80 xlO"^M KMn04 
and (a) 1.63x10-^ (b) 2.17 x 10•^ (c) 3.25 x 10•^ (d) 5.42 x 10"^ 
(e) 7.60 X 10 •\ (f) 9.76 x 10',(g) 1.08 x lo-^ (h) 1.19 x lO" and 
(i) 1.30x10'* M losartan potassium. 
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Table 2.2. : Initial rate of reaction at different concentration of Losartan 
potassium with [KMn04] = 1.80 x 10"^  M and (NaOH) = 0.12 M 
[Drug] Initial rate of reaction, u 
mol L-' s"' 
8.33 X 10-' 
1.17 X 10'^ 
1.78 X 10'^ 
2.94 X 10'" 
4.11 X 10-' 
5.28 X iO"' 
5.89 X 10'" 
6.44 X lO'" 
7.00 X lO'" 
mo! L 
1.63X 
2.17 > 
3.25 > 
5.42 
7.59 
9.76 
1.08 
1.19 
-1 
10-^  
: 10'' 
c 10'' 
X 10-' 
X I C ' 
X IQ-' 
X 10'" 
X 10-" 
1.30x10-^ 
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where K^, is the pseudo first order rate constant. Under the optimized 
experimental condition, the calibration graph (initial rate versus C) was found to be 
linear over the concentration range of 7.5-60.0 |ag ml''. The regression of initial 
rate versus C gave a linear regression equation, y= -6.422 x 10"^  + 1.173 x 10"^  C 
with coefficient of correlation, r = 0.99995. The confidence limits for the slope of 
the line of regression and intercept were computed using the relation b ± tSb and a 
± tSa at 95% confidence level and found to be 1.173 x 10"' ± 1.057 x 10'^  and -
6.422 X 10'^  ± 4.076 x 10'^ , respectively indicating the high reproducibility of the 
initial rate method. The limit of detection (LOD) and quantitation (LOQ) were 
calculated using statistical treatment of calibration data at nine concentration levels 
by the following equation:[18] 
LOD = 3 . 3 x S o / b and L O Q = 1 0 x S o / b 
where So and b are the standard deviation and slope of the calibration line. The 
LOD and LOQ were found to be 0.71 and 2.16 |ag ml ' , respectively. The variance 
(So )^ was calculated using the equation: 
n-2 
and found to be 6.420x 10''^ i^ g ml''. The low value of variance suggested the 
negligible scattering of the experimental data points around the line of regression. 
For evaluation of apparent activation parameter, the reaction was studied at 
298, 303, and 308 K at [losartan potassium] = 3.25 x 10"^  M. [KMn04] = 1.80 x 
10"^  M and [NaOH] = 1.20 x 10"' M. The Arrhenius plot of In kobs versus 1/T was 
found to be linear. (Fig. 2.4). Activation energy (Ea) was calculated from the slope 
(-Ea/R) of the Arrhenius plot and found to be 87.34 KJ mol"'. The Eyring plot of In 
kobs./ T versus 1/T was also linear. (Fig. 2.5). 
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Fig. 2.4: Arrhenius plot of log k versus 1/T at 298.0,303.0, and 308.0 K: 
losartan potassium (1.63 x 10""^  and 1.30 x 10'* M) with initial concentrations 
of KMn04 (1.80 x 10'^  M) and NaOH (0.12 M) for activation energy. 
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Fig. 2.5: Eyring plot of log kTT versus 1/T at 298.0, 303.0, and 308.0 K: 
losartan potassium (1.63 x 10''' and 1.30 x 10"'* M) with initial concentrations 
of KMn04 (1.80 x 10'^  M) and NaOH (0.12 M) for AH^  and AS\ 
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The value of AH* and AS* were evaluated from the slope (-A H*/ R) and intercept 
[In (kb / h) + AS* / R] of Eyring plot and found to be 84.86 KJ mof' and 50.96 JK"' 
mol"', respectively. The value of Gibbs free energy (AG*) of activation of the 
reaction product was -IS.lOKJmol' ' . 
In the fixed-time method, the absorbance of green coloured solution formed 
due to the reduction of KMn04 was recorded at a preselected fixed time for 
different concentrations of losartan potassium. The calibration graphs were 
constructed by plotting the absorbance against the initial concentrations of losartan 
potassium at a fixed time of 3, 6, 9, 12 and 15 min. 
The important parameters of these calibration curves are reported in Table 
2.3. It is clear from Table 2.3. that the most acceptable values of linearity, 
intercept, limit of detection and quantitation were obtained at a fixed time of 12 
min. Therefore, the fixed time of 12 min was selected as the optimum time for the 
determination of losartan potassium in pharmaceutical dosage forms. 
In the equilibrium time method, the absorbance of green coloured solution 
was measured after attaining the equilibrium (at 90 min) for different 
concentrations of losartan potassium. The linear regression equation and other 
statistical parameters of this method are summarized in Table 2.3. 
Solution stability 
The stability of the test solution of losartan potassium in distilled water was 
studied by recording UV absorption spectra of losartan potassium for three days. 
The drug solution having A,max at 206 nm, showing no change in the absorption 
spectra of the test and sample solutions of drug for at least three days, when the 
solutions were stored at room temperature in the dark. 
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Robustness 
In the proposed methods conditions for the determination of losartan 
potassium in pure form as well as in dosage forms are very robust. Each 
operational parameter was tested and challenged for the robustness of the methods. 
The operational robust parameters that are investigated were as follows: 
• volume of 0.60 M NaOH (± 0.4 ml) 
• volume of 9.0 x 10"^  M KMn04 (± 0.3 ml) 
Under these conditions sample solutions from three dosage forms containing 
60.0 f.ig ml"' of active losartan potassium was assayed by performing five 
independent analyses by the initial rate and fixed time methods. The results of 
mean recovery, standard deviation and relative standard deviation indicated good 
sensitivity and appreciable recovery. Thus the conditions of the proposed methods 
are very robust. 
Accuracy and precision 
The accuracy and precision of the proposed methods was established by 
measuring the content of losartan potassium at three different concentration levels 
(low, medium and high) on each day as well as on five consecutive days. The intra 
day assay (or the daily precision) was performed by measuring five independent 
analyses at 10.0, 35.0 and 55.0 i^g ml"' concentration levels within one day and 
inter day assay (or within day precision) was done at the same specified levels of 
concentration by measuring five replicate analyses on five consecutive days (Table 
2.4.). The results of standard deviation, relative standard deviation and mean 
recoveries obtained by intra day and inter day precisions for initial rate, fixed time 
and equilibrium fixed time methods are acceptable and can be considered to be 
very satisfactory. 
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Table 2.4.:Intra day and inter day assays: test of precision of the initial rate, 
fixed time and equilibrium methods 
Proposed methods 
Initial rate method 
Intra day assay 
Inter day assay 
Fixed time method 
Intra day assay 
Inter day assay 
Equilibrium method 
Intra day assay 
Inter day assay 
Amount 
(^gm|-') 
Taken 
10.0 
35.0 
55.0 
10.0 
35.0 
55.0 
10.0 
35.0 
55.0 
10.0 
35.0 
55.0 
10.0 
35.0 
55.0 
10.0 
35.0 
55.0 
Found ± SD" 
10.026 ±0.043 
34.996 ±0.118 
55.013 ±0.070 
9.992 ±0.092 
34.996 ±0.192 
55.048 ±0.124 
10.013 ±0.085 
35.127±0.158 
55.051 ±0.134 
9.975 ±0.134 
35.051 ±0.169 
55.051 ±0.268 
9.990 ±0.042 
34.987 ±0.051 
55.040 ±0.059 
10.008 ±0.070 
35.011 ±0.104 
55,020 ±0.070 
Recovery 
(%) 
100.20 
99.98 
100.02 
99.92 
99.98 
100.08 
100.13 
100.36 
100.09 
99.75 
100.15 
100.09 
99.90 
99.96 
100.07 
100.08 
100.03 
100.03 
RSD" 
(%) 
0.429 
0.336 
0.127 
0.922 
0.548 
0.226 
0.846 
0.451 
0.243 
1.342 
0.483 
0.486 
0.421 
0.146 
0.107 
0.700 
0.297 
0.123 
SAE'' 
0.019 
0.053 
0.031 
0.041 
0.086 
0.060 
0.038 
0.071 
0.060 
0.060 
0.076 
0.119 
0.019 
0.023 
0.026 
0.031 
0.050 
0.030 
C.L.^  
0.053 
0.146 
0.087 
0.114 
0.238 
0.155 
0.105 
0.197 
0.166 
0.166 
0.210 
0.333 
0.052 
0.063 
0.073 
0.087 
0,129 
0.084 
'Mean for five independent analyses. 
'' SAE, standard analytical error'^ C.L., confidence limit at 95 % confidence level and four 
degrees of freedom (t = 2.776). 
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Performing recovery experiments through standard addition method also 
checked the validity of the proposed methods. For this, a known amount of the 
pure drug was added to preanalysed dosage forms at two concentration levels and 
the total amount was determined by measuring five replicate analyses following 
the recommended procedures for the determination of active drug. The results are 
summarized in Table 2.5, which showed excellent recoveries (99.80-100.14%) It 
is also clear from the data that no interference from the common excipients used in 
tablets was observed. The selectivity of the proposed methods was also assessed by 
determining the losartan potassium (50 mg ml"') in the presence of common 
excipient such as com starch, lactose, talc, and magnesium stearate. It was found 
that these excipient did not interfere with the determination process. 
Applicability of the proposed methods 
The initial rate, fixed time and equilibrium fixed time methods were 
successfully applied to the determination of losartan potassium in pharmaceutical 
formulations. The results of the proposed methods were compared with those of 
the reference method using point and interval hypothesis tests [19] and are 
summarized in Table 2.6. The calculated t- (paired) and F- values at 95% 
confidence level do not exceed the theorefical ones [20] indicating no significant 
differences between the performance of the proposed methods and the reference 
method. A bias of ± 2 %, which is based on recovery experiments, is permissible 
by The Canadian Health Protection Branch [21]. Therefore, the acceptable limit 
lies within GL = 0.98 and Ou = 1.02. 
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It is evident from Table 2.6. that the true bias of all samples of drug is smaller than 
± 2 % and thus confirming that the proposed methods are reliable with acceptable 
recovery. 
The proposed kinetic method is appreciable with a view that the oxidation 
of drug can be exploited for the routine quality control analysis of losartan 
potassium in pharmaceutical formulations. The method is sensitive with a simple 
calibration system that does not require any laborious clean up procedure prior to 
analysis. Moreover the present technique has the advantage of using inexpensive 
and easily available reagents and therefore can be frequently used in the 
laboratories of research, hospitals and pharmaceutical industries. 
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Chapter 3 
Quantitative AnaCysis of IrSesartan in CommerciaC 
(Dosage Torms 6y %inetic Spectropfiotometry 
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INTRODUCTION 
Irbesartan is chemically known as 2-butyl-3- [[2-(lH-tetrazole-5-yl) (1,1 -
biphenyl)-4-yl] methyl]-1,3-diazaspiro [4,4] non-l-en-4-one, which is a potent, 
long-acting non peptide angiotensin II receptor antagonist with high selectivity for 
the AT] sub type. This is potentially safe and more tolerable than other classes of 
antihypertensive drugs to improve symptoms, quality of life, exercise capacity, 
reduce hospital admissions for cardiac failure and reduce the incidence of 
myocardial infarction, sudden death, and death from progressive systolic failure 
[1]. The drug is very helpful in reducing the morbidity and mortality associated 
with these hypertension conditions. Therefore, it is necessary to quantitate the drug 
in pharmaceutical formulations. 
The drug is officially listed in Martindale The Extra Pharmacopoeia [2]. 
The assay procedure in pure and dosage forms is not official in any pharmacopoeia 
and therefore the development of an analytical procedure for the determination of 
irbesartan in pharmaceutical preparations is of great significance. The various 
analytical methods such as high performance thin layer chromatography (HPTLC) 
[3], liquid chromatography (LC) [4], high performance liquid chromatography 
(HPLC) [5,6], capillary zone electrophoresis (CZE) [7.8], and derivative 
spectrophotometry [9,10] have been described for its determination. 
The literature is still lacking analytical procedures based on kinetics for the 
determination of irbesartan in commercial dosage forms. There are certain 
advantages associated with kinetic methods such as [11 ]: 
• simplicity owing to elimination of some experimental steps such as filtration, 
extraction prior to absorbance measurements. 
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• high selectivity due to the measurement of the evolution of the absorbance as a 
function of reaction time instead of measuring the concrete absorbance value. 
• no interference from other active compounds present in the commercial 
dosage forms, if they resist the chemical reaction conditions. 
This chapter describes a kinetic spectrophotometric method for the 
determination of irbesartan in commercial dosage forms. The method is based on 
the oxidation of irbesartan with potassium iodate to form a carboxyiic acid 
derivative, thus in the presence of -COOH group iodide is oxidized by iodate 
resulting in the formation of triiodide ion, which absorbs maximally at 352 nm. 
The absorbance increases with time and therefore, the initial-rate and fixed-time 
methods are adopted for the determination of irbesartan in commercial dosage 
forms. 
EXPERIMENTAL 
Materials and Methods 
Apparatus 
A Shimadzu UV-visib!e 1601 spectrophotometer (Model no. 1601. Kyoto, 
Japan) with matched quartz cells was used for spectral run. Absorbance 
measurement was made on Spectronic 20D^ spectrophotometer (Milton Roy, 
USA). A water bath shaker (NSW 133, New Delhi, India) was used to maintain a 
constant temperature for colour development. 
Reagents and Standards 
All chemicals and reagents used were of analytical or pharmaceutical 
grade. Irbesartan reference standard (Batch No. IB-110021102) was kindly 
provided by Biochem Pharmaceutical Industries (Mumbai, India). Standard 
solution of irbesartan (0.5 mg ml"') was prepared by dissolving 50 mg in 100 ml 
109 
dimethyl sulphoxide. This solution was used to prepare calibration curve and 
quality control samples. Quality control samples were prepared at three 
concentration levels of 10, 30 and 60 fag ml''. Commercial dosage forms of 
irbesartan such as Irovel-150 (Sun Pharma, Mumbai, India), Irbest-150 (Biochem 
Pharma Industries, Mumbai, India) and Xarb-150 (Nicholas Piramal India Ltd., 
Mumbai, India) were obtained from local market. 
A 0.05 M KI (Fluka Chemie AG, Switzerland) solution was freshly 
prepared in distilled water. The solution was standardized by the recommended 
procedure [12]. A 0.003 M KIOi (i-'luka Chcmic ACi. Switzerland) was also 
freshly prepared in distilled water. 
Recommended procedures for the determination of irbesartan 
Initial rate method 
Aliquots of 0.2-1.2 ml reference standard solution of irbesartan (0.5 mg 
ml"') were pipetted into a series of 10 ml standard volumetric flasks. To each 
flask, 1.8 ml of 0.003 M KIO3 was added followed by 2.3 ml of 0.05 M Kl and 
then diluted to volume with distilled water at 30i:1°C The contents of each tlask 
were mixed well and the increase in absorbance at 352 nm was recorded as a 
function of time against the reagent blank prepared similarly. The initial rate of the 
reaction (v) at different concentration was obtained by measuring the slope of the 
tangent to the absorbance-time plot. The calibration graph was obtained by plotting 
the initial rate of reaction (v) versus the molar concentration of the irbesartan. The 
amount of the drug was calculated either from the calibration graph or the 
regression equation. 
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Fixed-time (A A) method 
In this method, the absorbance of each sample solution was measured at 
352 nm against a reagent blank prepared similarly except drug at a preselected 
fixed time. The difference between the absorbance obtained at 2 min and the 
absorbance at 4, 6, 8 or 10 min was plotted against the concentration of irbesartan 
to yield the calibration curve. The amount of the drug was computed either from 
calibration curve or from corresponding regression equation. 
Determination of irbesartan in commercial dosage forms 
The powdered contents of 2 tablets of 150 mg strength were weighed and 
grounded. The powder equivalent to 50 mg irbesartan was stirred well with 
dimethyl sulphoxide. The solution was filtered through Whatmann No. 42 filter 
paper (Whatmann International Limited, Kent. UK) in a 100 ml standard 
volumetric flask and the residue was washed well with dimethyl sulphoxide for 
complete recovery of the drug. The content of standard volumetric flask was then 
diluted to 100 ml with dimethyl sulphoxide. The amount of irbesrtan was 
determined following the proposed procedures. 
Procedure for reference method 
Aliquots of 0.05-0.6 ml of 0.025 % irbesartan were pipetted into a series of 
10 ml standard volumetric flasks and diluting to volume with ethanol. The 
absorbance was measured against the solvent blank at 207 nm. The amount of the 
drug in a given sample was computed from the calibration graph or linear 
regression equation. 
I l l 
Validation 
The proposed method has been validated for specificity, linearity, 
precision, accuracy, recovery, limit of detection, and quantitation. 
Specificity 
Samples of irbesartan tablets were subjected to stress conditions of light, 
heat and base. All stressed samples were analyzed for active irbesartan content and 
compared to an unstressed time zero reference solution. The time zero solution 
provided a reference assay value for the unstressed product. The content of 
degradation in the stressed and control samples was calculated relative to this assay 
value. 
Linearity 
The linearity of the initial rate and fixed time methods were assessed in the 
concentration range 10-60 and 7.5 - 60 |ag ml"', respectively. 
Accuracy and precision 
The accuracy and precision of the proposed procedures was ascertained 
based on the analysis of quality control samples. Quality control sample 
concentrations were 10.0, 30.0 and 60.0 |j,g ml''. Five replicate quality control 
samples at each concentration were analyzed within one day as well as for five 
consecutive days. The standard deviations (SD), relative standard deviations (% 
RSD), standard analytical error (SAE) and confidence limit (CL) were calculated 
by standard methods. 
Recovery Studies 
Recovery experiments were carried out by standard addition method. For 
this, 4.0 ml (or 6.0 ml) of reference irbesartan solution (0.5 mg ml'') was 
transferred into a 100.0 ml volumetric flask followed by 2.0 ml (or 4.0 ml) of 
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sample solution (0.5 mg ml"') and volume was completed to the mark with distilled 
water. The nominal value was determined by the recommended procedures. 
Limit of detection (LOD) and quantitation (LOQ) 
According to International Conference on Harmonisation (ICH) guidelines 
[13], the following expressions are used to evaluate LOD and LOQ. 
LOD = 3.3 X So / band LOQ = 10 x So/b 
where So and b are standard deviation and slope of the calibration line, 
respectively. 
Evaluation of bias 
The bias has been evaluated by means of point and interval hypothesis tests 
[14,15]. In interval hypothesis the proposed method (method 2) is accepted when 
the true mean is within ± 2% of that of the true reference method (method 1), i.e. 
- 0.02 m<(^2-m)< 0.02 m 
The above equation can also be written as: 
0.98<H2/ni < 1.02 
which can be generalized to 
where 0L and 0u are lower and upper acceptance limits, respectively. The limits of 
this confidence interval can be calculated as the two roots of the following 
quadratic equation. 
where 
_ c 2/ 2 
a = x^ 
"i 
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b = -2X|X2 
2 "^p ^lah 
^ 1 
" 2 
The values of OL and 0u of the confidence interval can be obtained as: 
0,-
0 = 
-b-ylb^-4ac 
la 
-h + yjh^ -Aac 
la 
RESULTS AND DISCUSSION 
Spectral Studies 
The absorption spectrum of irbesartan in dimethyl sulphoxide-water (1:9) 
medium shows an absorption band at 223 nm (Fig. 3.1a). The addition of aqueous 
solutions of KIO3 and KI to the drug solution causes a change in the absorption 
spectrum with new characteristic bands peaking at 298 and 352 nm (Fig. 3.1c) 
while the mixture of KIO3 and KI solution shows two absorption maxima peaking 
at 275 and 290 nm and a negligible absorbance at 352 nm (Fig 3.1b). The molar 
absorptivity is higher at 352 nm than those obtained at 298 nm and hence the 
absorbance measurements for the determination of irbesartan were made at 352 
nm. The equilibrium is attained in about 50 min, which formed the basis to develop 
a kinetic spectrophotometric method for determination of irbesartan. 
Mechanism of the colour reaction 
Chando et al. [16] have suggested that the terminal methyl group of the 
butyl side chain of irbesartan undergoes oxidation resulting in the formation of a 
carboxylic acid derivative. 
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200 220 240 260 280 300 320 340 360 380 400 420 440 
Wavelength (nm) 
Fig. 3.1: Absorption spectra of (a) 3.91 x 10'^  M standard irbesartan solution in 
dimethyl sulphoxide-water medium, (b) blank solution: 6.0x10"* M potassium iodate 
and 1.15 xlO"^ M potassium iodide in distilled water, (c) sample solution: 60.0 [ig ml ' of 
irbesartan, 6.0x10"* M potassium iodate and 1.15 xlO'^ M potassium iodide in distilled 
water. 
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In the present study, a carboxylic acid derivative is formed on oxidation of 
irbesartan with iodate. Then generation of triiodide ion takes place as iodide is 
oxidized by iodate in presence of acid formed. The reaction sequence is shown in 
Scheme 3.1. 
Solution stability 
The solution stability of irbesartan was checked by recording UV spectra of 
the drug for seven days. The reference standard of the drug showed an absorption 
peak at 223 nm. The standard and quality control sample solutions were kept at 
room temperature for seven days and it was observed that there was no change in 
the absorption spectra of these solutions. The solution stability was also 
ascertained by applying the standard and quality control samples on TLC plates 
coated with silica gel G (Merck Limited, Mumbai, India) and developed in ethyl 
acetate-toluene-acetic acid (6: 4: 0.1 v/v/v) solvent system. The plates were air-
dried and spots were detected in the iodine chamber. In both the cases, a single 
spot was observed with Rf = 0.47 corresponding to irbesartan. 
Specificity 
The standard drug and quality control sample solutions were stressed by 
light and heal (up to 50 °C) for 2, and 1-day time points, respectively. It was 
observed that stress by such conditions did not cause significant degradation. There 
was no change in the absorption spectra and a single spot was observed on TLC 
plate with Rf value of 0.47. However, the samples degraded significantly when 
stressed by base (O.IM NaOH) for 12 hours. All stressed samples (light and heat) 
and unstressed reference solution were analyzed for the active content of 
irbesartan, which gave acceptable recoveries of the drug. 
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[A] 
N=N 
/ \ 
+ 10, 
I + H.O 
COOH 
Carboxylic acid derivative of irbesartan 
[B] 6 H + IO3 + 51' 2 1, 3H2O 
triiodide ions 
(coloured species) 
Scheme 3.1: Reaction sequence of the proposed kinetic method 
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The influence of frequently encountered excipients in pharmaceutical 
dosage forms of irbesartan on the proposed method was studied by adding different 
amounts of possible interferents to the sample. It was observed that glucose, 
fructose, sucrose, cellulose, lactose, starch, magnesium stearate, sodium stearyl 
fumarate and colloidal silica did not interfere with the proposed method. However, 
acids such as HCl, H2SO4, CH3COOH and sulphosalicylic acid and oxidizing 
agents such as N-bromosuccinimide, chloramine T, ammonium molybdate, 
potassium persulphate except potassium bromate interfere with the determination 
process. 
Optimization of variables 
The optimum conditions affecting the rate of reaction in the formation of 
triiodide ions were studied and maintained throughout the experiment to determine 
the quantity of irbesartan in pure form and drug formulations. 
Effect of the concentration ofKIOj 
The effect of the concentration of KIO3 on the initial rate of reaction was 
studied in the range 6.0x10'"- 6.6x10''' M (Fig. 3.2) keeping all other experimental 
parameters constant, [irbesartran] = 1.167 x 10"''and [KI] = 1.1 x lO'^ ^M. It can be 
seen that the initial rate of reaction was increased with increasing concentration of 
KIO3 and became constant at 3.9 x 10''' M, above this concentration up to 
6.6 X 10"^  M, the initial rate of reaction was unchanged. Thus, the adoption of 
5.4 X 10"^  M KIO3 in the final solution proved to be sufficient for the maximum 
concentration of irbesartan used in the calibration graph 
0.0060 
0.0055 
0.0050 
c 
TO 0.0045 
o 
0) 
(0 
*^ 
'c 
0.0040 -
0.0035 
0.0030 -
- • • • 
0.0025 -I 1 1 r 
0.0000 0.0001 0.0002 0.0003 0.0004 0.0005 0.0006 0.0007 
Concentration of KIO, (M) 
Fig. 3.2: Effect of molar concentration of KIO3 on initial rate of reaction 
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Effect of the concentration ofKI 
The influence of the concentration of KI on the initial rate of reaction was 
examined in the range of 1 .Ox 10'^ -1.3 x 10"^  M. The initial rate of reaction (Fig. 3.3) 
increased with increasing the concentration of KI and became constant at 9.5 xlO''' 
M and beyond this concentration up to 1.30 xlO' M KI, the initial rate remained 
constant. Therefore, 1.15x10"^ M KI was recommended for the determination 
process. 
Effect of the temperature 
The effect of temperature on the initial rate of reaction was investigated at 
303, 308 and 313 K. The absorbance-time curves obtained at these temperatures 
indicated the temperature dependence of the reaction rate. The initial rate for 
different concentrations of drug at each temperature was calculated and utilized for 
plotting the calibration curve. It was found that the calibration graph obtained at 
303 K possessed good linearity (r = 0.9999) and is recommended that the 
determination be carried out at 303 K. 
ANALYTICAL DATA 
Initial rate method 
Under the optimized experimental conditions, high concentrations of KIO3 
and KI solutions were employed, which established a pseudo-order reaction 
condition with respect to the reagents concentration. Therefore, on the basis of 
experimental observations, kinetic equation for the reaction may be written as: 
rate = k [C]" [YilO^T [KI]' 
For [KIO.1] > 5.4 xlO'" Mand [KI] > 1.15x10'' M at 303 K. 
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0.006 
0.000 0.002 0.004 0.006 0.008 0.010 
Concentration of Kl (M) 
0.012 0.014 
Fig. 3.3: Effect of Molar concentration of Kl on initial rate of reaction 
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The above equation reduces to: 
rate = k,, [C]" 
where K^ is the pseudo-order rate constant, C is the concentration of irbesartan and 
n is the order of reaction. The logarithmic form of the equation may be written as: 
log (rate) = log Ky + n log C 
The initial rates of reaction were determined at different concentrations of 
irbesartan by measuring the slopes of the initial tangent to the absorbance (at 352 
nm)-time curves during the first 10 min of the reaction (Fig. 3.4) and are 
summarized in Table 3.1. The plot of log rate versus log C gave the following 
linear equation: 
log (rate) = 1.657+ 1.000 log C 
with coefficient of correlation, r = 0.9999. The value of n in the equation 
confirmed that the reaction is first order with respect to irbesartan and rate constant 
is 45.39 s-'. 
A calibration curve was constructed by plotting the initial rate of reaction 
versus initial concentration of irbesartan, which showed a linear response over the 
concentration range of 10.0 - 60.0 (.ig ml"'. The linear regression analysis of 
calibration data (n = 7) was made to evaluate slope, intercept and correlation 
coefficient. The regression of rate versus concentration of irbesartan (|j.g ml"') gave 
the following linear regression equation: 
Rate = -2.138x10"^+ 1.058x10"''C 
with a correlation coefficient (r) of 0.9999. The limits of detection (LOD) and 
quantitation (LOQ) were found to be 0.21 and 0.63 \ig ml"', respectively. The 
variance (So )^ of the calibration line was evaluated to be 4.478x10'" |ag ml"' which 
is very low showing negligible scattering of the experimental data points around 
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Fig. 3.4: Absorbance-time curves for the initial rate of reaction at varying 
concentration of irbesartan (a) 10, (b) 20, (c) 25, (d) 30, (e) 50, (f) 55 and (g) 60 
i-t Hg ml' keeping [KIO3] = 5.4 xlO"^  M and [KIJ > 1.15x10"^ M constant. 
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Table 3.1: Initial rate of reaction at different concentration of irbesartan, 
keeping [KIO3] and [KI] constant 
C, [Drug] 
mol r' 
2.334x10-' 
4.667 X 10"' 
5.834 X lO"' 
7.001 X 10-' 
1.167 X 10"^  
1.284 X lO"" 
1.400 X lO-' 
logC 
-4.632 
-4.331 
-4.234 
-4.155 
-3.778 
-3.892 
-3.854 
Initial rate of reaction, u 
mol r' S-' 
1.057 X lO"' 
2.118 X 10"' 
2.642 X 10"' 
3.169 X 10-' 
5.299 X IQ-^  
5.808 X iO-
6.348X 10"' 
log!) 
-2.975 
-2.674 
-2.578 
-2.499 
-2.276 
-2.236 
-2.197 
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the line of regression. The values of confidence limil for Ihc slope (b ± iSb) and 
intercept (a ± tSa) of the calibration line were computed [17] and found to be 
1.058xlO'^ ± 3.65x10"'' and - 2.138x10"^ ± 1.46xl0"^ respectively for n-2 degrees 
of freedom at 95% confidence level. The values of the confidence limit are 
appreciably low thus indicating the high reproducibility of the initial rate method. 
Fixed-time method (AA) 
The absorbance of the yellow coloured solution at 352 nm was recorded 
during the first 10 min at a regular interval of 2.0 min. The change in absorbance 
(AA) between the times ti (2 min) and ii (4 or 6,8,10 min) was computed and 
plotted against the concentration of irbesartan.The corresponding linear regression 
equations with coefficient of correlations are summarized in Table 3.2. It is 
evident from the table that the most acceptable linearity was obtained when the 
calibration graph was plotted by considering the change in absorbance between 2 
and 6 min (i.e. AA= A6-A2). This fixed time was recommended for analysis. The 
calibration curve was linear in the range of 7.5-60.0 |ag ml"' of irbesartan. The 
values of LOD, LOQ and variance were found to be 2.40, 7.26 and 5.57x10"^ \x% 
mi'', respectively 
Activation parameters of the proposed method 
The apparent activation parameters were evaluated by studying the reaction 
rate at 303, 308 and 313 K keeping the following reaction conditions: 
[irbesartan] = 4.667x10"^M, [KIO3] = 6.0x10"'' M and [KI] = 1.15x10"^ M. 
A linear Arrhenius curve was obtained by plotting In kobs versus 1/T. The 
activation energy (Ea) was calculated from the slope (-R;, / R) of the Arrhenius 
curve and found to be 70.95±0.43 KJmol"'. The values of enthalpy (AH*), entropy: 
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Table 3.2: Coefficient of correlation (r) for the calibration equations 
at A4-A2, A6-A2, A8-A2 and A10-A2 for method B 
AA Calibration equation r ±tSa ±tSb 
A4-A2 AA = -1.73x10-^ +2.06 X 10"'C 0.9945 g.lOOxlO'' 2.202x10-' 
A6-A2 AA= -3.75x10-'+ 3.25 X 10-^  C 0.9995 5.383x10-' 1.468x10"' 
Ag-Aj AA = -2.89xl0-' + 4.44x 10"'C 0.9990 7.243x10"' 1.958x10-' 
A10-A2 AA = -2.00x10"' +5.41 X 10"'C 0.9989 9.225x10"' 2.447x10-'' 
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(AS )^ and free energy of activation (AG )^ of the reaction were also calculated using 
Eyring equation 
A//M 
T R R T 
The plot of In kobs/T versus 1/T was found to be linear. AH* and AS^ were 
calculated from the slope (-A H* / R) and the intercept [In (kb /h) + AS^ / R] and 
were found to be 68.48±0.21 KJ mol"' and 16.54±0.24 JK"' mol"', respectively. The 
Gibbs free energy of activation i.e. AG* al .'^ O.'^  K was cvalualcd by the equation 
(AG^ = AH* - TAS*) and found to be -4.94±0.07 KJ mol"'. The values of activation 
parameters indicated that the reaction is feasible. 
Accuracy and Precision of the Proposed Methods 
The accuracy and precision of the proposed methods was established by 
performing intra day and inter day assays by determining the content of irbesartan 
in quality control samples at three different concentration levels (low, medium and 
high). These assays were investigated by measuring five independent analyses at 
10.0, 30.0 and 60.0 \xg ml"' concentration levels within one day and on five 
consecutive days, respectively (Table 3.3). The standard deviation, relative 
standard deviation and standard analytical error obtained by both methods are 
acceptable i.e. within the permissible bias range and therefore can be considered to 
be satisfactory. 
Validity of the proposed methods 
Standard addition method was employed to check the validity of the 
proposed procedures. In this method, a known amount of pure irbesartan was 
added to its formulated tablets at two different concentration levels and the 
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Table 3.3: Evaluation of accuracy and precision of the proposed methods by 
Intra day and inter day assays 
Proposed methods 
Initial rate 
Intra day assay 
Inter day assay 
Fixed time (A A) 
Intra day assay 
Inter day assay 
Amount 
(ligml-') 
Talcen 
10.0 
30.0 
60.0 
10.0 
30.0 
60.0 
10.0 
30.0 
60.0 
10.0 
30.0 
60.0 
Found ± SD' 
9.99 ±0.06 
29.99 ±0.06 
60.03 ±0.10 
10.01 ±0.08 
30.02 ±0.10 
59.97 ±0.14 
9.99 ±0.07 
30.01 ±0.05 
59.97 ±0.06 
10.01±0.13 
30.04 ±0.09 
60.03 ±0.06 
RSD 
(%) 
0.64 
0.19 
0.17 
0.84 
0.33 
0.23 
0.74 
0.16 
0.10 
1.34 
0.28 
, 0.11 
SAE" 
0.029 
0.025 
0.045 
0.038 
0.045 
0.060 
0.033 
0.022 
0.026 
0.060 
0.038 
0.029 
C.L.^  
0.080 
0.070 
0.124 
0.104 
0.124 
0.168 
0.091 
0.060 
0.073 
0.167 
0.106 
0.079 
^Mean for five independent analyses. 
*" SAE, standard analytical error. 
"^ C.L., confidence limit at 95 % confidence level and four degrees of freedom (t = 2.776). 
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nominal value of the drug was determined following the proposed procedures. The 
results are summarized in Table 3.4. As can be seen from the table, that the 
recoveries obtained by both the procedures are quite satisfactory with low RSD. 
Robustness 
The robustness of the proposed procedure was ascertained by challenging 
the following operational parameters: 
• volume of 0.003 M KIO3 (± 0.4 ml) 
• volume of 0.05 M KI (± 0.3 ml) 
Under these conditions, quality control samples were analyzed at two 
concentration levels: 25.0, and 45.0 fig ml"'. The results are quite satisfactory with 
acceptable recovery and low RSD values. 
Applicability of the proposed methods 
The applicability of the proposed methods for the assay of irbesartan in 
drug formulations has been tested on commercially available tablets. The results of 
the proposed methods were statistically compared with those of the developed 
reference method using point and interval hypothesis tests. Table 3.5 shows that 
the calculated t- (paired) and F-values at 95% confidence level are less than the 
theoretical ones, confirming no significant difference between the methods 
compared. It can also be seen from the table that the bias evaluated by interval 
hypothesis test is within the acceptable range of i^\= 0.98 and ^n = 1.02. The 
performance of the proposed kinetic spectrophotometric method was compared 
with other methods (Table 3.6). It can be seen from Table 3.6 that HPTLC method 
is time consuming and tedious. The precision is also somewhat poor. 
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Table 3.6: Comparison of the proposed kinetic spectrophotometric method 
with other methods for determination of irbesartan 
Methods 
HPTLC 
HPLC 
CZE 
CZE 
Spectrophotometry 
hiitiai rate method 
Fixed-time method (AA) 
Linear dynamic range 
(^gml-') 
60-180 
0.001-1.0 
60-300 
80-400 
10-60 
7.5-60 
RSD 
(%) 
1.81-2.49 
<8 
0.93 
0.28-0.49 
0.17-0.84 
0.10-0.74 
References 
[3] 
[5] 
[7] 
[8] 
i'liis work 
This work 
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HPLC method is sensitive enough but it requires solid phase extraction of 
irbesartan before analysis and RSD is also higher. CZE [7,8] gives accurate results 
but the technique is expensive. The present kinetic spectrophotometric method is 
simple, fast and accurate because it does not involve any pretreatment step prior to 
analysis. 
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INTRODUCTION 
Nicorandil, N-[2-(nitroxy)ethyl] 3-pyridne carboxamide, is a cardiovascular 
drug with both nitrate-like and ATP- sensitive potassium-channel (K^ ATP) 
activating properties [1]. By virtue of this dual mechanism of action, the drug acts 
as a balanced coronary and peripheral vasodilator and reduces both preload and 
after load. Initial interest in the drug focused on its activity in ischaemic heart 
disease. Overtime, however, the potential cardioprotective effect of the drug has 
received increasing attention. Nicorandil is primarily metabolized via oxidation to 
nicorandil-N-oxide and hydroxy nicorandil and by denitration to N - [2-hydroxy 
ethyl] nicotinamide. The latter is further transformed to nicotinamide, nicotine and 
N-methyl-nicotinamide. 
The drug is listed in Martindale The Extra Pharmacopoeia [2]. Many efforts 
have been made to determine nicorandil concentration in biological fluids and drug 
formulations. The techniques used for the assay which include high performance 
liquid chromatography [3-8], high performance thin layer chromatography [9], gas 
chromatography coupled with mass spectrometry [10], and polarography [11]. The 
literature reveals that few spectrophotometric methods have also been developed to 
determine nicorandil in drug formulations and biological fluids. The nicorandil 
reacts with 4-(methylamino) phenol sulphate and 3-methyl-2-benzothiazolinone 
hydrazone hydrochloride (MBTH) resulting in the formation of a coloured product 
with Xmax of 560 nm nm. Beer's law is obeyed in the concentration range of 0.4 -
2.2 \ig ml''. The present work introduces a new method for the spectrophotometric 
determination of nicorandil in pharmaceutical formulations. The assay of drug was 
based on exploiting the presence of nitrate moiety in the chemical structure of the 
drug [12]. The quantitation of the drug has also been done based on its reaction 
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with sulphanilic acid in presence of cyanogen bromide [13], phenoldisulphonic 
acid [14], phloroglucinol-sulphanilic acid reagent in sulphuric acid medium [15]. 
Nicorandil oxidizes the MBTH and DL-2, 3-dihydroxyphenyI alanine and finally a 
coloured product is formed owing to the oxidative coupling of MBTH with DL-
2,3-dihydroxyphenyl alanine [15]. 
In the present chapter, the nitroxy ethyl group of nicorandil is reduced to 
carbonyl derivative of nicorandil and nitrite ion by Zn / NH4CI. The nitrite ion 
obtained undergoes diazotization reaction with sulphanilamide in presence of HCl 
followed by coupling with N - (1-naphthyl) ethylenediamine dihydrochloride 
(NED) to give an intense coloured product with >.niax at 525 nm. The proposed 
method is optimized and validated as per the International Conference on 
Harmonization (ICH) guidelines [16]. 
EXPRIMENTAL 
Materials and Methods 
Apparatus 
A Shimadzu UV-Visible Spectrophotometer (model 1601) Kyoto, Japan 
with matched quartz cells was used for recording the absorption spectra. 
+ 
Absorbance measurements were made on Spectronic 20D spectrophotometer 
(Milton Roy, USA). 
Reagents and Standards 
Reference standard sample of nicorandil was kindly provided by M/s. 
Zydus Medica, Ahmedabad, India and was used as received. The commercial 
dosage forms of nicorandil such as Nikoran (Torrent IMiarmaceutical, Ahmedabad, 
India), Korandil (Sun Pharma. Industries Ltd., Mumbai, India) and Zynicor (Zydus 
Medica, Ahmedabad, India) were purchased from the local market. 
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• Standard solution of nicorandil (0.2 mg ml"') was prepared in distilled water 
• 2.32x10"^ M sulphanilamide solution (Sigma Chemical Company, USA) was 
prepared by dissolving 0.40 g in 5 ml of 0.1 M HCl and then diluted up to 100 
ml with distilled water. 
• 0.05 M HCl solution 
• 0.15 M ammonium chloride (E.Merck, India) was prepared in distilled water. 
• 3.09x10"^ M NED solution (Koch-light laboratories, England) was prepared by 
dissolving 0.08 g imlOO ml distilled water. 
Preparation of the degraded product 
500 mg of nicorandil was hydrolyzed with 4 N HCl at 100 °C for 30 min. 
[9]. The degraded product was isolated by preparative thin layer chromatography 
using plate coated with silica gel G as stationary phase and 
chloroform:methanol:ethyl acetate (4:1:5 v/v/v/) as mobile phase. The band 
corresponding to the degradation product was located under UV lamp. The band 
was scrapped and extracted with chloroform. Finally, the pure degradation product 
(denitrated nicorandil) was obtained after removal of chloroform under vaccum 
distillation. 
Recommended procedure for quantitation of nicorandil 
Aliquots of standards nicorandil solution (0.2 mg ml'') in the concentration 
range of 0.4 - 12.0 |ig ml"' were pipetted into a series of 25 ml beakers. To each 
beaker, 3.5ml of 0.15 M NH4CI and 0.1 g zinc powder were added and left for 3 
min. The whole content was filtered through Whatmann No. 42 filter paper 
(Whatmann International Limited, Kent, UK) in a 25 ml volumetric flask. To the 
flask, 1.5 ml of 2.32x10""' M sulphanilamide was added followed by 1.2 ml of 0.05 
M HCl with shaking and left still in an ice bath (0-3 °C) for 1 min. Then 1.3 ml of 
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3.09 X 10-^  M NED was added and the volume was completed with distilled water. 
The absorbance of the coloured product was measured at 525nm against the 
reagent blank. 
Quantitation of nicorandil in drug formulations 
Five tablets were weighed and grounded. The powder equivalent to 5 mg of 
nicorandil was weighed accurately and dissolved in 10 ml of distilled vv'ater. The 
undissolved particle was then allowed to settle down and filtered through 
Whatmann No. 42 filter paper. The residue was washed with additional 10 ml of 
distilled water for recovery of drug. Then the filtrate was diluted to 25 ml with 
distilled water and subjected to recommended procedure for determination of 
nicorandil. 
Recovery studies 
Recovery experiments were carried out by standard addition method. For 
this 2.0 ml (or 4.0 ml) of reference nicorandil (0.2 mg ml'') was transferred into 
100 ml volumetric flask followed by 1.0 ml of sample solution (0.2 mg ml''). The 
volume was completed with distilled water and the nominal value was determined 
by the proposed procedure. 
Limits of detection (LOD) and quantitation (LOQ) 
The values of the LOD and LOQ were calculated using the expression: 
LOD = 3.3 X So/band LOQ = lOxSo/b 
where So and b are standard deviation and slope of the calibration line, 
respectively. 
Evaluation of bias. 
The bias has been evaluated by means of point and interval hypothesis tests 
[17,18], In interval hypothesis the proposed method (method 2) is accepted when 
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the true mean is within ± 2% of that of the reference method (method 1), i.e., 0.98 
< ^2 / Ri < 1 -02, which can be generalized to 9L < H2 / l^ i < 0u where 9L and 9u are 
lower and upper acceptance limits, respectively. The limits of this confidence 
interval can be calculated using the following quadratic equation: 
e^^-Sy/n,)-207,T,+{^,-Sy/n,)=O 
RESULTS AND DISCUSSION 
Zinc is one of the most frequently used reducing agent for reduction of 
nitrate into nitrite [19] while ammonium chloride is used to assist the reduction 
process [20]. The same concept has been utilized in the present communication. 
The nicoremdil possesses nitroxy ethyl group which on treatment with Zn / NH4CI 
yields carbonyl derivative of nicorandil and nitrite ion. The nitrite thus obtained 
undergoes diaizotization with sulphanilamide and then subsequently coupling with 
NED to give a coloured product. The related absorption spectra are depicted in 
Figure 4.1 and the reaction sequence is shown in Scheme 4.1. The absorption 
spectrum of the reaction product has an absorption maximum at 525 nm. The 
reagents do not absorb radiation at 525 nm. 
Optimization of variables 
Various parameters responsible for the formation of the coloured product 
were studied and optimized by conducting a series of experiments. 
Effect of zinc 
To examine the effect of zinc on the reduction of nicorandil to yield nitrite 
ion, a known amount of nicorandil (280 ^g) was treated with different amount of 
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Fig. 4.1: Absorption spectra of (a) 1.0 ml of 0.01% nicorandil (10 |j,g ml"') in 
10 ml distilled water (b) 1.0 ml of 0.01% nicorandil with 3.5 ml of 0.15 M 
NH4CI and 0.2g of zinc dust followed by filtration through Whatmann No. 42 
filter paper (c) blank solution: 1.39 xlO"'* M sulphanilamide, 2.8xlO"^M HCl 
and 1.730x10"^ M NED in 25 ml volumetric flask and diluted to volume with 
distilled water (d) sample solution: 1.4 ml of 0.02% nicorandil with blank 
solution in 25 ml volumetric flask and diluted to volume with distilled water. 
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Scheme 4.1: Reaction sequence for the formation of coloured product of nicorandil 
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zinc dust (0.005 - 0.2 g) in presence of a constant concentration of NH4CI (2.1 x 
lO"'^  M). It was observed that a constant absorbance was obtained at 0.05 g of zinc, 
which remained constant up to 0.2 g. Therefore, 0.1 g of zinc dust was selected as 
an optimum quantity for the reduction process. 
Effect ofNH^l concentration on the reduction process 
The effect of ammonium chloride concentration on the reduction process 
was examined in the range of 6.0 x lO"^ - 2.4 x 10"^  M and keeping the constant 
amounts of nicorandil (280 |ig) and zinc dust (0.1 g). It was found that the 
maximum absorbance was obtained with 1.8 x lO'' M NH4CI, which remained 
constant up to 2.4 x 10"^  M (Figure 4.2). Therefore, 2.1 xi 0'^  M NH4CI was 
selected for further investigation. 
Effect of time on the reduction process 
The effect of time on the reduction process was studied by treating 280 |ig 
nicorandil with O.lg of zinc dust and 2.1 x 10"^  M NH4CI. A constant absorbance 
was obtained after 1 min. and remained constant up to 3 min. Hence, a time of 2 
min was selected as an optimum value for the reduction process. 
Effect of reaction time 
To optimize the reaction time for the colour development, the drug (280 
^g) was treated with 0.1 g zinc dust and 2.1 x lO''^  M NH4CI and left still for 2 min 
and then filtered through Whatmann No. 42 filter paper. To the filtrate containing 
nitrite ions, 1.5 ml of 2.32 xlO'^ M sulphanilamide was added followed by 1.2 ml 
of 0.05 M HCl and the reaction mixture was kept in an ice bath ( 0 - 3 °C) for 
different time intervals (0.25 to 3 min). After removing the flask from the ice bath, 
1.3 ml of 3.09 X 10"^  M NED was added and diluted to 25 ml with distilled water. 
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Fig. 4.2: Effect of ammonium chloride concentration on the reduction of 
nicorandil. 
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The maximum intensity of colour was obtained at 1 min and remained constant up 
to 3 min. Therefore, a time of 2 min was selected as an optimum time for the 
diazotization reaction. 
Effect of Sulphanilamide concentration 
The effect of the concentration of sulphanilamide on the colour 
development was examined in the range of 9.26 X 10"So 1.76 X lO'^'M. It can be 
seen from the Figure 4.3 that the highest absorbance was obtained with 1.02x10"* 
M sulphanilamide and remained constant up tol.76 x 10"\ Therefore, 1.39 x 10''' 
M sulphanilamide was used for further studies. 
Effect ofHCl concentration on diazotization 
The influence of HCl concentration on the absorbance of the coloured 
product was studied in the range of 1.0 x 10''' - 3.0 x 10"^  M. The results are shown 
in Fig. 4.4. It is apparent from figure that a constant absorbance was obtained in 
the concentration range of 1.8 x lO"^  to 3.0 x 10"^  M. Therefore, 2.4 x 10"^  M HCl 
was selected as an optimum concentration of HCl required for the colour 
development. 
Effect of NED on the colour development 
It was found that the constant absorbance was obtained in the concentration 
range of 1.24 xio"* - 1.98 x lO"" of NED. Therefore, 1.61 x lO"'' M NED was 
selected as an optimum value in the colour development (Figure 4.5). 
Solution Stability 
The stability of the nicorandil solution was checked by recording the UV 
spectra of pure nicorandil and quality control sample for four days. The band for 
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Fig. 4.3: Effect of sulphanilamide concentration on the absorbance of the 
reaction product. 
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Fig. 4.4: Effect of HCI concentration on diazotization reaction. 
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Fig. 4.5: Effect of NED concentration on the absorbance of the reaction 
product. 
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nicorandil was located at 260 nm whereas at this wavelength no band 
corresponding to the degradation product was observed. It was found that there 
was no change in the absorption spectra. The solution stability was also ascertained 
by applying the standard solution of nicorandil and quality control sample solution 
on TLC plates with silica gel G (Merck (India) limited, Mumbai) and developed in 
chloroform: methanol: 2.61 M NH3 system (2.5:1.5:0.4 v/v/v). The plates were air-
dried and spot was detected in iodine chamber. In both the cases Rf value was 
found to be 0.68 confirming the stability of the solution. 
ANAI.YTICAL DATA 
Under the optimized and validated experimental conditions the plot of 
absorbacce versus the concentration of nicorandil was found to be linear over the 
concentration range 0.4-12.0 |ig ml'' with molar absorptivity 1.92x10'' 1 mol"' cm''. 
The statistical treatment of calibration data (n = 11) yielded intersept (a), slope (b), 
correlation coefficient (r), confidence limits of intercept (± t Sg) and slope (± t Sb) 
at 95 % confidence level, variance, and detection and quantitation limits. The 
results are summarized in Table 4.1. The high value of correlation coefficient (r = 
0,9999) indicated the excellent linearity of the calibration line. The low value of 
variance of calibration line pointed towards the higher reproducibility of the 
proposed method. 
Accuracy and Precision of the Proposed Method 
The relative standard deviations (RSD) evaluated at concentrations of 0.8, 
5.6, 11.2 [xg ml'' in pure form for intra-day variations were 5.38, 0.85 and 0.38%, 
respectively; and for inter-day variations were 6.02, 0.93 and 0.48%, respectively 
(Table 4.2). The RSD evaluated at 12.0 [ig ml'' in pharmaceutical formulation for 
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Table 4.1: Optical and regression characteristics of the proposed method 
Parameters 
m^ax (nm) 
Stability (h) 
Beer's law limit (fig ml') 
Molar absorptivity (I moP' cm'') 
Linear regression equation 
Sa 
±tSa 
Sh 
±tSb 
Correlation coefficient (r) 
Variance (So^) 
Detection limit (ng ml'') 
Quantitation limit (|ig ml'') 
Proposed method 
525 
02 
0.4-12.0 
1.92 xlO' 
A = 6.304x 10-'' + 
9.130 X IQ-^ C 
7.35 X to-' 
1.66x10-' 
1.03 xJO-' 
2.34x10"' 
0.9999 
1.96x10"^  
0.05 
0.15 
S a^nd Share standard deviation of intercept and slope, respectively 
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Table 4.2. Intra-day and Inter-day assays: Determination of nicorandil in 
pure form 
Concentration 
(^gmI•') 
Taken 
Intra-dav assay 
0.8 
5.6 
11.2 
Inter-dav assay 
0.8 
5.6 
11.2 
Found ± SD' 
0.799 ± 0.043 
5.599 ±0.048 
11.209 ± 0.043 
0.79710.048 
5.601 ±0.052 
11.195 ±0.053 
Error 
(%) 
0.125 
0.018 
0.080 
0.375 
0.018 
0.045 
RSD 
(%) 
5.38 
0.85 
0.38 
6.02 
0.93 
0.48 
SAE" 
0.019 
0.021 
0.019 
0.022 
0.023 
0.024 
C.L.-^  
0.053 
0.059 
0.053 
0.060 
0.065 
0.066 
*Mean for five independent analyses. 
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intra-day variations were found to vary in the range 0.55 - 0.62 % and for inter-day 
varied over the range 0.61-1.09% (Table 4.3). 
Specificity 
The specificity of the proposed method was evaluated by determining the amount 
of nicorandil (8.0 |ig mr')in presence of its degraded product (0.1- 1.0 |ig ml"'). It 
was found that the degradation product of nicorandil did not interfere with the 
determination process (Table 4.4). 
The standard drug and quality control sample solutions were stressed by 
light and heat (up to 50 "C) for 2, and 1-day lime points, respectively. It was 
observed that stress by such conditions did not cause degradation as there was no 
change in the absorption spectra of pure drug and stressed sample solution. The 
specificity of the proposed method was also ascertained by determining the 
nicorandil in presence of various excipients commonly used in the formulations 
such as lactose, starch, magnesium stearate and talc. The results (Table 4.5) 
revealed that the exciepients did not interfere. However, oxidants such as N-
bromosuccinimide and potassium iodate did not interfere upto 4.0 x 10''' and 2.0 
X 10" M, respectively; above these concentration, interference was observed. 
Potassium persulphate even at very low concentration, interfere with the 
determination process. 
The results of recovery experiment are summarized in Table 4.6. As can be 
seen from the table that the mean recoveries and RSD for Nikoran, Korandil and 
Zynicor commercial tablets were in the range of 100.01 - 100.03%, 0.50 - 0.78%; 
99.99%, 0.50 - 0.77% and 100.02 - 100.04%, 0.5! - 0.88%, respectively. The 
recovery experiments have also confirmed that the common excipients present in 
tablets did not interfere. 
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Table 4.3. Intra-day and Inter-day assays: Determination of nicorandil in 
drug formulations 
Drug formulations Concentration Error RSD SAE'' C.L.' 
Taken Found ± SD' 
(Hgml-') (%) (%) 
Intra-day assay 
Nikoran-5 12.0 12.003 ±0.074 0.025 0.62 0.033 0.092 
(Samarth Pharma) 
K.orandil-5 12.0 11.997 ±0.070 0.025 0.58 0.031 0.087 
(Sun Pharma) 
Zynicor-5 12.0 12.005 ±0.066 0.042 0.55 0.030 0.082 
(Zydus Medica) 
Inter-day assay 
Nikoran-5 12.0 11.994 ±0.131 0.050 1.10 0.059 0.162 
(Samarth Pharma) 
Korandil-5 12.0 12.005 ±0.110 0.042 0.92 0.049 0.137 
(Sun Pharma) 
Zynicor-5 12.0 12.009 ±0.073 0.075 0.61 0.033 0.090 
(Zydus Medica) 
'Mean for fiye independent analyses. 
^ SAE, standard analytical error 
''C.L., confidence limit at 95% confidence level and four degree of freedom (t = 2.776) 
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Table 4.4: Determination of nicorandil in presence of denitrated nicorandil 
ConcentrationCngml-') Recovery RSD" 
Nicorandil Taken Denitrated nicorandil added Nicorandil fouund (%/ (%) 
8.0 10.0 8.0 100.0 1.32 
8,0 100.0 8.0 100.1 0.67 
8.0 1000.0 8.0 100.0 0.72 
a. Mean for five independent analyses 
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Table 4. 5: Determination of nicorandil in presence of excipients 
Nicorandil Concentration (|ig ml"') Recovery RSD 
Taken Found (%)" (%) 
5.6 5.6 100.0 0.78 
10.4 10.4 100.0 0.46 
a. Mean for five independent analyses 
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Table 4.6: Standard addition method: Evaluation of the validity of the 
proposed method for the recovery of Nicorandil 
Drug formulations^ 
Nikoran-5 
(Samarth Pharma) 
Korandil-5 
(Sun Pharma) 
Zynicor-5 
(Zydus Medica) 
Concentration 
(^ig mi-
Taken 
3.2 
3.2 
3.2 
3.2 
3.2 
3.2 
') 
Added 
4.0 
8.0 
4.0 
8.0 
4.0 
8.0 
Found ± SD' 
7.202 ±0.056 
11.201 ±0.056 
7.199 ±0.055 
11.199±0.055 
7.201 ±0.063 
11.205 ±0.057 
Recovery 
(%) 
100.03 
100.01 
99.99 
99.99 
100.02 
100.04 
RSD 
(%) 
0.78 
0.50 
0.77 
0.50 
0.88 
0.51 
SAE 
0.025 
0.025 
0.025 
0.025 
0.028 
0.026 
C.L. 
0.070 
0.069 
0.686 
0.069 
0.079 
0.071 
*Mean for five independent analyses. 
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The applicability of the proposed method has been tested for the determination of 
nicorandil in drug formulations. The results of the proposed method were 
compared with those obtained by the reference method [15] using point and 
interval hypothesis tests [17]. The results are summarized in Table 4.7. As can be 
seen from the Table 4.7 that student t- and F-values at 95% confidence level did 
not exceed the theoretical t- and F-values. This statistical comparison has indicated 
that there is no significant difference in the performance of the proposed method 
and the reference method. The bias based on the recovery experiments was 
calculated. It is evident from the table that the true bias of all samples is < ±2%, 
confirming the recommendations of Canadian Health Protection Branch. 
The proposed method is based on the reduction of nitroxyethyl group of 
nicorandil into nitrite ion and subsequent coupling with NED, which makes the 
method more sensitive and rapid. Statistical comparison of the results with those of 
reference method has proved that the proposed method is accurate, precise and 
reproducible. No interference was observed from the denitrated nicorandil and 
common excipients. 
158 
Table 4.7: Point and interval hypothesis tests: Evaluation of the applicability of the 
proposed method with the reference method at 95% confidence level 
Drug Proposed method Reference t- value F- BL'' Qyf' 
formulations' method value 
Recovery RSD' Recovery RSD" 
(%) (%) (%) (%) 
Nikoran-5 99.99 0.41 100.09 0.56 2.707 1.372 0.987 1.011 
(Torrent Pharma) 
Korandil-5 100.02 0.41 99.95 0.57 1.895 1.391 0.990 1.011 
(Sun Pharma) 
/ynicor-5 100.08 0.43 100.12 0.52 1.083 1.227 0.982 1.017 
(Zydus Medica) 
Mean for five independent analyses. 
Theoretical t-value (v = 8) and F-value (v = 4, 4) at 95 % confidence level are 2.306 and 
6.39, respectively. 
"^ In pharmaceutical analysis, a bias, based on recovery experiments, of ± 2% is acceptable. 
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INTRODUCTION 
Lisinopril, N -[(lS)-l-carboxy-3-phenylpropyl]-L-lysyl]-L-proline dihydrate 
is an orally active angiotensin converting enzyme (ACE) inhibitor used for the 
treatment of hypertension, heart failure and acute myocardial infarction [1]. In 
addition, the drug has been shown to produce beneficial effects on renal function in 
hypertensive patients with type 2 diabetes mellitus with incipient nephropathy and on 
renal function and retinopathy in patients with type 1 diabetes mellitus. In patients 
with heart failure, the recommended starting dose is 5 mg in U.S. and 2.5 mg in U.K. 
The dose should be administered once daily and increased to the high dose tolerated 
by the patient up to a maximum of 20 mg [2]. The drug is susceptible to the acidic 
degradation and therefore, it is necessary to develop a simple and reliable method for 
the quantification of lisinopril in commercial dosage forms, bearing in mind the 
requirement for stability during sample preparation and analytical process. The assay 
procedure for Irsinopril is cited in the monograph of The United States Pharmacopoeia 
[3], which recommends HPLC with UV-detection at 210 nm. The techniques that are 
used for determining lisinopril are HPTLC [4], HPLC [5-7], polarography [8, 9], 
capillary electrophoresis [10], radioimmunoassay [11], and fluoroimmunoassay [12]. 
There is no doubt that most of the assay methods are sensitive but expensive and 
require laborious clean up procedure prior to analysis. Several spectrophotometric 
methods have been employed for the quantification of lisinopril in commercial dosage 
forms [13-16]. The drug has been determined in the visible region based on the 
reaction of drug with reagents such as sodium hypochlorite and phenyl hydrazine [7], 
2,4-dinitrofluorobenzene [8], 2,4,6-trinitrobenzoic acid [17], 1,2-naphthoquinone-4-
sulphonic acid [18], chloranil, dichlone, acetyl acetone and formaldehyde [19], 
7-chIoro-4-nitrobenzo-2-oxa-l, 3-diazole [20], ninhydrin [21], 7,7,8,8-
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tetracyanoquinodimethane and chloranilic acid [22], ninhydrin, and ascorbic acid 
[23]. The drug content in pharmaceutical formulations was also determined by 
extractive spectrophotometric methods based on the chloroform extractable ternary 
complex of the drug with eosin and Cu (II) and / or Fe (III) at 545 nm [24]. In most 
cases, these spectrophotometric methods [7,8,19-21] require long heating time at 
elevated temperatures (60-100 °C) for colour development. It has been reported [21] 
that chloranil was utilized earlier for the spectrophotometric determination of 
lisinopril but the reaction condition was tedious and time consuming as the 
development of colour involved 45 min of heating at 60 °C and the linear range for 
quantification was also narrow. Therefore, there is a need to develop simple and 
accurate spectrophotometric methods to assay lisinopril in dosage forms. 
In the present chapter, two simple and sensitive spectrophotometric 
methods for the quantification of lisinopril in pharmaceutical formulations are 
described. Method A utilizes the reaction of primary amino group of the drug with 
N-bromosuccinimide in acetone to form a yellow coloured product peaking at 353 
nm. Method B is based on charge transfer complexation reaction of drug with 
chloranil in 1,4-dioxan-acetonitrile medium. The proposed methods are validated 
as per the guidelines of the International Conference on Harmonisation (ICH) [25]. 
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EXPERIMENTAL 
Materials and Methods 
Apparatus 
All absorption spectra were recorded on a Shimadzu UV-visible 
spectrophotometer (UV mini-1240, Shimadzu Corporation, Kyoto, Japan) with 
matched quartz cells. 
The absorbance was measured on a Spectronic 20 D"^  spectrophotometer 
(Milton Roy Company, USA) with 1 cm matched glass cells. 
Reagents and standards 
All chemicals and reagents were of analytical or pharmaceutical grade. 
Solutions of N-bromosuccinimide (2.25 x lO''^  M; S.d. fine Chem. Ltd., India) and 
chloranil (9.0 x 10' M; Fluka, Switzerland) were prepared in acetone and 1,4-
dioxan, respectively. 
Lisinopril reference standard (Batch No. LIS-0020303) was kindly 
provided by Unimark Remedies Limited (Vapi, Gujrat, India). 1.0 mg ml'' and 3.0 
mg m!'' lisinopril standard solutions were prepared in distilled water and methanol, 
respectively. These solutions were employed to prepare standard calibration 
curves. 
Quality control tablets of lisinopril such as Listril-2.5 mg (Torrent 
Pharmaceuticals Ltd., Gujrat, India), Linvas-2.5 mg (Zydus Cadila, Gujrat, India), 
and Lipril-2.5 mg (Lupin Laboratories, Mumbai, India) were obtained from local 
drug stores. 
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Procedure for the determination of lisinopril 
Method A 
Appropriate volumes of standard solution of lisinopril (1.0 mg ml'') 
corresponding to 50-1000 |J.g were transferred into a series of 5 ml volumetric 
flasks. To each flask, 2.0 ml of 2.25 x lO"'^  M N - bromosuccinimide was added 
I 
and diluted to volume with acetone. The contents of each flask were mixed well at 
room temperature (25 ± 1°C) and the absorbance was measured after 10 min of 
mixing at 353 nm against a reagent blank in which drug is omitted. The absorbance 
was plotted against the initial concentration to get the calibration curve. 
Alternatively, regression equation was derived. 
Method B 
Aliquots (0.04 - 1.0 ml) of standard solution of lisinopril (3.0 mg ml"') were 
pipetted into a series of 5 ml volumetric flasks. Then 1.0 ml of 9.0 x 10" M 
chloranil was added to each flask and diluted to volume with acetonitrile at 25 ± 
1°C. The intensity of the colour developed was measured after 10 min. of mixing 
at 520 nm against the reagent blank prepared similarly omitting the drug. The 
amount of the drug in a given sample can be estimated either from calibration 
graph or corresponding regression equation. 
Analysis of lisinopril in pharmaceutical formulations 
Ten and thirty tablets of 2.5 mg strength were taken separately in distilled 
water and methanol, respectively and left for 10 min for complete dispersion of 
drug. The aqueous and methanolic extracts were filtered through Whatmann No. 
42 filter paper (Whatmann International Limited, Kent, UK) in 25 ml volumetric 
flasks, separately. The residues were washed well with appropriate solvent for 
complete recovery of drug and diluted to volume with distilled water or methanol 
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as the case may be. The amount of the drug was determined following the 
proposed procedures. 
Determination of analytical performance parameters 
Methods A and B have been validated for specificity, linearity, limit of 
detection, precision, accuracy and recovery. 
Linearity. 
The linearity was evaluated by considering nine concentration levels, 10, 
20, 30, 40, 60, 100, 140, 180 and 200 lagml"' for method A and 24, 60, 90, 180, 
300, 420, 480, 540 and 600 |ig ml'' for method B. The determination was 
completed five times at each concentration level. 
Accuracy and precision. 
Intra day and inter day precisions were performed at three concentration 
levels: 20, 100, 200 ^g ml'' for method A and 60, 300, 540 i^g ml"' for method B. 
The determination was repeated five times at each concentration level using N-
bromosuccinimide and chloranil obtained from Central Drug House, Pvt. Ltd, 
India, and Shimadzu UV-visible spectrophotometer 
Recovery studies. 
The recovery experiments for method A (or method B) were performed 
using standard addition method by pipetting volumes of 1.0 ml (or 2.0 ml) and 5 
(or 10 ml) of quality control sample solution into 25.0 ml volumetric flasks which 
were spiked with 1.0, 2.0, 3.5, 4.5 and 5.5 ml (or 1.0, 2.0, 4.0, 5.0, and 9.5) and 
2.5, 5.0, 7.5, 10.0 and 12.5 ml (or 2.5, 4.0, 8.0, 12.0, and 15.0) of reference 
standard solution (1.0 or 3.0 mg ml'") and diluted up to volume with acetone (or 
acetonitrile) as the case may be. The total amount of lisinopril was determined by 
the proposed procedures. 
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Evaluation of bias 
The point and interval hypothesis tests have been performed to compare 
results of the proposed methods with those of the British pharmacopoeia method 
[26] at 95% confidence level. The proposed method is considered acceptable when 
its true mean is within ± 2.0 % of that of the reference method. This can be 
calculated from the following quadratic equation [27]: 
e^^l-sy In,)- 2dx,7[ + fcj - sy /«2 )= 0 
RESULTS AND DISCUSSION 
The aqueous solution of lisinopril absorbed maximally at 203 nm whereas 
N-bromosuccinimide in acetone exhibited Xmax at 209 nm. The addition of N-
bromosuccinimide to the drug solution generated a new characteristic band 
peaking at 353 nm (Fig. 5.1). It has been reported that the halogenation of amines 
at nitrogen is an oxidative reaction requiring a source of positive halogen. N-
bromosuccinimide is capable of acting as brominating agent for amines, 
presumably by direct exchange of bromine [28]. Lisinopril is a water-soluble drug 
possessing primary aliphatic amino group in its structure. In the present study, the 
amino group undergoes bromination resulting in the formation of yellow coloured 
bromo-derivative of lisinopril, which absorbed maximally at 353 nm. N-
bromosuccinimide was irreversibly reduced to succinimide and it has also been 
confirmed that bromine was not evolved during this reaction. The reaction 
sequence is outlined in scheme 5.L 
The absorption spectrum of chloranil in 1,4-dioxan showed a band peaking 
at 360 nm. The addition of chloranil to the lisinopril solution caused an immediate 
shift in the absorption band at 520 nm (Fig. 5.1). It is well known that chloranil. 
168 
c 
ro 
i ~ 
o (/> 
< 
210 240 270 300 330 360 390 420 450 480 510 540 570 600 630 660 690 
Wavelength (nm) 
Figure 5.1; Absorption spectra of (a) 1.132 xlO""* M (50.0 ^g ml') 
lisinopril in distilled water (b) 1.348x10'^ N-bromosuccinimide in 
acetone, (c) 4.530 x i o " M (200.0 ^g ml') lisinopril with 8.989 xlO'^ M 
N-bromosuccinimide in acetone, (d) 3.600 xlO'^ M chloranil in 1,4-
dioxan, (e) 1.087 xlO"^ M (480.0 ng ml') lisinopril with 3.600 xlO"^ M 
chloranil in 1,4-dioxan-acetonitrile medium. 
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Brominated lisinopril (yellow colored product) HO Succinimide 
Scheme 5.1. Reaction Sequence for the reaction of lisinopril with N-bromosuccinimide 
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being a ;i-acceptor, is able to react with basic nitrogenous compounds as n-donors 
to form charge transfer complexes or radical anions. Lisinopril, being n-donor, 
reacts with chloranil to form charge transfer complex. The absorption band 
observed at 520 nm is due to the formation of chloranil radical anion by complete 
transfer of electrons from lisinopril molecule to chloranil in 1,4-dioxan-acetonitrile 
medium. The stoichiometry between lisinopril and chloranil was established by 
mole ratio method (Fig. 5.2) and found to be 1:1, which confirmed the presence of 
one n-donating center in lisinopril molecule. The reaction sequence of the coloured 
chromogen is shown in scheme 5.2. The association constant and apparent molar 
absorptivity for lisinopril-chloranil charge transfer complex have been calculated 
using Ross and Labes equation [29]: 
[D][A] 1 1 1 1 
[D] + [A] d Ks {D] + [A\ £ 
where [D] and [A] are the molar concentrations of the donor and acceptor, 
respectively, d is the absorbance of the donor-acceptor complex at 520 nm. 8 and 
K are the apparent molar absorptivity and association constant of the charge 
transfer complex. A straight-line curve (Fig.5.3) was obtained by plotting y = [D] 
[A] / d ([D] + [A]) versus x = 1/ [D] + [A] with coefficient of correlation, r = 
0.999, thus indicated good linearity of the curve. The intercept and slope of the 
curve are equal to 1/ e and 1/ Ke, respectively. The association constant and 
apparent molar absorptivity calculated from slope and intercept were 1.21 x 10^  
and 7.25 x loM mol"' cm' , respectively. The apparent Gibb's free energy (AG )^ 
was calculated using equation, A G^  = - 2.303 RT log K and found to be -17.6 KJ 
mof' at 298 K. 
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Mole ratio (lisinopril / chloranil) 
Figure 5.2: Mole ratio plot for lisinopril-chloranil (1:1) charge transfer 
complex (9.0x10"^ M each for donor and acceptor). 
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H / O 
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. . C = 0 Lisinopril-chloranil charge transfer complex 
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Scheme 5.2. Reaction sequence for charge transfer complexation reaction of 
lisinopril with chloranil 
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0.00070 
0.00065 -
0.00060 -
0.00055 -
K 0.00050 
+ 
^ 0.00045 ^  
^ 0.00040 
Q 
0.00035 -
0.00030 -
0.00025 -
0.00020 —I 1 1 1 1 1 1 1 1 r 
660 693 726 759 792 825 858 891 924 957 990 1023 1056 
1/[D]+[A] 
Fig. 5.3: A straight-line plot of 1/ [D]+[A1 versus [D][A]/ dj ([D1+ [A]) for the 
charge transfer complexation reaction between lisinopril and chloranil (1:1). 
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Optimization of variables 
The optimum conditions for methods A and B have been established by 
studying the reactions as a function of the concentration of reagents, the nature of 
the solvent and the stability of the coloured species. 
For method A, the influence of the concentration of N-bromosuccinimide 
on the development of colour was investigated by treating varied concentration 
(1.35 X 10"^ - 1.13 X 10"'^  mol 1'') of N-bromosuccinimide with 1 ml of lisinopril 
(Img ml'') into a series of 5.0 ml standard volumetric flasks. The contents were 
diluted to volume with acetone at room temperature. It was observed that a stable 
colour of the reaction product was obtained within 10 min of mixing and the 
highest absorbance was achieved with 6.75 x 10'^  M N-bromosuccinimide (Fig. 
5.4). Further addition of N-bromosuccinimide caused no change in the absorbance 
and therefore 9.0 x 10"^  M N-bromosuccinimide was selected as an optimum 
concentration for determination process. 
For method B, the effect of the concentration of chloranil was studied over 
the concentration range of 9.0 x 10'^  - 2.23 x 10'^  M with 1 ml of lisinopril (3 mg 
ml"') in 5 ml standard volumetric flasks. The contents of the flask were diluted 
with acetonitrile. The highest absorbance was obtained with 1.26 x 10'^  M 
chloranil and remained constant up to 2.23 x lO''' M (Fig. 5.5). Therefore, 1.80 x 
10'^  M chloranil was chosen as an optimum value for all absorbance 
measurements. The purple coloured species gets stabilized within 10 min of 
mixing at room temperature and the absorbance remained constant for a further 90 
min. 
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Fig.5.4: Effect of the molar concentration of N-bromosuccinimide 
on the absorbance of the product (Method A; lisinopril 200.0 ^g 
ml'). 
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-0.00035 0.00000 0.00035 0.00070 0.00105 0.00140 0.00175 0.00210 0.00245 
Concentration of chloranil (M) 
Figure 5.5: Effect of the molar concentration of chloranil on the absorbance of 
the product (Method B; iisinopril 600.0 |j.g ml"'). 
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TLC study of lisinopril and its degraded product 
Reference lisinopril standard and its principal degraded product, lisinopril-
diketopiperazine were analyzed by thin layer chromatography. 10|al of sample 
solutions of reference drug and lisinopril-diketopiperazine were applied on TLC 
plates coated with silica gel G (Merck, India). The chromatograms were developed 
in chloroform: methanol: 2.67 M ammonia (25:15:3 vol/vol/vol) system. The 
plates were air-dried and spots were located on placing the plates in iodine 
chamber. The yellow coloured spots for lisinopril and lisinopril-diketopiperazine 
were observed with Rf value of 0.31 and 0.17, respectively. 
Solution stability 
Lisinopril is stable under neutral to moderately basic conditions [30]. The 
solution stability of lisinopril was investigated by observing uv-visible spectra and 
TLC plates too for four days. The UV-visible absorption spectrum of the drug 
solution showed one peak at 203 nm while the solution of lisinopril 
diketopiperazine degradation product exhibited absorption band peaking at 195 
nm. The standard drug and quality control sample solutions showed no change in 
the absorption spectra for at least 4 days if kept at room temperature. The spots on 
TLC plates for the drug and quality control sample solutions were monitored each 
day. A single spot was observed in each solution with Rf value of 0.31, which 
confirmed that no degradation of the drug occurred for at least four days. 
ANALYTICAL DATA 
Under the optimized experimental conditions, the absorbance values for 
methods A and B were found to be proportional to the lisinopril concentrations 
over the ranges stated in Table 5.L The results of regression analysis of calibration 
data (n = 9) for both the methods are given in Table 5.1. The student's t-test has 
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Table 5.1: Validation data for the determination of lisinopril 
Parameters Method A Method B 
>^ax(nm) 353 520 
Beer's law limit (^g ml'') 10-200 24-600 
Molar absorptivity (1 mol"' 1.40x10^ 7.28x10^ 
cm-') 
Linear regression equation' A = -2.44 x IQ"' + 3.16 x A = 5.39 x lO"'' + 1.65 x 10"^  C 
±tS, 1.96x10"' 
±tSb 1.79x10-' 
Correlation coefficient (r) 0.9999 
Variance (So )^ of calibration 2.34x10'^ 
line 
Detection limit (|j.g mP') 1.60 
Quantitation limit (\ig mP') 4.84 
A=absorbance, C= concentration of lisinopril in ^g mf 
itSaand ±tSb are the confidence interval of the intercept and slope, respectively at 95 % 
confidence level. 
6.50x10-^ 
3.90x10-' 
0.9999 
2.21x10-^ 
0.94 
2.85 
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confirmed that the experimental intercepts, a, for methods A and B are not 
different from the theoretical value of zero because the t-values calculated from the 
relation [31]: t = a / Sa, (0.294 and 1.962 for methods A and B), did not exceed the 
tabulated t-value (t = 2.365, when v = 7) at 95% confidence level. Therefore, it is 
concluded that methods A and B are completely free from constant errors. 
The accuracy and precision of the methods A and B were evaluated by 
determining the lisinopril content at three different concentration levels of 20, 100 
and 200 |ig mf' and 60, 300 and 540 |ag ml'', respectively. The accuracy of the 
proposed methods was expressed as mean percent relative error. As shown (Table 
5.2) in all cases error was less than 0.60 %. The precision (intra- and interday) of 
methods A and B was evaluated in terms of percent relative standard deviation (% 
1 
RSD). It is apparent from Table 5.2 that in all cases RSD was less that 1.60 %. 
The accuracy was also tested by performing recovery experiments using 
standard addition method (Fig 5.6, 5.7). The recovery results are summarized in 
Table 5.3. Recovery ranged from 99.83 - 100.09% and 99.95 - 100.11% for 
methods A and B, respectively. From the results presented in Table 5.3, it can be 
concluded that the tablet excipients did not interfere with determination process. 
The selectivity of the proposed methods was checked by determining the content 
of lisinopril in synthetic mixture. The synthetic mixture contains lisinopril (100 
mg), calcium hydrogen phosphate (150 mg), magnesium stearate (60 mg), starch 
(120 mg), lactose (60 mg), mannitol (60 mg), red ferric oxide (60 mg) and talc 
(120 mg). The solutions were prepared as described in "Analysis of lisinopril in 
1 
pharmaceutical formulations". The content of lisinopril was determined in 
presence of excipients and results are summarized in Table 5.4. As can be seen 
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Table 5.2: Test of precision of the proposed methods 
Proposed methods 
Method A 
Intra day assay 
hiter day assay 
Method B 
Intra day assay 
Inter day assay 
Concentrat 
(^g ml-') 
Taken 
20.0 
100.0 
200.0 
20.0 
100.0 
200.0 
60.0 
300.0 
540.0 
60.0 
300.0 
540.0 
ion 
Found ± SD' 
20.01 ±0.31 
100.26 ±0.48 
200.01 ±0.57 
19.89 ±0.45 
99.82 ±0.9 
200.20 ±0.7 
59.79 ±0.51 
300.04 ±0.33 
539.79 ±0.51 
59,92 ±0.08 
299.79 ±0.89 
539.66 ±0.62 
Error 
(%) 
0.05 
0.26 
0.01 
0.55 
0.18 
0.10 
0.35 
0.01 
0.04 
0.14 
0.07 
0.06 
RSD' 
(%) 
1.58 
0.48 
0.28 
2.27 
0.91 
0.36 
0.85 
0.11 
0.10 
1.35 
0.30 
0.12 
SAE' ' 
0.14 
0.21 
0.25 
0.20 
0.41 
0.33 
0.23 
0.15 
0.23 
0.36 
0.40 
0.28 
C.L.^  
0.39 
0.60 
0.70 
0.56 
1.12 
0.90 
0.63 
0.41 
0.63 
I.Ol 
1.11 
0.77 
'Mean for five independent determinations. 
""SAE, standard analytical error. 
•^ C.L., confidence limit at 95% confidence level and four degrees of freedom (t = 2.776). 
-100 -80 -60 -40 -20 0 20 40 60 80 100 120 
Nominal Concentration (i^ gml"'') Spiked 
Figure 5.6: Plot for the recovery of lisinopril by standard addition technique 
(Method A). 
:82 
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Figure 5.7: Plot for the recovei^ of lisinopril by standard addition technique 
(Method B). 
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Table 5.4: Determination of lisinopril in presence of e\cipients 
Methods 
Method A 
Method B 
Lisinopril 
Taken 
40 
140 
60 
420 
concentration (^gml"') 
Found 
39.95 
138,49 
59.67 
418.82 
Recovery (%)' 
99.87 
98.92 
99.46 
99.72 
RSD (%) 
0.97 
0.20 
0.72 
0.21 
a. Mean of five independent analyses 
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that the tablet excipients such as calcium hydrogen phosphate, magnesium stearate, 
maize starch, lactose, mannitol, red ferric oxide, and talc did not interfere with the 
determination procedures. 
The primary degradation product of lisinopril is lisinopril diketopiprazine which is 
formed through the intramolecular condensation. The proposed methods are based 
on the reaction of aliphatic amino group, -NH2, with the reagents. The degradation 
product contains -NH2, so it is not possible to determine its content in presence of 
lisinopril diketopiprazine. However, the degradation product can be estimated after 
separation by TLC. 
The same batch of single component commercial tablets of lisinopril were 
assayed by the proposed methods and British pharmacopoeia method [26]. The 
assay results, summarized in Table 5.5, show good agreement between proposed 
methods (A or B) and British pharmacopoeia method [26] with statistical 
equivalence using t- and F- tests and limits of interval less than ± 2% as required 
by the regulatory guidelines [32]. 
The performance of proposed spcctrophotometric methods have been 
compared with those of other existing spcctrophotometric methods (Table 5.6). 
Some of the spectrophotometric methods (7, 8, 19, 20, 21, 23) are time consuming 
and also require heating at elevated temperature. Moreover, chloranil has earlier 
been used as reagent but requiring 45 minute at 60°C to develop colour (Xmax 346 
nm) and linear range was also narrow. In the present method, less time (10 min.) is 
required for analysis and providing a wide linear range for determination. Thus, the 
present method is superior with regard to analysis time and linear range for 
determination. 
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Table 5.5: Analysis of lisinpril by the proposed methods and British 
pharmacopoeia method [261 
Formulations 
Listril 2.5 
(Torrent) 
Linvas 2.5 
(Zydus Cadila) 
Lipril 2.5 
(Lupin) 
Method A 
Recovery 
(%) 
100.01 
eu=0.995 
t =0.66 
99.94 
eL=0.995 
t=0.58 
100.01 
eL=0.996 
t =0.07 
RSD 
(%) 
0.16 
eu=i.oo3 
F=2.05 
0.08 
eu=1.003 
F= 2.70 
0.08 
eu= 1.004 
F= 1.97 
Method B 
Recovery 
(%) 
100.02 
eL=0.997 
t =0.43 
99.89 
eL=0.994 
t=0.75 
99.95 
91=0,991 
t -0.27 
RSD 
(%) 
0.18 
eu=i.oo] 
F= 1.78 
0.15 
eu= 1.003 
F= 1.36 
0.18 
eu=1.007 
F= 1.86 
Reference method 
Recovery 
(%) 
100.10 
100.01 
100.02 
RSD 
(%) 
0.14 
0.13 
0.14 
Table 5.6: Comparison of the proposed methods with existing 
spectrophotometric methods 
187 
Reagents 
Sodium hypochlorite and 
phenyl hydrazine 
2,4-dinitrofluorobenzene 
Chloranil 
Dichlone 
Acetyl acetone and 
formnldchyde 
7-ch loro-4-n itrobenzo-2-oxa-
1,3-diazole 
Ninhydrin 
7,7,8,8,tetracyanodquino-
dimethane 
p-chloranilic acid 
Ninhydrin: Initial rate 
Rate constant method 
Fixed time method 
Ascorbic Acid 
N-bromosuccinimide 
Chloranil 
^max 
362 
400 
346 
580 
356 
470 
410 
743 
525 
595 
595 
595 
530 
353 
520 
Range 
40-
200 
4-20 
4-40 
40-
120 
6-42 
2-20 
10-40 
2-26 
25-
300 
10-50 
10-40 
10-50 
5-50 
10-
200 
24-
600 
Reaction time 
20 min at 85°C 
30 min at 80°C 
45 min at 60°C 
10 min at rt 
10 min at rt 
30 min at 70°C 
10 mill at 
lOOT 
10 min at rt 
3 min at rt 
Immediately 
Immediately 
10 min at rt 
15 min at 
100°C 
10 min at rt 
10 min at rt 
Molar 
absorptivity 
-
-
2.07 X 10" 
2.60 X 10^  
9.62 X 10' 
-
1.85 X 10' 
1.43 X 10' 
1.19 X 10" 
-
-
4.70 X 10^  
4.55 X 10-^  
1.40 xio ' 
7.28 xio2 
Reference 
7 
8 
19 
19 
19 
20 
21 
22 
22 
23 
23 
23 
23 
This work 
This work 
rt = room temperature (25 ± 1°C) 
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The proposed methods are simple and reliable due the reaction of primary 
aliphatic amino group of the drug with N-bromosuccinimide and chloranil at two 
different wavelengths, i.e. on 353 and 520 nm for methods A and B, respectively in 
a different solvent system. Method A cannot react positively in solvent system of 
method B and vice versa. In addition, the proposed methods are performed at room 
temperature without the involvement of heat and any pretreatment of the drug 
sample. The proposed methods are specific and able to monitor drug in commercial 
dosage forms in the presence of pharmaceutical adjuvants and excipients. 
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The objective of this worl^  is to develop a new kinetic spectrophotometric method for the determination 
of irbesartan in pharmaceutical formulations. The method is based on the reaction of carboxylic acid group 
of the oxidized irbesartan with a mixture of potassium iodate (KIO,) and Iodide (Kt) to form yellow colored 
triiodide ions in aqueous medium at 30±I°C. The reaction is followed spectrophotometrically by measuring 
the rate of change of absorbance at 352 nm. The initial-rate and fixed-time (AA) methods are adopted for con-
structing the calibration curves, which were found to be linear over the concentration ranges of 10.0—60.0 
and 7.5—60.0/Ig ml"' respectively. The regression analysis of calibration data yielded the linear equations: 
rate=-2.138xlO-'+1.058xlO-''Cand 4A=-3 .75x l0 -^+3 .25x l0 - 'Cfor initial rate and fixed time (4A) meth-
ods, respectively. The limit of detection for initial rate and fixed time methods are 0.21 and 2.40^gmP', respec-
tively. The various activation parameters such as £, , AH^, A$^ and AG^ are also calculated for the reaction and 
found to be 70.95±0.43kJmor', 68.48±0.21 kJmol"', 16.54±0.24JK"'mor' and -4 .94±0.07kJmor' , re-
spectively. The proposed methods are optimized and validated as per the guidelines of International Conference 
on Harmonisation (U.S.A.). The point and interval hypothesis tests have been performed which indicate that 
there is no significant difference between the proposed methods and the reference method. The methods have 
been successfully applied to the determination of irbesartan in commercial dosage forms. 
Key words irbesartan; kinetic; spectrophotometry; validation; comntercial dosage form 
Irbesartan is chemically known as 2-butyl-3-[[2'-(i//-
te trazo le -5-y l ) ( l , l ' -b iphenyl ) -4-y lJmethyl ] - l ,3 -d iaza-
spiro[4,4]non-1-en-4-one, which is a potent, long-acting non 
peptide angiotensin II receptor antagonist with high selectiv-
ity for the AT, sub type. This is potentially safe and more tol-
erable than other classes of antihypertensive drugs to im-
prove symptoms, quality of life, exercise capacity, reduce 
hospital admissions for cardiac failure and reduce the inci-
dence of myocardial infarction, sudden death, and death from 
progressive systolic failure.'* The drug is very helpful in re-
ducing the morbidity and mortality associated with these hy-
pertension conditions. Therefore, it is necessary to quantitate 
the drug in pharmaceutical formulations. 
The drug is officially listed in Martindale The Extra Phar-
macopoeia.^' The assay procedure in pure and dosage forms 
is not official in any pharmacopoeia and ihcrt-'fort; Ihc devel-
opment of an analytical procedure for the determination of 
irbesartan in pharmaceutical preparations is of great signifi-
cance. The various analytical methods such as high perform-
ance thin layer chromatography (IIPTLC),'' liquid chro-
matography (LC),^' high performance liquid chromatography 
(HPLC),'*' capillary zone electrophoresis (CZE),'" and de-
rivative spectrophotometry'"" have been described for its de-
termination. 
The literature is still lacking analytical procedures based 
on kinetics for the determination of irbesartan in commercial 
dosage forms. There are certain advantages associated with 
kinetic methods such a s ' " : 
• simplicity owing to elimination of some experimental 
steps such as filtration, extraction prior to absorbance 
measurements. 
• high selectivity due to the measurement of the evolution of 
the absorbance as a function of reaction time instead of 
measuring the concrete absorbance value. 
• no interference from other active compounds present in the 
commercial dosage forms, if they resist the chemical reac-
tion conditions. 
Our present communication describes a kinetic spec-
trophotometric method for the determination of irbesartan in 
commercial dosage forms. The method is based on the oxi-
dation of irbesartan with potassium iodate to form a car-
boxylic acid derivative, thus in the presence of -COOH 
group iodide is oxidized by iodate resulting in the formation 
of triiodide ion, which absorbs maximally at 352 nm. The ab-
sorbance increases with time and therefore, the initial-rate 
and fixed-time methods are adopted for the determination of 
irbesartan in commercial dosage forms. 
Experimental 
Apparatus A Sliimadzu UV-visible 1601 spectrophotometer (Model no. 
1601, Kyoto, Japan) with mulched quartz cells was u.scd lor spectral run, 
Ahsorbuiicc mcusurcmcnl was iniidc on Spcclronic 201)' speciroplioion\elei 
(MiUon Roy. U.S.A.). A water batU shaker (NSW 1.1.1, New Dellii, India) 
was used to maintain a constant temperature for color development. 
Reagents and Standards All chemicals and reagents used were of ana-
lytical or pharmaceutical grade. Irbesartan reference standard (Batch No, 
IB-110021102) was kindly provided by Biochem Pharmaceutical Industries 
(Mumbai, India). Standard solution of irbesartan (0.5 mg ml ') was prepared 
by dissolving 50 mg in 100 ml dimethyl sulfoxide. This solution was used to 
prepare calibration curve and quality control samples. Quality control sam-
ples were prepared at three concentration levels of 10. 30 and 60/Jgml ', 
Commercial dosage forms of irbesartan such as lrovel-150 (Sun Pharma, 
Mumbai, India), lrbest-150 (Biochem Pharma Industries, Mumbai. India) 
and Xarb-150 (Nicholas Piramal India Ltd.. Mumbai. India) were obtained 
from local market. 
A 0.05 M KI (Fluka Chemie AG. Switzerland) .solution was freshly pre-
pared in distilled water. The solution was standardized by the recommended 
procedure.'^' A 0.003M KIOJ (Fluka Chemie AG, Switzerland) was also 
freshly prepared in distilled water. 
Recommended Procedures for the Determination of Irbesartan, Ini-
tial Rate Method Aliquots of 0.2—1.2 ml reference standard .solution of 
irbesartan (O.Smgml"') were pipetted into a series of 10ml standard volu-
metric flasks. To each flask, 1,8 ml of Q,QQ3 M KIO, was added fallowed by 
2..1ml of 0.05 M KI and then diluted to volume with distilled water at 
10± I °C. The contents of each fla.sk were mixed well and the increase in ah-
* To whom correspondence should be addrcs.sed, e-mail: chll 7nr(fi'yahoo.co,in 6 2006 Pharmaceutical Society of .lapan 
May 2006 627 
sorbance at 352 nm was recorded as a ftinction of time against the reagent 
blank prepared similarly. The initial rate of the reaction (V) at different con-
centration was obtained by measunng the slope of the tangent to the ab-
sorbance-time plot. The calibration graph was obtiimed by plotting the ini-
tial rate of reaction (V) versus the molar concentration of the irhesartan. Ihe 
amount of the drug was calculated either from the calibration graph or the 
regression equation. 
Fixed-Time (4.\) Metliod In this method, the ab,s<irb;ince of each sam-
ple .solution was measured at 352 nm against a reagent blank prepared simi-
larly except drug at a preselected fixed time. The difference between the ab-
sorbance obtained at 2min and the iib.soibaiice at 4. ft, S or KImin was plot-
ted against the concentration of irhesartan to yield the calibration curve. I he 
amount of the drug was con^putcd cither from calibration curve or trom cor-
responding regression equation. 
Determination of Irhesartan in Commercial Dosage Forms The 
powdered contents of 2 tablets of I5(lmg strength were weighed and 
grounded. The powder equivalent to 50mg irbesarian was stirred well with 
dimethyl sulfoxide. The solution was filtered diroiigh Whatmann No. 42 fil-
ter paper (Whatmann International Limited, K.ent, U.K.) ma 100ml standard 
volumetric flask and the residue was washed well with dimethyl sulfoxide 
for complete recovery of the drug. The content of standard volumetric flask 
was then diluted to 100 ml with dimethyl sulfoxide. The ainount of irbesnan 
was determined following the proposed procedures. 
Procedure for Reference Method Aliqviots of 0.05 0.6ml of 0.025% 
irhesartan were pipetted into a series of 10 ml standard volumetric flasks and 
diluting to volume with ethanol. The absorbance was measured against the 
solvent blank at 207 nm. The amount of the drug in a given sample was 
computed from the calibration graph or linear regression equation. 
Validation The propo.sed method has been validated for specificity, lin-
earity, precision, accuracy, recovery, limit of detection, and c|uantitation. 
Specificity Samples of irhesartan tablets were subjected to stress condi-
tions of light, heat and base. All stressed samples were analyzed for active 
irhesartan content and compared to an unstressed time zero relerence solu-
tion. The time zero solution jitovidcd a reference assay value for the un-
stressed product. Ihe content of degradation in the stressed and control sam-
ples was calculated relative to this assay value. 
Linearity The linearity of the initial rate and fixed time methods were 
assessed in the concentration range 10—60 and 7.5—bO/Jgnil"', respec-
tively. 
Accuracy and Precision The accuracy and precision of the proposed 
procedures was ascertained based on the analysis of quality control samples. 
Qviality control sample coitcentrations were 10.0, 30.0 and 6U.0f(gml 
Five replicate quality control samples at each concentration were analyzed 
within 1 d as well as for 5 consecutive days. The standard deviations (S.D.), 
relative standard deviations (%RSD), standard analytical error (SAT.) and 
confidence limit (CL) were calculated by standard methods. 
Recovery Studies Recovery experiments were carried out by standard 
addition method. For this, 4.0 ml (or 6.0 ml) of reference irhesartan solution 
(O.Smgmr'j was transferred into a lOO.Oml volumetric flask followed by 
2.0 ml (or 4.0 ml) of sample solution (0.5mgmr ') and volume was com-
pleted to tlic mark with distilled water The noniiiial value was deleriuineil 
by the recomiiiciided procedures 
Limit of Detection (LOD) and Quantitation (LOQ) According to In-
ternational Conference on Harmonisation (ICH) guidelines,'"' the following 
expressions are used to evaluate LOD and LOQ. 
LOD-3 .3XV* and LOQ-IOX.V„/7> 
where S„ and h are .standard deviation and slope of the calibration line, re-
spectively. 
Evaluation of Bais The bias has been evaluated by means of point and 
interval hypothesis tests.''*'"' In interval hypothesis the proposed method 
(method 2) is accepted when the true mean is within ±2% of that of the true 
reference method (method I), i.e. 
-0.02/i |<(/ i j - / / | )<0.02// | 
The above equation can also be written as: 
0.98</;,//j,<1.02 
>((bkh can be generalized to 
Sl.<^'y'^',<e^, 
where (*, and t*,, are lower and upper acceptance liniil.s. respectively Ihe 
limits of this confidence interval can be calculated as the two roots of the 
following quadratic equation. 
where 
— C . 2 , : S'tL 
h=-2x,X2 
— V'r' 
C = . t ; 1 
The values of S, and S^ , of the confidence interval can be obtained as: 
^0 = -
A-\/6'-4ac 
Ya 
Ta 
Results and Discussion 
Spectral Studies The absorption spectrum of irhesartan 
in dimetiiyl suifoxide-water (1 ; 9) medium shows an absorp-
tion band at 223 nin (Fig, la). The addition of aqueous sohi-
tions of KIO, and Kl to the drug solution cau.ses a change in 
the absorption spectrum with new characteristic bands peak-
ing at 298 and 352 nm (Fig. Ic) while the inixture of KlOj 
and Kl solution shows two absorption maxima peaking at 
275 and 290 nm and a negligible absorbance at 352 nm (Fig. 
lb). The molar absorptivity is higher at 352 nin than those 
obtained at 298 nm and hence the absorbance measurements 
for the determination of irhesartan were made at 352 nm. The 
equilthrium is attained in about SOmin, which formed the 
basis to develop a kinetic spectrophotometric method for de-
termination of irhesartan. 
Mechanism of the Color Reaction Chando et <-(/."'* 
have suggested that the terminal methyl group of the butyl 
side chain of irhesartan undergoes oxidation resulting in the 
200 220 240 260 290 300 320 340 360 380 400 420 440 
Wavelength (nm) 
Fig. I. Absorption Spectra of (a) 3.91X10 ' M Standard Irhesartan Solu-
tion in Dimethyl Sulfoxide-Water Medium, (b) Blank Solution: 6.0X10 *M 
Potassium lodate and 1.15X10 '^ M Potassium Iodide in Distilled Water, (c) 
Sample Solution: 60.0/jgml ' of Irhesartan, 6.0X10 •*« Potassium lodate 
and 1.15X10 ' M Potassium Iodide in Distilled Water 
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(A) 
lo, 
C O O H 
Cwbox/ lc mcM] dsrivalive of ift>esartan 
|B) 6 H + 10, • - 2 1, + 3 H,0 
triiodiile tons 
(colored species) 
Chart 1. Reaction Sequence of the Proposed Kinetic Method 
formation of a carboxylic acid derivative. In the present 
study, a carboxylic acid derivative is formed on oxidation of 
irbesartan with iodate. Then generation of triiodide ion talces 
place as iodide is oxidized by iodate in presence of acid 
form. The reaction sequence is shown in Chart I. 
Solution Stability The solution stability of irbesartan 
was checked by recording UV spectra of the drug for 7 d. 
The reference standard of the drug showed an absorption 
peak at 223 nm. The standard and quality control sample so-
lutions were kept at room temperature for 7 d and it was ob-
served that there was no change in the absorption spectra of 
these solutions. The solution stability was also ascertained by 
applying the standard and quality control samples on TLC 
plates coated with silica gel G (Merck Limited, Mumbai. 
India) and developed in ethyl acetate-toluene-acetic acid 
(6-.4'.0.1 v/v/v) solvent system. The plates were air-dried 
and spots were detected in the iodine chamber. In both the 
cases, a single spot was observed with /?/=0,47 correspond-
ing to irbesartan. 
SpeciUcity The standard drug and quality control sample 
solutions were stressed by light and heat (up to 50 °C) for 2, 
and 1-d time points, respectively. It was observed that stress 
by such conditions did not cause significant degradation. 
There was no change in the absorption spectra and a single 
spot was observed on TLC plate with Rf value of 0.47. How-
ever, the samples degraded significantly when stressed by 
base (0.1 M NaOH) for 12 h. All stressed samples (light and 
heat) and unstressed reference solution were analyzed for the 
active content of irbesartan, which gave acceptable recoveries 
of the drug. The influence of frequently encountered excipi-
ents in pharmaceutical dosage forms of irbesartan on the pro-
posed method was studied by adding different amounts of 
possible interferents to the sample. It was observed that glu-
cose, fructose, sucrose, cellulose, lactose, starch, magnesium 
stearate, sodium stearyJ ftjmarate and colloidal silica did not 
interfere with the proposed method. However, acids such as 
HCl, H2SO4, CH3COOH and sulphosalicylic acid and oxidiz-
ing agents such as A/-bromosuccinimide, chloramine T, am-
0.000 0002 0.004 o.ooe o.ooe 0.010 0012 0014 
Motaf concentration 
Fig. 2. Effect of the Molar Concentration of (a) KIO, and (b) Kl on the 
Initial Rate of Reaction 
monium molybdate, potassium persulphate except potassium 
bromate interfere with the determination process. 
Optimization of Variables The optimum conditions af-
fecting the rate of reaction in the formation of triiodide ions 
were studied and maintained throughout the experiment to 
determine the quantity of irbesartan in pure form and drug 
formulations. 
Effect of the Concentration of KIO, The effect of the 
concentration of K.IO3 on the initial rate of reaction was stud-
ied in the range 6.0X 10"'—6.6X 10"" M (Fig. 2a) keeping all 
other experimental parameters constant, [irbesartran]= 
1.167X10'' and [ K I ] = 1 , 1 X 1 0 ' - M . It can be seen thai the 
initial rate of reaction was increased with increasing concen-
tration of KIO3 and became constant at S.gxlO'^M; above 
this concentration up to 6 . 6 X 1 0 " " M , the initial rate of reac-
tion was unchanged. Thus, the adoption of 5.4x 10"* M KIO3 
in the final solution proved to be sufficient for the maximum 
concentration of irbesartan used in the calibration graph. 
Effect of the Concentration of KI The influence of the 
concentration of KI on the initial rate of reaction examined in 
the range of l.OX 10"^—1.3X 10"^M. The initial rate of reac-
tion (Fig. 2b) increased with increasing the concentration of 
KI and became constant at 9 . 5 X I 0 " ' ' M and beyond this con-
centration up to 1.30X10"^M KI, the initial rate remained 
constant. Therefore 1 . I 5 X I 0 " ^ M KI was recommended for 
the determination process. 
Effect of the Temperature The effect of temperature on 
the initial rate of reaction was investigated at 303, 308 and 
3i3K. The absorbance-time curves obtained at these tem-
peratures indicated the temperature dependence of the reac-
tion rate. The initial rate for different concentrations of drug 
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at each temperature was calculated and utilized for plotting 
the calibration curve. It was found that the calibration graph 
obtained at 303 K possessed good linearity (r=0.9999) and is 
recommended that the determination be carried out at 303 K, 
Analytical Data. Initial Rate Method Under the opti-
mized experimental conditions, high concenirations of KIO, 
and Kl solutions were employed, which established a pseudo-
order reaction, condition with respect to the reagents concen-
tration. Therefore, on the basis of experimental observations, 
kinetic equation for the reaction may be written as: 
rate=*(C]"[KI03]"[Kl]' 
for [KI03]^5.4X 10"" M and [KI]s 1.15X10 ^ M at 303 K. 
The above equation reduces to: 
rate=*4Cl" 
where K^ is the pseudo-order rate constant, C is the concen-
tration of irbesartan and n is the order of reaction. The loga-
rithmic form of the equation may be written as: 
log(rate)=Ic^ /Cy+ n log C 
The initial rates of reaction were determined at different con-
centrations of irbesartan by measuring the slopes of the ini-
tial tangent to the absorbance (at 352 nm) time curves during 
the first lOmin of the reaction (Fig. 3) and are summarized in 
Table 1. The plot of log rate versus logC gave the following 
linear equation: 
log(ratc)= 1.657 +1.000 log C 
with coefficient of correlation, r=0.9999. The value of « in 
the equation confirmed that the reaction is first order with re-
spect to irbesartan and rate constant is 45.39s '. 
A calibration curve was constructed by plotting the initial 
rate of reaction versus initial concentration of irbesartan, 
which showed a linear response showing the linear dynamic 
range over the concentration range of 10.0—60.0/jgml '. 
The linear regression analysis using the method of least 
square treatment of calibration data {n=l) was made to eval-
uate slope, intercept and correlation coefficient. The regres-
sion of rate versus concentration of irbesartan {/ygml') gave 
the following linear regression equation: 
RaK=-2.138X10 '+1,058X10 *C 
with a correlation coefficient (r) of 0.9999. The limits of de-
tection (LOD) and quantitation (LOQ) were found to be 0.21 
and 0.63 ^gml" ' , respectively. The variance {S^) of the cali-
bration line was evaluated to be 4.478X10"" / x g ^ r ' which 
is very low showing negligible scattering of the experimental 
data points around the line of regression. The values of confi-
dence limit for the slope {b±tS^ and intercept («±(S„) of the 
calibration line were computed"* and found to be 
1.058X10 •'±3.65X10 ••' and -2.138X10 "±1.46X10 \ 
respectively for n-1 degrees of freedom at 95% confidence 
level. The values of the confidence limit are appreciably low 
thus indicating the high reproducibility of the initial rate 
method. 
Fixed-Time Method (4A) The absorbance of the yellow 
colored solution at 352 nm was recorded during the first 
lOmin at a regular interval of 2.0 min. The change in ab-
sorbance (AA) between the times /, (2 min) and t-^ (4 or 6, 8, 
10 min) was computed and plotted against the concentration 
of irbesartan at ( i=8) . The corresponding linear regression 
equations with coefficient of correlations are summarized in 
Table 2. It is evident from the table that the most acceptable 
linearity was obtained when the calibration graphs was plot-
ted by considering the change in absorbance between 2 and 
liiblo 1, Injtiul Rate of Reaction at Diffca'iit Concenir.ition of Irbcsanan, 
Kcqiiiij; [K10,l anil IKI) Coivstum 
Time (min) 
Fig. 3. Absorbance-Time Curves for the Initial Rate of Reaction at Vary-
ing Concentration of Irbesartan (a) 10, (b) 20. (c) 25, (d) 30, (e) 50, (f) 55 
and (g) 60/igml 
Constant 
Keeping (KlO,] = 5.4X10 "M and 1KI]>1,15X10 
C [Drug] 
moll"' 
2.334X10 ' 
4.667XI0-' 
5.W4XiO"' 
7.001X10"' 
1.167X10-' 
1.284X10-' 
1.400X10"^ 
logC 
-4,632 
•4.331 
-4.214 
-4.155 
-3.778 
-3.892 
-3.854 
Initial rate of reaction, v 
m o i r ' s ' ' 
1.057X10 ' 
2.118X10"' 
2.642X10"' 
3.169X10"' 
5.299X10"' 
5.808X10"' 
6.348X10"' 
log V 
-2.975 
2.674 
-2,57» 
-2.499 
-2.276 
-2.236 
-2.197 
Table 2. Coefficient of Correlation (i) for the Calibration Equation.s at Aj-A, . A^-A,. A , - A j and A| | , -A, for Method B 
4 A 
A , - A j 
A , - A ; 
A i f -A^ 
A i f l - A , 
Calibration equation 
4 A = - 1 . 7 3 X 1 0 ' + 2,06X10 ' C 
J A = - 3 . 7 5 X 1 0 ' + 3.25X10 'C 
4 A = - 2 . 8 9 X I 0 ' + 4.44X10 ' C 
^ A = ' 2 , O O X 1 0 " ' ( 5 . 4 I X I O " ' C ' 
r 
0,9945 
0,9995 
0.9990 
0.9989 
±IS, 
8 . 1 0 0 X 1 0 ' 
5 .383X10" ' 
7.243X10 ' 
9 .225X10" ' 
i ; 5 , 
2,202X10 •• 
1 .468X10" 
1.958X10 ' 
2 . 4 4 7 X 1 0 " 
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Table 3. Evaluation of Accuracy and Precision of the Proposed Methods by Intra Day and Inter Day Assays 
Proposed methods 
Initial rale 
Intra, day assay 
Inter day assay 
Fixed time (4A) 
Intra day assay 
Inter day assay 
Amount (fig 
Taken 
IQQ 
30.0 
60.0 
10.0 
30.0 
60.0 
10.0 
30.0 
60.0 
10.0 
30.0 
60.0 
ml ') 
FouniliS.D.'" 
9.99±Q,06 
29.99i0.06 
60.03 ±0,10 
10.01 ±0.08 
30.02 ±0.10 
59.97±0.14 
9.99±0.07 
30,01 ±0.05 
59.97±0.06 
10.01±0.13 
30.04±0.09 
60.03 ±0.06 
RSD (%) 
0,64 
0.19 
0.17 
0.84 
0.33 
0.23 
0.74 
0.16 
0.10 
1.34 
0.28 
0.11 
SAE"' 
0.029 
0.025 
0.045 
0.038 
0.045 
0.060 
0.033 
0.022 
0.026 
0.060 
0.038 
0.029 
CL''' 
0.080 
0.070 
0.124 
0.104 
0.124 
0.168 
0.091 
0.060 
0.073 
0.167 
0.106 
0.079 
a) Mean for five independent analyses, b) SAE, standard analytical error, c) CL. confidence limit at 95% confidence level and 4 degrees of freedom (/ = 2 776). 
Tabic 4. Standard Addition Method for the Determination of Irbesartan in Commercial Dosage Forms 
Formulations 
Irbest-150 
(Biochem Pharm) 
Irovel-150 
(Sun Pharm) 
Xarb-150 
(N?ll,) 
1 nilial rate method 
Amount (/ig ml ') 
Taken 
20.0 
20.0 
20.0 
20.0 
20.0 
20.0 
Added 
10.0 
30.0 
10.0 
30.0 
10.0 
30.0 
Found±S.D."' 
29.99±0.07 
50.04±0.05 
29.95±0.I2 
49.97 + 0.06 
30.00 + 0.13 
50.03 ±0.06 
Recovery 
(%) 
99,95 
100,08 
99,84 
99,94 
100.01 
100.05 
RSD 
(%) 
0.22 
0.10 
0.39 
0.12 
0.44 
0.12 
SAE 
0.029 
0.022 
0.052 
0.026 
0.058 
0.026 
fixeii time {AA) method 
Amount (ng 
Taken 
20,0 
20.0 
20.0 
20.0 
20.0 
20.0 
Added 
10.0 
30.0 
10.0 
30.0 
10.0 
30.0 
ml ') 
FoundtS.D."' 
30.04±0.06 
49,98 ±0.05 
29.98+0.12 
50.03+0.05 
30.00 ±0.08 
50.06+0.04 
Recovery 
(%) 
100.11 
99.96 
99.94 
100.05 
99.98 
100.12 
RSD 
(%) 
0.23 
0.10 
0.14 
0.09 
0.26 
0.08 
SAE 
0.029 
0.022 
0.055 
0.021 
0.034 
0.018 
a) Mean for five independent analyses. 
6min {i.e. AA^A^^-Ai). This fixed time was recommended 
for analysis. The calibration curve was linear in the range of 
7.5—60.0 ^g ml ' of irbesartan. The values of LOD, LOQ 
and variance were found to be 2.40, 7.26 and 5.57x 
10~';Ugmr', respectively. 
Activation Parameters of the Proposed Methods The 
apparent activation parameters were evaluated by studying 
the reaction rate at 303, 308 and 313 K keeping the following 
reaction conditions: 
l irbcsartanj=4.667X10 ' M , IK.10,) =^6.0X10 ' M , 1 K 1 ) = I . 1 5 X 1 0 ' M 
The Arrhenius curve was obtained by plotting In k^^,^ ver-
sus 1/rand found to be linear with coefficient of correlation, 
r=-0.9995. The activation energy (£J was calculated from 
the slope (-E.JR) of the Arrhenius curve and found to be 
70.95±0.43kJmor'. The values of enthalpy (4/-/'), entropy 
(AS') and free energy of activation (4G*) of the reaction 
were also calculated using Eyring equation: 
AS> 
R lnj=]HkJh) + -
AH' I 
fl 
The Eyring plot of Ink^^^JT ver.ms l/Twas linear with coeffi-
cient of correlation, r=-0.9995. 4/Y* and AS* were calcu-
lated from the slope (-Alf^/R) and the intercept [\n{k^/h}-i-
AS^IR] of the Eyring graph and were found to be 
68.48±0.21kJmol ' and 16.54i0.24JK ' m o l ' , respec-
tively. The Gibbs free energy of activation i.e. AG^ at 303 K 
was evaluated by the equation (AG* = Af/^-TAS*) and found 
to be -4.94±0.07kJmol '. The values of activation param-
eters indicated that the reaction is feasible. 
Accuracy and Precision of the Proposed Methods The 
accuracy and precision of the proposed methods was estab-
lished by performing intra day and inter day assays by deter-
mining the content of irbesartan in quality control samples at 
three different concentration levels (low, medium and high). 
These assays were investigated by measuring five independ-
ent analyses at 10.0, 30.0 and 60.0/jg ml ' concentration 
levels within I d and on 5 consecutive days, respectively 
(Table 3). The standard deviation, relative standard deviation 
and standard analytical error obtained by both methods are 
acceptable i.e. within the permissible bias range and there-
fore can be considered to be satisfactory. 
Validity of the Proposed Methods Standard addition 
method was employed to check the validity of the proposed 
procedures. In this method, a known amount of pure irbesar-
tan was added to its formulated tablets at two different con-
centration levels and the nominal value of the drug was cal-
culated following the proposed procedures. The results are 
.suininarized in Table 4. As can be seen from the table, that 
the recoveries obtained by both the procedures are quite sat-
isfactory with low RSD. 
Robustness The robustness of the proposed procedure 
was ascertained by challenging the following operational pa-
rameters: 
• volume of0.003MKIO3 (±0,4 ml) 
• volume ofO.OSMKI (±0.3 ml) 
May 2006 631 
Table 5. Point and Interval Hypothesis Tests: Evaluation of the Applicahility of the Proposed Methods with the Reference Method at 95% Confidence 
Level 
I'omiulatjons 
Irbest 150 
(Biochem) 
Irovel 150 
(Sun) 
Xarb 
(NPIL) 
Initial rate method 
Recovery 
100.12 
99.86 
99.93 
RSD"' 
(%) 
0.46 
0.87 
0.84 
Point hypothesis tests 
l-'ixed time 
[AA) method 
Recoveiy 
(%) 
100.15 
100.09 
100.09 
RSty' 
(%) 
0.41 
0.80 
0.80 
Reference 
Recovery 
100.24 
100.06 
99.87 
method 
RSI) 
(%) 
1.01 
0.65 
0.77 
1 
1-
values 
0.62 
0.39 
0.15 
Interval hypothesis tests 
nitial rate method 
F-
values 
2.84 
1.78 
1.47 
e.. 
0.99 
0.98 
0.98 
Ov 
1.01 
1.01 
1.01 
h'ixed 
I-
values 
0.22 
0.06 
0.25 
time [dA) mellioil 
/ • • -
values 
3.35 
1.13 
1.60 
9, 
0.99 
0.98 
0.98 
1 
9« 
1.01 
1.01 
1.01 
Table 6. Comparison of the Proposed Kinetic Spectrophotometric Method 
with Other Methods for Determination of Irbesartan 
Methods Linear dynamic RSD tBngc(;jgm! ') (%) References 
HPTLC 
HPLC 
CZE 
CZE 
Spectrophotometry 
Initial rate method 
Fixed-time method (AA) 
60—180 
0.001 1.0 
60 300 
80 400 
10^-60 
7 .5 -60 
1.81-
<8 
0.93 
0.28 
0.17-
0.10 
-2.49 
0.49 
0.84 
fl.74 
3) 
5) 
7| 
S) 
This work 
This work 
Under these conditions quality control sainples were ana-
lyzed at two concentration levels: 25.0 and 45.0 mg ml '. 
The results are quite satisfactory with acceptable recovery 
and low RSD values. 
Applicability of tlie Proposed Metliods The applicabil-
ity of the proposed methods for the assay of irbesartan in 
drug formulations has been tested on commercially available 
tablets. The results of the proposed methods were statistically 
compared with those of the developed reference method 
using point and interval hypothesis tests. Table 5 shows that 
the calculated t- (paired) and F-values at 95% confidence 
level are less than the theoretical ones, confirming no signifi-
cant difference between the methods compared. It can also be 
seen from the table that the bias evaluated by interval hypnth-
esis test is within the acceptable range of 0L = "•''** ''"^' 
The performance of the proposed kinetic spectrophotomet-
ric method was compared with other methods (Table 6). It 
can be seen from Table 6 that IIPTLC method is time con-
suming and tedious. The precision is also somewhat poor 
HPLC method is sensitive enough but it requires solid phase 
extraction of irbesartan before analysis and RSD is also 
higher. CZE'*' gives accurate results but the technique is ex-
pensive. The present kinetic spectrophotometric method is 
simple, fast and accurate because it does not involve any pre-
treatment step prior to analysis. 
Conclusion 
The proposed method is a direct method, applicable in 
aqueous medium at 30 °C and thus there is no fear of decom-
position of the drug due to heat, acid or base. No interfer-
ences have been observed with excipients found in drug for-
mulations. The proposed method is a stability-indicating 
assay method for the determination of irbesartan in the pres-
ence of its degradation products. Therefore, it is concluded 
that the proposed method is suitable for the determination of 
irbesartan in drug formulations and can be used for routine 
quality control analyses of active drug in the laboratories of 
hospitals, pharmaceutical industries and research institutions. 
Acknowledgements Financial assistance provided by Council of Scien-
tific and Industrial Research (CSIR), New Delhi. India to Dr Syed Najmul 
Hcjaz Azmi as Research A.ssociate (Award No. 9/112(329)/2002-EMR-l) is 
gratefully acknowledged. The authors wish to express their gratitude to M/s. 
Biochem Pharmaceutical lndu.stries (Mumbai, India) for the .sample of refer-
ence standard of irbesartan. 
References 
1) Markham A.. Spencer C, M., Jarvis B., Drugx. 59, 1187—1206 
(2000). 
2) "Martindale the Extra Pharmacopoeia," 33rd ed.. Royal Pharmaceuti-
cal Society, London, 2002, p. 914. 
Sane R. T, Francis M.. Pawar S.. liiJian Dnigs. 39, 32—35 (2002). 
Erk N.,J. C/iivmarogr. B. 784, 195—201 (2003). 
Chang S. Y., Whigan D. B., Vachharajani N. N., Patel R., J. Chro-
malogr S.702, 149—155 (1997). 
Li J., Wu Q., Wang L., Yaowu Fenxi Zuzhi. 21. 249 250 (2001). 
Hillaert S., Vandcn-Bossche W., J. Chromatogt. A. 979, 323 333 
12002). 
Hillaert S., Vandcn-Hosschc W.,./. I'lumn. KMnwd Aiuil. 31, .^ M 
339(2003). 
Isabel I., Rodenas V, Garcia S., Sanchcz-Pedreno C, J. Pharm. Bio-
nwJ. Anal., 29, 299 305 (2002). 
Erk N., Pharmazie. 58, 543 548 (2003). 
Pcrez-Bendito D., Gomez-Hens A., Silva M., J. Plumn. BiomeJ Anal.. 
14,917-930(1996). 
Sierra-Jimenez F., Sanchez-Pcdreno C , Annies real Sac. Espan. Fii. i 
</uim„ 54 8,541 552(1958). 
International conference on Harmonisation, ICH Harmonised Tripar-
tite Guideline— Text on Validation of Analytical Procedures. Fed. Re/f-
m , 60, 11260(1995). 
Hartmann C , Smeyers-Verbeke J.. Penninckx W.. Heyden Y. V, Van-
kcerberghen P, Mas.sart D. L., Anal. Chem.. 67, 4491 - 4499 (1995). 
Canada Health Protection Branch, Drugs Diivcionite guidelines. Ac-
ceptable method.s. Ministry of National Health and Welfare, Draft. 
1992. 
Chando T J., Everett D. W.. Kahle A. D., Starrett A. M., Vachharajani 
N.. Shyu W. C , Kriplani K. J., Barbhaiya R. H.. Orug Melah. Di.spos.. 
25.408—417(1998). 
Miller J, N.,Analyst. 116, .3—14 (1991). 
10) 
11) 
13) 
16) 
17) 
Journal of the Chinese Chemical Society, 2006, 53, 735-743 735 
Development and Validation of Kinetic Spectrophotometric Method for the 
Deternnination of Losartan Potassium in Pure and Commercial Tablets 
Nafisur Rahman,* Masoom Raza Siddiqui and Syed Najmul Hejaz Azmi 
Department of Chemistry, Aligarh Muslim University, Aligarh-202002 (U.P.), India 
A validated kinetic spectrophotometric method has been developed for the determination of losartan 
potassium in pure and dosage forms. The method is based on oxidation of the losartan potassium with al-
kaline potassium permanganate at room temperature (25 ± I °C). The reaction is followed spectrophoto-
metrically by measuring the increase in absorbance with time at 603 nm, and the initial rate, fixed time lat 
12.0 min) and equilibrium time (at 90.0 min) methods are adopted for constructing the calibration graphs. 
All the calibration graphs are linear in the concentration range of 7.5-60.0 |ig mL"' and the calibration data 
resulted in the linear regression equations ofv =-6.422 X 10"'+ l.!73x 10''C, A = 3.30x 10'"+5.28x lO' 
CandA = -2.09x 10" + 1.05 x l O ' C for initial-rate, fixed time and equilibrium time methods, respec-
tively. The limits of detection for initial rate, fixed time and equilibrium time methods are 0.71, 0.21 and 
0.19 i^g mL' , respectively. The activation parameters such as E,, A H ' , AS* and AG* are also determined 
for the reaction and found to be 87.34 K.J mol ' , 84,86 KJ mof', 50.96 JK'' mol"' and -15.10 KJ mol ' , re-
spectively. The variables are optimized and the proposed methods are validated as per ICll guidelines. The 
method has been applied successfully to the estimation of losartan potassium in commercial tablets. The 
performance of the proposed methods was judged by calculating paired t- and F- values. The analytical re-
sults of the proposed methods when compared with those of the reference method show no significant dif-
ference in accuracy and precision and have acceptable bias. 
Keywords: Kinetic; Spectrophotometry; Losartan potassium; Validations; Tablets. 
INTRODUCTION capillary electrophoresis.'*'' In the literature, only a few 
spectrophotometric methods have been described for the 
Losartan potassium is chemically known as 2-butyl-4- determination of losartan potassium. The drug content in 
chloro-1 [[2'-( 1 H-tetrazol-5-y n[ 1,1 '-biphenyl]-4-yl]meth- pharmaceutical formulations was determined by UV-deriv-
yl]-lH-imidazole-5-methano!, which belongs to the anti- ative spectrophotometric procedure.'" The extractive spec-
hypertensive group of drugs known as angiotensin II recep- trophotometric method'' has also been utilized by forming 
tor antagonists. It is a highly selective and orally active ion-pair complexes of the drug with calmagite and orange-
non-peptide antagonist used in the treatment of hyperten- 11 having maximum absorbance at 491 and 486 nm, respec-
sion with heart failure or renal impairmeni by blocking the tively. However analytical procedures based on kinetic 
binding of angiotensin II to the AT| receptor level found in spectrophotometry are still lacking in the literature for the 
vascular smooth muscles, adrenal glands, etc. It is metabo- determination of losartan potassium in pharmaceutical for-
lized in the body to a pharmacologically active carboxylic mulations. Kinetic spectrophotometry is the best choice of 
acid metabolite (EXP-3174). The drug is very much con- the analytical chemist because of its high sensitivity, selec-
fined with the cardio protective effects; therefore, it is im- tivity and low limit of detection.'^ In this method of analy-
portant to assay losartan potassium in drug formulations. sis measurement can be made under dynamic reaction con-
The drug is only listed in Martindale's Extra Pharma- ditions in which the reactants and products are changing 
copoeia,' but is not official in any pharmacopoeia. The re- continuously with time, Moreover, alkaline potassium per-
ported analytical techniques that are reported for its estima- manganate has been used for kinetic spectrophotometric 
tion include high performance thin layer chromatogra- determination of famotidine" and ritodrine hydrochlo-
phy, '^^  high performance liquid chromatography,*'' and ride'" in dosage forms. Therefore there is a need to develop 
• Corresponding author E-mail: chl 17nr@yahoo,co,in 
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a kinetic spectrophotometric method for assay of losarian 
potassium in pure form and in pharmaceutical formula-
tions. 
This paper describes the development and validation 
of a kinetic spectrophotometric method for the determina-
tion of losartan potassium in pure and commercial tablets. 
The method is based on the oxidation of drug with alkaline 
potassium permanganate at 25 ± 1 °C, and subsequently the 
rate of appearance of the green coloured product was mea-
sured at 603 nm. The initial rate, fixed time and equilibrium 
time methods are followed for the determination of losartan 
potassium in commercial tablets. 
EXPERIMENTAL 
Apparatus 
The absorbance of the solutions was measured with a 
Shimadzu UV-visible speclrophotometer (Model no. 1601, 
Kyoto, Tokyo, Japan) with matched quartz cells. 
The heating temperature for color development was 
monitored using a water bath shaker (NSW 133, New Delhi, 
India). 
Reagents and standards 
0.6 M sodium hydroxide (GR Grade, Merck Limited. 
Mumbai, India) and 9.00 x 10"^  M potassium permanganate 
(GR Grade, Merck Limited, Mumbai, India) were prepared 
in distilled water Potassium permanganate solution should 
be freshly prepared and standardized for its apparent purity 
by titrimetric procedure." The standard test solution of 
0,05% losartan potassium (Cipla Ltd., Mumbai, India.) was 
prepared in distilled water. The fonnulated tablet forms of 
losartan potassium such as Zaart-25 (Cipla Ltd., Mumbai, 
India), Losacar-25 (Zydus Mcdica, Ahmcdabad, India) and 
Losium-25 (Cadila Pharma, Ahmedabad, India) were pur-
chased from the local market. 
Recommended procedures for the determination of 
losartan potassium 
Initial rate method 
Aliquots of 0.15-1.2 mL of 0.05% losartan potassium 
were pipetted into a series of 10 niL standard flasks. To 
each flask, 2.0 mL of 0.60 M NaOH and 9.00 x IQ-' M po-
tassium permanganate were added successively and then 
diluted with distilled water at 25 + 1 °C. The contents of 
each flask were mixed well, and the increase in absorbance 
as a function of time was measured at 603 nm. The initial 
rate of the reaction (v) at different concentrations was eval-
uated by measuring the slope of the tangent to the absorb-
ance-time plot. The calibration graphs were obtained by 
plotting the initial rate of reaction (v) versus the molar con-
centration of the losartan potassium (C). The amount of the 
drug was calculated either from the calibration graph or the 
regression equation. 
Fixed time method 
A fixed time of 12.0 min was selected for the fixed-
time method. Al this preselected fixed time, the absorbance 
of each sample of drug solution was measured at 603 nm 
against a reagent blank prepared similarly except without 
the drug. The calibration curve was obtained by plotting the 
absorbance against the initial concentration of losartan po-
tassium. The amount of the drug was computed either from 
a calibration curve or regression equation. 
Equilibrium time method 
The equilibrium reaction condition was achieved at 
90.0 min and at this time, the absorbance of each sample of 
drug solution was measured at 603 nm against a reagent 
blank prepared similarly except without the drug. The cali-
bration graph was constnicted by plotting the absorbance 
against the initial concentration of losartan potassium, and 
the concentration of the drug was calculated either from a 
calibration graph or corresponding regression equation. 
Determination procedure for losartan potassium in 
commercial tablets 
For sample preparation of different tablets, the mixed 
contents of 5.0 tablets were weighed and ground. The pow-
der equivalent of 50 mg losartan potassium was stirred well 
with doubly distilled water. The solution was filtered through 
Whatman No. 42 filter paper (Whatman International 
Limited, Kent, UK) in a 100.0 mL standard volumetric 
flask and the residue was washed well with doubly distilled 
water for complete recovery of the drug. The content of 
each standard volumetric flask was then diluted to 100.0 mL 
with doubly distilled water. The recovery of the losartan 
potassium was calculated from the corresponding linear re-
gression equations or calibration graphs. 
Determination procedure for synthetic mixtures of 
losartan potassium 
Synthetic mixtures of losartan potassium were pre-
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pared by taking various excipients commonly used in tablet 
dosage forms with 500.0 ^g of losartan potassium in 10 mL 
standard volumetric flask and tested to study the interfer-
ences of these excipients. It was observed that corn starch, 
glucose, lactose, talc and magnesium stearate could be tol-
erated with maximum amounts of 10.0, 18.0,51.3. lO.Oand 
51.3 mg, respectively. 
RESULTS AND DISCUSSION 
Spectral studies 
The aqueous solution of losartan potassium absorbs 
maximally at 206 nm while that of alkaline potassium per-
manganate solution exhibits an absorption band at 530 nm. 
The course of the reaction starts on the addition of aqueous 
alkaline potassium permanganate to the solution of losartan 
potassium resulting in the shift of absorption band peak-
ing at 603 nm (Fig. 1). This band is attributed to the forma-
tion of manganate ion, in the presence of drug. The inten-
sity of the colored product increases with time leading to 
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Fig. 1. Absorption spectra of (a) l.OmL of 1.085 x lO"* 
M losartan potassium in doubly distilled water 
(b) 1.0 mL of 4.50 X 10' M KMnO^ ^ 2.0 mL of 
0.6 M NaOH solutions in doubly distilled water 
and (c) 1.0 mL of 1.085 x 10 •' M losartan potas-
sium + 2.0 mL of 9.00 x lO^ M KMn04 and 2.0 
mL of 0.6 M NaOH solutions in doubly distilled 
water. Each set is diluted in 10 mL standard 
flask with doubly distilled water. 
the oxidation of drug and therefore, a kinetic approach has 
been exploited for the spectrophotometric determination of 
losartan potassium in drug formulations. 
The stoichiometric ratio between losartan potassium 
and potassium permanganate was evaluated by limiting 
logarithmic method,"' In this method two .sets of experi-
ments were performed. In the first set the concentration of 
losartan potassium was varied keeping a constant concen-
tration of KMn04, while in the second set, the concentra-
tion of losartan potassium was kept constant and the KMn04 
concentration was varied, Log absorbance versus log [Losartan 
potassium] or [KMn04] (Figs. 2a and b) was plotted to 
evaluate the slope of the respective line to determine the or-
der of reaction of the dnig with respect to KMn04 or vice 
versa. The slope was found to be unity in the first case and it 
was two in magnitude in the second case thus confirming 
the molar combining ratio of 1:2 between losartan potas-
sium and potassium permanganate. Hence the results indi-
cated that the two moles of potassium permanganate were 
consumed by one mole of losartan potassium. The litera-
ture survey reveals that losartan potassium undergoes oxi-
dation of the 5-hydroxy methyl group on the imidazole 
ring,'^ resulting in the formation of a carboxylic acid deriv-
ative of losartan potassium. The reaction proceeds in the 
same way, thus potassium permanganate oxidizes losartan 
i •' 
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log [Lourtan potassium] or [KMnOJ 
Fig. 2. Limiting logarithmic plot for sloichiomelric ra-
tio between losartan potassium and KMnOi (a) 
log A vs. log [losartan potassium] and (b) log A 
vs. log[KMn04]. 
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potassium in allcaiine medium. On this basis, the following 
reaction mechanism (Scheme I) is proposed. 
Optimization of variables 
The optimum conditions for the proposed methods re-
sponsible for the formation of green colored manganate ion 
were studied and maintained throughout the experiment. 
The effect of temperature on the initial rate of reac-
tion was studied at 298,303 and 308 K. It was observed that 
losartan potassium reacts faster with potassium permanga-
nate with increase in temperature. At higher temperatures 
the reaction product may decompose and reproducibility 
was not better. To avoid this and for the sake of good re-
sults, theoptimum temperature of 298 K was selected for 
the determination process. 
The effect of the KMn04 concentration on the initial 
rate of reaction (v) was studied in the range of 1.80 x 10" -
1.98 X l O ' M. The initial rate of reaction was increased 
with increase in the concentration of KMn04 and became 
constant at 1,08 x I O ' M and remained as such up to 1.98 x 
IO"^M.The results are summarized in Table 1. Therefore, a 
concentration of 1.80 x 10'' M was used as an optimum 
value for the assay procedure. 
Table 1 shows the effect of NaOH concentration on 
the initial rate of reaction. The v value increased with in-
crease in the concentration of NaOH up to 1.08 x 10" M, 
after which further increase in the concentration of NaOH 
resulted in no change in the initial rate of reaction. Thus, 
the concentration of 1.20 x 10"' M was found to be the most 
suitable concentration in a volume of 10.0 mL-
Analytical parameters and method validation 
All kinetic parameters were performed under pseudo-
Table 1. Effect of [KMn04] and [NaOH] on the initial rate of 
reaction at [Losartan Potassium] = 1.08 x 10"^  
[KMn04] 
(mol L"') 
1.80 X lO"* 
3.60 X 10"" 
5.40 X 10"" 
7.20 X 10"* 
9.00 X lO"* 
1.08 X 10"' 
1.26 X 10"' 
1.44 X 10"' 
1.62 X 10"' 
1.80 X 10"' 
1,98 X 10"' 
[NaOH] 
(mol L"') 
1.20 X 10"^  
2.40 X 10"^  
3.60 X 10"^  
4.80 X 10"^  
6.00 X lO"^  
7.20 X 10"^  
8.40 X 10"^  
9.60 X 10"^  
1.08 X 10"' 
1.20 X 10"' 
1.32 X 10"' 
Initial rate of reaction, 
KMn04 
6.67 X 10"' 
1.29 X 10"" 
1.96 X 10"" 
2.44 X 10"" 
2.58 X 10"" 
5.89 X 10"" 
5.89 X 10"" 
5.89 X lO" 
5.89 X 10"" 
5.89 X 10"" 
5.89 X 10" 
0 (mol L"' s"') 
NaOH 
1.00 X 10" 
1.33 X 10"" 
1.83 X 10"" 
2.22 X 10"" 
2.43 X 10"" 
3.11 X 10"" 
3.60 X 10"" 
4.10 X 10"" 
5.89 X 10"" 
5.89 X 10"" 
5.89 X 10"" 
first order conditions at 25 + I °C. The initial rates of the re-
action were determined from absorbance-time plot (Fig. 3) 
by measuring the slopes of the initial tangent to the absorb-
ance-linie curves and are summarized in Table 2. The ki-
netic equation for the oxidation of losartan potassium by 
potassium permanganate in alkaline medium is written as; 
v = — = /:,C" C 
dt 1 ' " tST "^ KMtiO, ^ NciOH 
(1) 
ForQ„„o_ > 1.08 X 10"' M and CS„OH> 108 x 10"' M 
The equation (1) reduced to 
— = K,C" 
dt 
(2) 
The order with respect to losartan potassium was deter-
mined from the plot of the logarithm of the initial rate of re-
action (log v) versus logarithm of molar concentration of 
losartan potassium (log C) and was found to be unity. Thus, 
Scheme I 
CI 
N / + 2MnOi 
H ^ ^ ^ C H ^ H 
N NK 
+ 2Mn04 + H2O + H2 
Losartan potassium Oxidized losartan potassium 
Determination of Losartan Potassium J. Chin. Chem. Soc, Vol. 53. No. 3. 2006 739 
Table 2. Initial rate of reaction at different concentrations of 
Losartan potassium with [KMnO^] = 1.80 xlO-* M and 
[NaOH]-0.12M 
[Drug] mol L"' Initial rate of reaction, u mol L"' s'' 
1.63x10' 
2.17x10-' 
3.25 X 10"' 
5.42 X 10-' 
7.59 X 10' 
9.76 X lO' 
1.08 X lO-** 
1.19 X 10-* 
1.30x10-* 
8.33 X 10-' 
1.17 X 10-* 
1.78 X 10-" 
2.94 X 10-* 
4.11 X lO-* 
5.28 X lO-* 
5.89 X lO-* 
6.44 X 10-* 
7.00 X 10-* 
centration range of 7.5-60.0 \ig mL-'. The regression of ini-
tial rate versus C gave a linear regression equation, v = 
-6.422 X IQ-'' + 1,173 X IQ-' C with coefficient of correla-
tion, r = 0.99995. The confidence limits for the slope of the 
line of regression and intercept were computed using the 
relation b ± tSb and a ± tS , at a 9 5 % confidence level and 
found to be 1. 173 X 1 0 ' ± 1.057 X IQ-' and -6.422 x 1Q-' ± 
4.076 X iO"'", respectively, indicating the high reproduci-
bility of the initial rate method. The limit of detection (LOD) 
and quantitation (LOQ) were calculated using statistical 
treatment of calibration data at nine concentration levels by 
the following equation:'" 
the oxidation of losartan potassium would obey the pseudo 
first order reaction and equation (2) reduced to 
v = ^ = J^,C 
dt 
(3) 
where K^^ is the pseudo first order rate constant. Under the 
optimized experimental condition, the calibration graph 
(initial rate versus C) was found to be linear over the con-
Tims (min) 
Fig. 3. Absorbance-time plot for the oxidation of 
losartan potassium with KMn04 in alkaline me-
dium: 1.80 xlO-' M KMn04 and (a) 1.63 x 10' 
(b) 2.17 X 10-', (c) 3.25 x 10"', (d) 5.42 x 10', 
(e) 7.60 X 10-\ (f) 9.76 x 10"', (g) 1.08 x 10-*, 
(h) I.19x lO-'and(i) 1.30 x IO* M losartan po-
tassium. 
LOD = 3.3xSo/b and LOQ=10xSo/b 
where So and b are the standard deviation and slope of the 
calibration line. The LOD and LOQ were found to be 0.71 
and 2.16 |ig mL-', respectively. The variance (So") was cal-
culated using the equation: 
e 2 ZJVC'P' ~^reg ) 
and found to be 6.420 x IQ-'^  |ig mL ' . The low value of 
variance suggested the negligible scattering of the experi-
mental data points around the line of regression. 
For evaluation of apparent activation parameter, the 
reaction was studied at 298,303, and 308 K at [losartan po-
tassium] = 3.25 X 10-' M, [KMn04] = 1.80 x lO"' M and 
[NaOH]=1.20x 10"' M. The Arrhenius plot of In k„bs. ver-
sus l/T was found to be linear with a correlation coefficient 
of-0.9993 (Fig. 4). The Eyring plot of In kobs./ T versus l/T 
was linear with a correlation coefficient of-0.9993 (Fig. 5). 
The value of AH' and AS' were evaluated from the slope 
( -AHVR) and intercept [In (kb/h) + AS'/R] of Eyring plot 
and found to be 84.86 KJ mor' and 50.96 JK"' mol ' , re-
spectively. The value of Gibbs free energy (AG*) of activa-
tion ofthe reaction product was -15.10 K.J mol' . 
In the fixed-time method, the absorbance of green 
colored solution formed due to the reduction of KMn04 
was recorded at a preselected fixed time for different con-
centrations of losartan potassium. The calibration graphs 
were constructed by plotting the absorbance against the ini-
tial concentrations of losartan potassium at a fixed time of 
3, 6, 9, 12 and 15 min. The important parameters of these 
calibration curves are reported in Table 3. It is clear from 
Table 3 that the most acceptable values of linearity, inter-
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cept, limit of detection and quantitation were obtained at a 
fixed time of 12 min. Therefore, the fixed time of 12 min 
was selected as the optimum time for the determination of 
losartan potassium in pharmaceutical dosage forms. 
In the equilibrium time method, the absorbance of 
green colored solution was measured after attaining the 
equilibrium (at 90 min) for different concentrations of 
tosartan potassium. The linear regression equation and 
other statistical parameters of this method are summarized 
in Table 3. 
Solution stability 
The stability of the test solution of losartan potassium 
in distilled water was studied by recording UV absorption 
spectra of losartan potassium for three days. The drug solu-
tion having Xmax at 206 nm, showed no change in the ab-
sorption spectra of the test and sample solutions of dnig for 
at least three days, when the solutions were stored at room 
temperature in the dark. 
Robustness 
The proposed method conditions for the determina-
tion of losartan potassium in pure form as well as in dosage 
forms are very robust. Each operational parameter was 
tested and challenged for the robustness of the methods. 
The operational robust parameters that are investigated 
were as follows; 
• volume of 0.60 M NaOH (± 0.4 mL) 
• volume of 9.0 x 10"' M KMn04 (± 0.3 mL) 
Under these conditions sample solutions from three 
dosage forms containing 60.0 |ig mL"' of active losartan 
potassium was assayed by performing five independent 
analyses by the initial rate and fixed time methods. The re-
sults of mean recovery, standard deviation and relative 
standard deviation indicated good sensitivity and apprecia-
ble recovery. Thus the conditions of the proposed methods 
are very robust. 
Accuracy and precision 
The accuracy and precision of the proposed methods 
was established by measuring the content of losartan potas-
sium at three different concentration levels (low, medium 
and high) on each day as well as on five consecutive days. 
The intra day assay (or the daily precision) was performed 
by measuring fwe independent analyses at lO.O, 35.0 and 
55.0 ng mL"' concentration levels within one day and inter 
day assay (or within day precision) was done at the same 
specified levels of concentration by measuring five repli-
O.00M4 O.0O326 000328 0,00330 0 00332 
in-(K) 
0,00334 0,00336 0,00338 
Fig. 4. Arrheniu.s plot of log k versus 1/T at 298.0, 
303.0, and 308.0 K: losartan potassium (1.63 x 
10"' - 1.30 X 10''' M) with initial concentrations 
of KMnOi (1.80 X 10' M) and NaOH (0.12 M) 
for activation energy. 
000324 0,00328 0.00328 0.00330 000332 
i/T(K) 
0,00334 000336 0,00338 
Fig. 5. Eyring plot of log k/T versus 1/T al 298.0, 
303.0, and 308.0 K: losartan potassium (1.63 x 
10"*- 1.30x IO"'M) with initial concentrations 
ofKMnO4(I.80x lO"'M)and NaOH (0.12 M) 
for b.W and AS^ 
Determination of Losartan Potassium ./. Chin. Chem. Soc. Vol. 5.?, No. 3. 2006 741 
Table 3. Optical characteristics and analytical data for the fixed time method 
Fixed-time method 
Parameters 3 min 6 min 9 min 12min 15 min 
Equilibrium 
method 
Beer's law limit (ng mL' 
Regression equation 
So 
S. 
Sb 
Correlation coefficient (r) 
Detection limit (ng mU') 
Quantitation limit (ng mL'' 
Variance, %o (v-% mL"') 
7.5 - 60.0 
A = 6.0>^ 10^+ 
2.09 X 10-'C 
6.80 X 10^ 
4.60 X 10-^  
1.00 X 10' 
0.9998 
1.074 
3,253 
4.62 X 10-' 
7.5 - 60.0 
A = -4.00x 10" 
3.56 X 10''C 
7.00 X 10^ 
4.80 X IQ-^  
1.00 X 10' 
0.9999 
0.649 
1.966 
4.90 X lO' 
7.5 - 60.0 
A = 4.6x 10"* + 
4.49 X 10''C 
8.30 X I0-* 
5.70 X lO"* 
1.00 X 10' 
0.9999 
0.610 
1.849 
6.89 X 10' 
7.5 - 60.0 
A = 3.30x 10'' + 
5.28 X 10"'C 
3.40 X lO"* 
2.30 X lO"* 
6.00x10'' 
0.9999 
0.213 
0.644 
1.15x10"' 
7.5 - 60.0 
A=1.74x 10"^  H 
5.92 X 10"^  C 
1.02x10"' 
6.90 X 10"* 
2.00 X 10"' 
0.9999 
0.636 
1.928 
1.04 X lO"* 
7.5 - 60.0 
A = -2,09x 10"^  + 
1.05 X 10"'C 
6.02 X 10"' 
4.09 X 10"' 
1.06 X lO'' 
0.9996 
0.190 
0.570 
3.60 X 10"' 
So is the standard deviation of the calibration line. 
Table 4. Intra day and inter day assays: test of precision of the initial rate, fixed time and equilibrium methods 
Proposed methods 
Initial rate method 
Intra day assay 
Inter day assay 
Fixed time method 
Intra day assay 
Inter day assay 
Equilibrium method 
Intra day assay 
Inler day assay 
Amount 
Taken 
10.0 
35.0 
55.0 
10.0 
35.0 
55.0 
10.0 
35.0 
55.0 
10.0 
35.0 
55.0 
10.0 
35.0 
55.0 
10.0 
35.0 
55.0 
(HgmL"') 
Found ± SD" 
10.026 + 0.043 
34.996 + 0.118 
55.013 ±0.070 
9.992 ± 0.092 
34.99610.192 
55.04810.124 
10.013+0.085 
35.12710.158 
55.051 ±0.134 
9.97510.134 
35,05110.169 
55.051 10.268 
9.990 + 0.042 
34.98710.051 
55.040 ±0.059 
10.008 t 0.070 
35.011 ±0.104 
55.02010.070 
Recovery 
(%) 
100.20 
99.98 
100.02 
99.92 
99.98 
100.08 
100.13 
100.36 
100.09 
99.75 
100.15 
100.09 
99.90 
99.96 
100.07 
100.08 
100.03 
100,03 
RSD' 
(%) 
0,429 
0.336 
0.127 
0.922 
0.548 
0.226 
0,846 
0.451 
0.243 
1.342 
0.483 
0.486 
0.421 
0.146 
0.107 
0.700 
0.297 
0.123 
SAE" 
0.019 
0.053 
0.031 
0.041 
0.086 
0.060 
0.038 
0.071 
0.060 
0.060 
0.076 
0.119 
0.019 
0.023 
0.026 
0,031 
0,050 
0.030 
C.L.' 
0.053 
0.146 
0.087 
0.114 
0.238 
0.155 
0.105 
0.197 
0.166 
0.166 
0.210 
0.333 
0.052 
0.063 
0.073 
0.087 
0.129 
0.084 
" Mean for five independent analyses. SAE, standard analytical error 
' C.L., confidence limit at 95% confidence level and four degrees of freedom (t = 2.776), 
cate analyses on five consecutive days (Table 4). The re-
sults of standard deviation, relative standard deviation and 
mean recoveries obtained by intra day and inter day preci-
sions for initial rate, fixed time and equilibrium fixed time 
methods are acceptable and can be considered to be very 
satisfactory. 
Performing recovery experiments through standard 
addition method also checked the validity of the proposed 
methods. For this, a known amount of the pure drug was 
added to preanalysed dosage forms at two concentration 
levels by measuring five replicate analyses following the 
recommended procedures for the determination of active 
drug. The results summarized in Table 5 showed excellent 
recoveries (99.80-100.14%) with low values of relative 
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Table 5. Standard addition method for the determination of losartan potassium in commercial tablets 
Formulations 
Zaart25 
(Cipla) 
Losacar 25 
(Zydus Medica) 
Losium 25 
(Cadila) 
Taken 
5.0 
15.0 
5.0 
15.0 
5.0 
15.0 
Initial rate method 
Amount ( 
Added 
10.0 
10.0 
10.0 
10.0 
10.0 
10.0 
;ngmL"') 
Found ± SD" 
15.020 ±0.030 
24.951 ±0.180 
14.97810.040 
25.036 ±0.235 
14.992 ±0.222 
24.993 + 0.153 
Recovery 
(%) 
100.13 
99.80 
99.85 
100.14 
99.94 
99.97 
SAE 
0.014 
0.080 
0.017 
0.105 
0.010 
0.068 
C.L. 
0.038 
0.223 
0.046 
0.029 
0.028 
0.189 
Taken 
5.0 
15.0 
5.0 
15.0 
5.0 
15.0 
Fixed time method 
Amount (ng mL'') 
Added 
10.0 
10.0 
10.0 
10.0 
10.0 
10.0 
Found ± SD" 
15.013 ±0.169 
24.975 ± 0.847 
14.975 ±0.369 
25.051 ±0.104 
15.013 ±0.287 
25.013 ±0.216 
Recovery 
(%) 
100.08 
99.90 
99.83 
100.20 
100.08 
100.05 
SAE 
0.076 
0.038 
0.165 
0.046 
0.128 
0.096 
C.L 
0.210 
0.105 
0.458 
0.129 
0.356 
0.268 
' Mean for five independent analyses. 
Table 6. Point and interval hypothesis tests: comparison of the proposed methods with the reference method at 95% confidence level 
Formulations ~ 
Zaart25 
(Cipla) 
Losacar 25 
(Zydus Medica) 
Losium 25 
(Cadila) 
Initial rate method 
Recovery % 
100.07 
9L = 0.991 
t = 0.25 
100.08 
SL = 0.988 
t = 0.13 
100. 07 
6L = 0.984 
t - 0.02 
RSD % 
0.11 
eu= 1.011 
F= 1.40 
0.09 
eu= 1.014 
F = 2.46 
0.09 
eu= 1.015 
F = 2.18 
Fixed time method 
Recovery % 
100.02 
eL = 0.988 
t = 0.11 
100.08 
8,. = 0.983 
t = 0.10 
100.02 
OL = 0.982 
t = 0.09 
RSD % 
0.14 
9u= 1.012 
F = 2.52 
0.17 
%= 1.017 
F= 1.41 
0.14 
eu= 1.017 
F=1.82 
Equilibrium method 
Recovei-y % 
100.01 
eL = 0.991 
t = O.I2 
99.98 
6,, = 0.986 
t = 0.08 
100.04 
OL = 0.983 
t = 0.07 
RSD % 
0.09 
Ou =1.011 
F= 1.05 
0.10 
eu= 1.012 
F= 1.48 
0.10 
6u= 1.015 
F = 1.97 
Reference method 
Recovery % 
99.97 
100.02 
100.08 
RSD % 
0.09 
0.15 
0.19 
Theoretical t- (v = 8) and F-values (v = 4, 4) at 95% confidence level are 2.306 and 6.39, respectively. 
OL and % are within the acceptable limits of ±2%. 
standard deviations (0.15-0.94%). It is also clear from the 
data that no interference from the common excipients used 
in tablets was observed. An attractive feature of the method 
is its relative freedom from interference by the usual tablet 
diluents and excipients in amounts far in excess of their 
normal occurrence in pharmaceutical preparations. 
Health Protection Branch.^' Therefore, the acceptable limit 
lies within ^L- 0-98 and (j)u = 1.02. It is evident from Table 
6 that the true bias of all samples of drug is smaller than ± 
2% and thus confirming that the proposed methods are reli-
able with acceptable recovery. 
Applicability of tlic proposed methods 
The initial rate, fixed time and equilibrium fixed time 
methods were successfully applied to the determination of 
losartan potassium in pharmaceutical formulations. The re-
sults of the proposed methods were compared with those of 
the reference method using point and interval hypothesis 
tests" and are summarized in Table 6. The calculated t-
(paired) and F- values at 95% confidence level do not ex-
ceed the theoretical ones^" indicating no significant differ-
ences between the performance of the proposed methods 
and the reference method. A bias of ± 2%, which is based 
on recovery experiments, is permissible by The Canadian 
CONCLUSION 
The proposed kinetic method is appreciable with a 
view that the oxidation of drug can be exploited for the rou-
tine quality control analysis of losartan potassium in phar-
maceutical formulations. The method is sensitive with a 
simple calibration system that does not require any labori-
ous clean up procedure prior to analysis. Moreover the pres-
ent technique has the advantage of using inexpensive and 
easily available reagents and therefore can be frequently 
used in the laboratories of research, hospitals and pharma-
ceutical industries. 
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